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EDTA; ethylene diamine tetra-acetate
EGF; epidermal growth factor
FBS; foetal bovine serum
G418; geneticin sulfate
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PBS; phosphate buffered saline
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C: Techniques, genetic abbreviations and others
APC; adenomatous polyposis coli
CDNA; copy DNA
CIN; cervical intraepithelial neoplasm
DCC; deleted in colorectal carcinoma
DI; DNA index
ds; double stranded
ELISA; enzyme-linked immunosorbent assay
FAP; familial adenomatous polyposis
GAP; GTPase activating protein
GS; Gardner syndrome
GTP; guanosine triphosphate
HPV; human papilloma virus
log; logarithm
LOH; loss of heterozygosity
MCC: mutated in colorectal carcinoma
MMTV; mouse mammary tumour virus
MRC; Medical Research Council
OD; optical density
PCR; polymerase chain reaction
RFLP; restriction fragment length polymorphisms
SCID; severe combined immunodeficiency syndrome
SV40;simian virus 40
UV; ultra violet light
VNTR;. variable number tandem repeats
v/v; volume for volume
w/v; weight for volume
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Abstract
Colorectal cancers carry multiple gene abnormalities
at both oncosuppressor and oncogene loci. The role of
these defects, singly and in combination with each other,
in defining colorectal tumour origin and progression is
not known. One means to address this important problem
experimentally would be to assess the effects of
correcting these gene defects in human tumour cell lines
against backgrounds of normality, or defined abnormality
at other key loci. Such studies demand the existence of
colorectal carcinoma lines in which the major colorectal
tumour-associated gene defects are defined.
This thesis describes the derivation of 12 such
lines and compares them with 6 lines derived elsewhere.
Lines derived in this study were propagated firstly as
xenografts in immunodeficient mice and briefly as primary
cultures. Tumour xenografts were shown to remain stable,
faithfully conserving defects or normality, at all sites
tested. Stability of the more global index of DNA ploidy
was also dempnstrated, often over 1-2 years and in one
case over 25 monthly passages in vivo. Moreover, of the
many lines which grew as primary cultures in vitro (in
which genetic manipulation could take place), 2 were
subsequently re-implanted in vivo and grew as. xenografts
with unchanged properties.
In contrast to the stability of these xenografts a
cell line, intentionally exposed to potential mutagens in
vitro, showed a specific rearrangement at the critical
locus on 5q21 in association with acquired
tumorigenicity. This constitutes the first demonstration
of such is. vitro effects in direct association with
specific APC and MCC alterations.
One of the disadvantages of obtaining "anonymous"
long-passaged colorectal lines is demonstrated in that
genetic analysis showed 5 lines, considered to arise from
different patients, to have become colonized by a single
strongly growing line prior to arrival in our laboratory.
Although exploitation of the lines described is
largely a future prospect, experiments with a candidate
oncosuppressor explored possible effects on cell growth
in vitro and tumorigenicity in vivo. while preliminary
investigations were made into optimal gene transfer
conditions for the new lines.
The newly characterized colorectal cancer lines
described provide uniquely favourable vehicles for future
oncosuppressor assays, and renewable purified tumour
resources ideal for detailed study of gene defects and




1.1 The study of colorectal cancer
The biology, genetics and common occurrence of
colorectal carcinoma make its study important and
•informative. This carcinoma is the second commonest cause
of cancer deaths in the Western world. In Scotland alone
(with 5.1 million population) 2,800 new cases are
diagnosed every year. Its incidence in the urbanised
societies of the Pacific rim- traditionally low- is
rising very rapidly. Only in the developing world is this
malignant tumour rare. Biopsy specimens are available
from putative stages of neoplastic progression from
normal colonic epithelium through a prolonged non-
infiltrative adenoma stage to malignant adenocarcinoma
9
and finally to metastatic disease. Analysis of phenotypic
and genotypic changes at each stage may ultimately
elucidate factors involved in tumour progression. There
are many known genetic associations with colorectal
carcinoma, including the existence of a clearly
identifiable familial syndrome with an inherited
predisposition to colorectal carcinoma. Investigation
into the genetics of both this syndrome and spontaneous
cases has helped to provide a genetic framework on which
9
to build an understanding of the loss of control during
tumorigenesis. Understanding of this common human cancer
»
may also provide valuable leads for the analysis of other
neoplasms for which information and biopsy specimens are
less accessable.
3
1.2 Models of tumour progression
The concept of linear tumour progression in the
adenoma to carcinonma sequence (Muto et al 1975) is
widely accepted for colorectal tumours. Genetic
alterations have been found to occur at various stages of
neoplasia (Vogelstein et al 1988) and a genetic model for
9
tumour progression has been proposed (Fearon and
Vogelstein 1990). However, none of the tumour-associated
genetic lesions has been detected in more than 75% of
colorectal tumours and some are found in less than 50%
(Vogelstein et al 1988). No single lesion is therefore
necessary for the generation of carcinoma and in some
cases, none of the known colon-associated genetic changes
is detected (Delattre et al 1989, Vogelstein et al 1988).
Multiple genetic alterations have been shown to occur
9
9
significantly more frequently in tumours removed from the
distal colon (from the splenic flexure to the end of the
sigmoid bowel), while tumours of proximal location were
less likely to show such changes (Delattre et al 1989).
This observation suggests that different genetic
mechanisms may be responsible for the generation of
ft
proximal versus distal carcinomas. A linear genetic model
for tumour progression such as proposed by Fearon and
Vogelstein 1990, would therefore be insufficient to
%
explain the genesis of all colorectal tumours. A more
emancipated model of tumorigenesis might allow for both
the genesis of carcinoma by different mechanisms and for
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carcinoma even in the inherited syndrome FAP. A precedent
for a different molecular basis underlying phenotypically
f
similar neoplasms with variable malignant potential may
be seen in CIN (cervical intraepithelial neoplasm)
lesions in the pathology of cervical carcinoma. A wide
range of HPV (human papilloma virus) types are commonly
f>
found in epithelial cells at early CIN stages but only a
subset of these types such as HPV18 are found in
carcinoma (Coleman et al 1986) . Much research on
colorectal cancer evolution will be required to fully
f:
elucidate the pathways and mechanisms involved. Currently
attention is focussed on the loci involved in
Vogelstein's genetic model of linear progression, and the
evidence for involvement in colon tumorigenesis at many
of these loci will now be discussed.
1.3 Inherited colorectal cancer in FAP patients
6
In familial adenomatous polyposis (FAP), hundreds to
s
thousands of adenomatous polyps develop in the mucosa of
the large intestine and rectum. Colorectal adenocarcinoma
invariably arises in affected individuals if the
adenomatous large bowel is not removed by surgery. The
5
6
syndrome is inherited in an autosomal dominant fashion in
accordance with a one gene' hypothesis. A case report of
ft
the constitutional deletion of a region of chromosome 5
in a mentally retarded individual . with multiple
developmental abnormalities and FAP (Herrera et al 1986)
has led to the localisation and recent isolation of this
gene.
1.3.1 The APC gene was localised to chromosome 5
The APC gene (adenomatous polyposis coli) was first
*
localised to the long arm of chromosome 5 by two
independent efforts (Bodmer et al 1987, Leppert et al
1987) . By first constructing a linkage map of chromosome
*
5 with 16 polymorphic markers and then examining the
#
constitutional DNA of 5 affected kindreds using these
markers as probes, Leppert was able to show linkage to
the disease gene and localise it within this primary
genetic map. Similarly, Bodmer investigated 13 families
using 5 unmapped chromosome 5 probes and on finding close
*
linkage to FAP, localized the linked markers to
chromosome 5q by in situ hybridisation.
1.3.2 The APC gene in sporadic and inherited cancers
According to Knudson's two mutation model for human
cancer (Knudson 1987), both sporadic and inherited forms
result from mutations in the same gene. Minisatellite
9
probes to 5q were therefore used to show tumour specific
allelic loss in at least 20% of sporadic cases (Solomon
et al 1987). Following these discoveries further




established for each and their order was determined
(Nakamura et al 1988, Meera Khan et al 1988, Dunlop et al
1989, Dunlop et al 1990). Using these linked probes it
%
was then possible to detect tumour specific allelic loss
9
at a higher frequency and to characterize the nature of
such losses. As predicted by both Knudson's theory of
*
somatic mutation and by the cautious definition of APC as
a tumour suppressor gene, inherited forms of the cancer
showed one allele (presumably the normal allelic copy of
T
the gene) to be deleted during the development of
adenocarcinoma (Miyaki et al 1990). Furthermore, results
%
from our laboratory probing sporadic tumours with markers
closely linked to APC established the incidence of loss
was high (over 40%), and ascertained that the major cause
of loss was interstitial deletion followed by mitotic
recombination (Ashton-Rickardt et al 1989), unlike the
high incidences of whole chromosome loss being reported
4
for other putative oncosuppressor genes (Muleris et al
1990). Subsequent studies concluded that tumour
t
progression involved losses of a similar molecular nature
in inherited cases (Okamoto et al 1990), suggesting that
i
i
the same genetic alterations occur in both familial and
sporadic cancers. The remaining copy of APC in sporadic
tumours, as in inherited cases, is assumed to carry a
point mutation or other small defect which is sufficient
to inactivate the gene. The recombinogenic nature of the
favoured methods of allelic loss i.e. mitotic
recombinations and interstitial deletions may suggest a
%
7
clustering of breakpoints in this region or may indicate
'
a selective advantage for retention of the region
telomeric to the APC gene, although existing rare cases
of whole chromosome loss argue against the latter.
1.3.3 Tumour-specific APC loss earlv in tumoriqenesis
LOH (loss of heterozygosity) at 5q21 is detected in
29% of sporadic and up to 20% of familial adenomas
(Vogelstein et al 1988, Miyaki et al 1990), and in at
least 42% of sporadic and 52% of familial carcinomas
(Ashton-Rickardt et al 1991, Miyaki et al 1990). Frequent
detection of the LOH event in adenomas may suggest its
involvement during benign stages of tumorigenesis.
Moreover, since most familial polyps do not show LOH and
therefore can be considered to have heterozygous defects
only, single allele abnormalities appear sufficient to
permit polyp formation. Although this implies a role for
APC in tumour initiation, the maximal frequency LOH is
>
detected at the carcinoma stage, allowing the possibility
that defects around the APC locus exert important effects
throughout progression.
1.3.4 Identification of APC and MCC genes
The APC gene was recently isolated by two
independent efforts both making use of YACs (yeast
%
artificial chromosomes) to clone large contiguous regions
of 5q21 (Joslyn et al 1991, Kinzler et al 1991b). 3 and 6
new genes respectively were isolated by these groups.
Using PCR (polymerase chain reaction), searches for
mutations in these genes in FAP patients resulted in
8
selection of the same candidate APC gene by both groups
(Groden et al 1991, Nishisho et al 1991) . In one case the
same mutation was found in FAP and GS (Gardner syndrome)
patients suggesting both to be environmental variants of




location is suggested for the unusually large predicted
protein of the APC gene which bears local sequence
0
similarities to myosins and intermediate filament
proteins (Kinzler et al 1991b). The predicted coiled-coil
structure of the amino terminal quarter of the APC
protein is expected to interact with other proteins
(Bourne 1991). Such interaction may be necessary for
o
protein function and, in defective proteins, could lead
to dominant negative action analogous to that suggested
for p53 protein (section 1.5.1). Mutations were also
detected in some sporadic colorectal cancers in another
of the 6 genes in which no inherited defects were found
(Kinzler et al 1991a). The transcription unit of this
gene MCC (mutated in colorectal cancers) is close but
I
points in the opposite direction to that of APC. Both
proteins are expressed in normal colonic mucosa and a
wide variety of other tissues.
It is interesting to note that in a search of over
200 sporadic tumours for somatic mutations in large
portions of either of these genes, only 2 were found
(Nishisho et al 1991). Furthermore, of mutations detected
in a total of 10 patients, all led ultimately to
unscheduled stop codons and unexpectedly, only 2 showed
Figure 2 CHROMOSOMAL ABNORMALITIES
IN COLORECTAL CANCER
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}
coincident 5q21 allele loss (Nishisho et al 1991) .
ft
1.4 An allelotvoe for colorectal cancer
Besides the putative tumour suppressor gene on
chromosome 5 many other genes are involved in both
4
sporadic and inherited colorectal cancers. In 1989
Vogelstein published an allelotype of colorectal cancer
(Vogelstein et al 1989), in which polymorphic markers
from every non-acrocentric autosomal arm were used to
9
compile a list of the frequencies of tumour specific loss
for each. All markers were lost in at least some tumours
but the most frequently detected arm losses, in
descending order, were as follows; 17p, 18q, 8p, 18p, 5q,
4
22q, 6q, lq, 21q, 9q, 4p. The final members of this list
ft
showed about 25% loss (figure 2). This begs the question
that if all chromosome arms are sometimes lost are there
tumour suppressor activities on each? If, on the other
hand, many of the losses can be attributed to random loss
due to aneuploidy and the resulting chromosome
rearrangements during turaorigenesis, at what frequency of
loss can oncosuppressor function be inferred? The answers
to these questions are still unclear and may remain so
for some time since the study of oncosuppressor genes is
still in its infancy, with their discovery hindered by
their recessive nature. However, some of Vogelstein's
high frequency of loss candidates have been assigned
9
tumour suppressive activity which has been confirmed by
functional data.
9
Oncosuppressor function can only be confidently
0
11
assigned to a gene by the demonstration of
oncosuppression specifically by that gene in genetic
manipulation studies. A colon-associated tumour
suppressor gene for which such functional data is
available is the p53 gene residing at 17pl3.
• 1.5 The p53 gene is an oncosuppressor
The p53 protein, originally discovered in co mplex
with the large T antigen of SV40 in transformed cells
(Lane and Crawford 1979), has undergpne intense study
over the last decade. Early experiments, in which
mixtures of activated ras and the o53 gene were
9
transfected into cell lines, suggested that the p53 gene
possessed transforming capabilities. It later transpired
that these experiments were misleading since the copy of
the p53 gene in use, thought to be wild type, carried a
single point mutation. This activating mutation was shown
to produce a protein with decreased binding affinity to
4
large T, ability.to complex with the cellular heat shock
protein hsc70, and a greatly increased half life (Finlay
et al 1988). By elegant co-transfection experiments it
9
was shown that contrary to previous ideas, wild type p53
could decrease the transforming function of the original
point-mutated p53 and activated ras mixtures.
Furthermore, wild type p53 could decrease the
*
transforming function in the same experiment when mutated
p53 was substituted with adenovirus transforming protein
Ela (Finlay et al 1989) . These findings helped to
reclassify p53 as a tumour suppressor gene rather than an
12
oncogene, and suggested a central role in growth control.
1.5.1 p53 protein may have a dominant negative effect
Besides reclass ifying p53 as an oncosuppressor gene,
0
the above observations give rise to an apparent paradox.
How can a gene function in wild type as a tumour
✓
suppressor by virtue of its central role in growth
control yet, after a single point mutation, gain the
function of an ac tively transforming oncogene? Since
oligomerization of the p53 protein correlates with
transformation (Kraiss et al 1988), mutant p53 has been
hypothesised to sequester co-existing wild type protein
in inactive complex, so forcing the neglect of p53
function in growth control (figure 3). In this way the
mutant protein is said to have a dominant negative
effect, yet the wild type gene remains an oncosuppressor.
*
This theory is upheld by the observation of a greatly
increased half-life of mutant protein, thought to exist
in a stabilized protein aggregate.
1.5.2 Dominant activating p53 mutations mav also exist
9
♦
There are, however, some problems with this
simplified dominant negative theory of p53 action. The
ability to produce progressive tumours only after
C
introduction of mutated p53 has been observed for a cell
line which was known not to express p53 (Wolf et al
1984). The mutated p53 protein can not work in this case
by sequestering wild type protein, yet transforming
ability is demonstrated. Furthermore, transfections with
✓
different p53 mutant genes have been shown to display
13
different transforming capacities in the same in vitro
assay, yet all bind wild type p53 with the same
efficiency (Halevy et al 1990). Such observations are
evidence that the suppressor activity and the
*
*
transforming potential of p53 are 2 distinct functions. A
recent hypothesis suggests that wild type control, depends
P
on allosteric regulation and mutant p53 adopts an active
0
growth conformation. In this way mutant proteins may have
%
variable activity yet regulate wild type protein in a
dominant negative fashion by driving it into a mutant
0
conformation. Such alterations in wild type conformation
by mutant protein have been demonstrated (Milner and
Medcalf 1991).
1.5.3 p53 mutations are detected in many human tumours
Despite having different transforming potentials,
different point mutations in the p53 gene are thought to
exert common conformational changes in the protein which
promote self-oligomerization. These common conformational
changes together with the resulting increased half-life
allow the detection of mutant protein by
immunocytochemistry. A number of antibodies have been
raised to p53 and used to detect the expression of
*
accumulated protein in both fixed and frozen pathological
specimens. By this method it was found that mutated p53
%
protein could be detected in 45% to 55% of colorectal
cancers (Van Den Berg et al 1989, Purdie et al 1991), and
at similar frequencies in a variety of other human
tumours including breast (Cattoretti et al 1988, Davidoff
14
et al 1991), leukemia (Koeffler et al 1986), ovary (Marks
et al 1991), lung (Iggo et al 1990), stomach, bladder,
✓
✓
testis, soft-tissue sarcomas and melanomas (Bartek et al
ft
1991).
p53 mutations are also often detected by PCR
amplification and sequencing. The majority of mutations
detected in this way cluster between amino acid residues
ft
130 and 290 (out of 393), and are localized in 4 regions
corresponding to high regions of conservation between
A
species (Soussi et al 1990). There exist residue hotspots
for p53 mutation which differ between cancer types.
Transversions are strikingly frequent at position 3 of
residue 249 in the p53 genes of hepatocellular carcinomas
*
of South African (Bressac et al 1991) and Chinese (Hsu et
al 1991) patients, who may be exposed to similar
carcinogens. Point mutations detected in p53 for the
majority of all cancers are usually missense giving rise
to altered rather than truncated protein.
The p53 gene has recently been shown to be inherited
as a germ-line mutation in a study of five families
affected by the dominantly inherited familial Li-Fraumeni
cancer syndrome (LFS) (Malkin et al 1990). These
mutations, so far, seem also to have restricted
distribution in the p53 locus. The restricted
*
distribution of Li-Fraumeni p53 mutations may represent a
less severe mutation than many others somatically
acquired, and constitutional p53 mutations with more
severe effects may not permit survival.
15
1.5.4 17p allele loss commonly includes loss of p53 gene
Since the p53 gene was known to reside at 17pl3, it
ft
was provocative that the most frequently detected arm
|
loss in Vogelstein's allelotype was of 17p. Further
ft
investigation of this tumour specific loss in colorectal
>
cancer using 20 polymorphic probes established that the
area of common loss could be localised to the region
containing the p53 gene (Baker et al 1989). Furthermore,
* V
s
sequencing of the remaining copy for two cases revealed
point mutations in the highly conserved regions
previously implicated in murine p53 mutations. Further
studies to evaluate the generality of these observations
showed that for a variety of human tumour types (breast,
lung, brain, and colon) the majority of 17p losses left
hemizygous p53 ' mutations which were also sometimes
present in the heterozygote (Nigro et al 1989).
1.5.5 17p alterations at the adenoma-carcinoma boundary
In order to establish the timing and order of these
chromosome 17 alterations in the evolution of colorectal
A
cancers, both 17p loss and p53 mutations were studied for
a large series of adenomas and carcinomas (Baker et al
1990a). p53 mutations were found rarely in adenomas and
rarely in 17p heterozygotes, but commonly in carcinomas
where allelic loss was observed. This suggests a
synchrony of the two events occurring at the adenoma-
carcinoma boundary. Indeed one carcinoma was discovered
to have both lost heterozygosity and acquired a p53
mutation yet contained an area of adenoma in which
I
16
neither event had occurred. These observations suggest
the occurrence of one of these events to provide strong
selection for the other to follow. Such selection demands
that the two events must co-operate, an idea which does
not fit easily into the domin ant-negative p53. or the
oncogenically activated p53 schools of thought. However,
there are cases in which mutations within the p53 gene
and 17p allele loss do not coexist (Davidoff et al 1991,
Shirasawa et al 1991, Coles et al 1990, C Purdie
unpublished observations). Furthermore, reports exist of
p53 mutations in adenomatous polyps from FPC patients
(Shirasawa et al 1991) and in sporadic adenomas (Purdie
et al 1991) suggesting occasional earlier involvement.
1.5.6 Functional evidencee for growth suppression by p53
The described LOH and mutations of the p53 gene
conform to the predicted pattern for inactivation of a
tumour suppressor gene. This descriptive definition must
however be supplemented with functional information. To
c
provide such information, constructs expressing wild type
p53 have been transfected into a number of cell lines
(Finlay et al 1989, Baker et al 1990b, Diller et al 1990,
Mercer et al 1990). In all cases selection resulted in a
dramatically reduced number of p53 transfectant colonies
in comparison to numbers obtained in control
transfections. All p53 transfectants displayed either
increased doubling times and lower saturation densities,
or were growth arrested. Such observations led to
proposals that p53 could monitor progression through the
t
17
cell cycle and confirmed the suggestion that p53 could
suppress growth.
1.5.7 p53 may have a role in cell cvcle control
On herpes virus infection the cellular replication
machinery becomes localised to sites of viral
r
replication. Both p53 protein and that of another well
studied oncosuppressor (Rb) were recently shown to
colocalise with the replication machinery under these
circumstances (Wilcock and Lane 1991). Furthermore, a
temperature sensitive p53 mutant exists which inhibits
growth and is localised in the nucleus at 32°C but moves
to the cytoplasm of growing cells at 37°C. Movement of
this protein from the cytoplasm to the nucleus was shown
to coincide with inhibition of DNA synthesis (Gannon and
Lane 1991). Expression of wild-type p53 in a human
glioblastoma cell line was shown to block cell cycle
progression in association with a marked decrease in
histone H3 expression, which was subsequently,shown to be
accompanied by selective down-regulation of PCNA
(proliferating-cell nuclear antigen) expression, whose
protein is a component of the cellular replication
machinery (Mercer et al 1991). Such evidence may suggest
a regulatory role for p53 in the assembly or function of
the DNA replication-initiation complex. However, there is
a different school of thought that p53 may act as a
transactivator of gene transcription (for review see
Levine et al 1991). p53 has often been compared with, and
shares many functions of, the oncosuppressor gene Rb. The
18
Rb protein has recently been shown to complex with a
cellular transcription factor (Bandara and Lathangue
0
1991) and.is now thought to regulate transcription. Wild
ft
type p53 has recently been shown to have sequence-
ft
specific DNA-binding properties (Kern et al 1991), the
effects of which are not yet known.
Regardless- of mechanism of action, functional
evidence implicates a role for p53 in cell-cycle control.
Moreover, induction of apoptotic cell death by
transfection and expression of an exogenous wild-type p53
ft
gene has recently been demonstrated (Yonish-Rouach et al
1991).
Despite the obvious importance of the p53 protein,
it is worthy of note that many cells both in vitro and in
vivo continue to grow in the complete absence of p53
ft
expression. Furthermore, Li-Fraumeni patients carry
constitutional p53 mutations yet develop normally, the
9 1
only obvious phenotype being a predisposition to
carcinogenesis (Malkin et al 1990) . Despite the
undeniable importance of the role of o53 there may well
be other mechanisms at work which may substitute for and
co-operate with p53 under certain circumstances.
1.6 The DCC gene: An oncosuppressor on 18o?
After 17p, the chromosome arm loss most frequently
ft
detected in colorectal cancer is 18q (figure 2). The gene
0
of interest on 18q has recently been identified (Fearon
et al 1990). This involved an exhaustive exon connection
strategy by reverse transcriptase PCR using primers to
areas of open reading frame. The gene termed DCC (for
deleted in colorectal cancer) consists of at least 8
i
exons in 370Kb of DNA, with the predicted amino acid
sequence of a cell surface glycoprotein similar to the
neural cell adhesion molecule. Its loss occurs about as
frequently in colorectal carcinomas as that of the p53
gene (about 70%). Unlike 17p losses, 18q losses occur in
47% of late adenomas suggesting loss to be an
intermediate event in tumorigenesis (Vogelstein et al
1988) . Also unlike the t>53 gene, expression of DCC was
V
greatly reduced or absent in the colorectal carcinomas
0
0
tested. No functional information for the cloned gene has
been published to date.
1.7 Colon tumour-associated LOH is confirmed at other loci
Studies have been conducted to check frequencies of
allele loss for both FAP tumours and sporadic tumours.
These studies confirm the frequent loss of some of the
other members of the allelotype series such as 22q
»
(Okamoto et al 1988) and 14 (Sasaki et al 1989). However,
the methods used to construct the allelotype were
fallible owing to the use of few probes per arm, or
sometimes only one. Loss of heterozygosity can be
confined to small chromosome regions (Ashton-Rickardt et
al 1991), and such losses may not be detected by
sparsely located probes. Loss of heterozygosity has
subsequently been discovered in 42% of colorectal cancers
|
at lp35 (Leister et al 1990), a chromosome whose loss was





1.8 Ki-ras mutations detected early in tumoriaenesis
As well as oncosuppressor genes, oncogenes have a'
#
role in tumorigenesis. The ras oncogene in particular is
implicated in colorectal (Bos et al 1987, Forrester et al
1987), amongst many other cancers. Ras p21 is a membrane
localised protein involved in GTP hydrolysis and with
presumpptive signal-transduction capacity (Sigal 1988,
Barbacid 1987 & 1990). The gene is activated, acquiring a
transforming funtion, by point mutations in codons 12, 13
and 61. Such mutations are found in a variety of human
*
and murine cancers and occur in the K-ras gene in about
50% of colorectal carcinomas and late adenomas. In our
group mutations have also been detected at a similar
4
incidence in hyperplastic polyps (P Romanowski,
unpublished). In contrast, Ki-ras mutations have been
*
found in under 10% of adenomas less than 1cm in size
(Vogelstein et al 1988). Such a discrepancy may reflect
the fact that the small adenomas studied were selected on
the basis of being FAP patient adenomas, and this group
was then characterized as being less than 1cm in size
(Vogelstein et al 1988). Such a set of tumours may not
accurately reflect the sporadic incidence of mutations in
small adenomas.
1.9 Other oncogenes mav be involved in colorectal tumours
k
Other oncogenes implicated in colorectal
tumorigenesis include c-src. c-fos and c-mvc. The latter
is thought to produce a nuclear transcription factor
promoting entry into the G1 phase of the cell-cycle and
21
retention thereafter in the cycling state. Accordingly,
mvc transfection of cultured cells leads to
immortalisation without transformation. C-mvc mRNA is
found to be more highly expressed in both colorectal
carcinomas and adenomas than in normal mucosa and such
overexpressing tumours have been positively correlated
with deletions around the APC gene (Erisman et al 1989).
However, such altered expression may merely reflect the
increased growth rate of the cells. It has been suggested
that since an inherited APC defect allows polyposis, 5q
defects may be associated with increased proliferation
4
thus leading to the detection of apparent increases in Qz
o
myc expression (Maestro et al 1991). An increased
activity in colonic tumours is also reported for the
membrane localised tyrosine kinase c-src (Bolen et al
1987), and a decrease in expression of c-fos mRNA has
been detected (Klimpfinger et al 1990).
Such altered expressions and activities need not be
due to changes in coding sequence and indeed, known cases
*
of specific oncogene amplification or rearrangements in
Q
colonic tumours are rare (Fearon and Vogelstein 1990). It
is therefore possible that many of these altered
activities are a consequence of the neoplastic state, as
hypothesised for c-mvc over-expression. Alternatively,
*
proto-oncogene expression may be altered in a significant
way by mutations in the upstream regulatory sequences
rather than the coding region, for which some evidence
I
o #




1991). At present there is no clear indication of the
extent to which such modification of upstream sequences
(by mutation, rearrangement, or binding of transcription
factors) is part of tumour progression in colorectal
mucosa.
1.10 Aneuploidv is common in colorectal tumours
Another potentially important step is the
significant tumour-specific reduction in DNA methylation
evident in early benign lesions. This could inhibit
chromosome condensation and lead to mitotic non¬
disjunction. Whether resulting from this or other causes
of genomic instability, DNA aneuploidy is detected by
flow cytometry in about 60% of colorectal cancers
(Giaretti et al 1990) and is a good prognostic indicator
(Quirke et al 1987, Armitage et al 1991). Aneuploidy is
rarely detected in adenomas and carcinoma ploidy
abnormalities increase progressively with size. and
histological type (Van den Ingh et al 1985) . In practice
4
karyotypically aneuploid tumours are known to fall into
two broad classes (Reichmann et al 1982, Muleris et al
1990)- near-diploid tumours (where single chromosomes
tend to become lost) and tetraploid and severely
t
aneuploid tumours. Only the second class is readily
detected by flow cytometry. In either case it is clear
that such karyotypic abnormalities may be involved in the
generation of allelic losses. While non-specific allelic
i
losses may be generated and evident in Vogelstein's






















critical for tumour progression may be present within
this set.
1.11 Accumulation of genetic lesions during progression
A model has been proposed to incorporate the major
genes involved in colorectal tumour progression and their
observed timing throughout this process (Fearon and
Vogelstein 1990, and figure 4). However, the authors
found many tumours which did not conform to the
%
prescribed qrder of genetic changes within this model.
None of these changes was entirely restricted to its
proposed stage of action and each was sometimes found to
occur out of sequence relative to the other events in the
model (Fearon and Vogelstein 1990). Given that the timing
and order of these events were not obligatory, complex
*
interplay between different combinations of genetic
4
lesions may be suggested. The authors drew the conclusion
that the accumulation rather than ordder of these lesions
was the critical factor. However, as already discussed,
the linear genetic model (figure 4) has limitations and
an alternative model (figure 1) may be . more generally
'
applicable.
1.12 Co-operation of lesions in oncosuppressor tests
If combinations of genetic lesions are co-operating
9
to make the tumour phenotype, the genetic background of
*
the cell will decide what effects any new lesion may
»
have. This idea may have consequences in functional tests
by transfection of these genes. If transfected into
uncharacterized recipient cell lines, the unknown genetic
ft
25
background of recipient cells may confound interpretation
of the effects of the transfected gene. Phenotypic
effects may vary according to genetic lesions available
in the recipient cell for co-operation with the exogenous
gene.
w
I.13 Oncosuppressor genes inferred from cell hybrids
Oncosuppressor genes require functional testing in
vitro. The existence of such genes was first demonstrated
by somatic cell hybrids (reviewed in Stanbridge 1990).
Chromosomes 1, 4 and 11 were identified as of major
importance in the control of tumorigenesis. In these
experiments, however, not only was the genetic background
of the recipient cell incompletely characterized but
chromosomes were introduced in random combinations. An
improvement on this method was the development of
microcell transfer and tagging with selectable markers to
allow selective introduction of single specific
chromosomes into tumour cells. Using this method tumour
*
suppression was demonstrated by'chromosomes 1, 3, 6, 9,
9
II, 13 and 17 on introduction into certain tumour cell
4
lines. Although this method was preferable to the
introduction of whole genomes into recipient cells, the
genetic material introduced in a single chromosome is
9
still enormous. Effects of the large number of genes
introduced interacting with each other and with
endogenous genes may be sufficiently complex to preclude
meaningful interpretation. Perhaps for this reason, some
of the chromosomes implicated in these early studies seem
26
so far to bear little relevance to current knowledge of
locations of oncosuppressor genes.
I.14 Oncosuppression of Wilms' tumour bv chromosome 11
Following these experiments, the microcell technique
has been used with some success to demonstrate the
control of tumorigeniciity by chromosomes predicted from
cytogenetic and RFLP analyses. The pediatric
ft
nephroblastoma Wilms' tumour is associated with deletions
on chromosome llpl3 and llpl5 (Koufos et al 1989). In
agreement with the postulate that an oncosuppressor gene
resides in this area, control of tumorigenicity was
demonstrated in a Wilms' tumour cell line by microcell
introduction of a normal chromosome 11 (Weissman et al
\
1987) . Despite the persistence of phenotypic transformed
ft
traits including expression of several proto-oncogenes in
culture, tumorigenicity in nude mice was completely
ft
suppressed. This non-tumorigenic line was also shown to
have lost the ability to grow in serum-free medium and to
o
resume growth in the presence of specific growth factors
(Dowdy et al 1991). Control microcell fusions of
chromosomes 13 and X had no effect. However, despite the
clear significance of this work, the lack of specificity
of whole chromosome introduction and the lack of
recipient cell line characterization attracts criticism.
ft
ft
The recipient line was an established Wilms' tumour cell
*
line with two cytogenetically normal copies of chromosome
II. There was therefore no certainty that a chromosome 11
defect was originally present for correction by the
♦
27
raicrocell transfer. Indeed, certain familial forms do not
appear to map to chromosome 11 at all (Huff et al 1988).
Thus, although tumour suppression by chromosome 11 is
♦
clearly demonstrated in this experiment, it is not
possible to conclude that correction of a specific Wilms'
tumour gene defect is demonstrated. Indeed, tumour
suppression can be demonstrated by introduction of
m





1.15 Oncosuppression bv the retinoblastoma gene
Specific oncosuppression by the Rb (retinoblastoma)
gene has been demonstrated. Mutational inactivation of
the Rb gene was proposed as a necessary step in the
development of retinoblastoma and a possible step in the
genesis of some other tumours. In order to test the
♦
inferred oncosuppressor function, the cloned
retinoblastoma gene was introduced by retroviral mediated
gene transfer into both retinoblastoma and osteosarcoma
cell lines containing inactivated Rb (Huang et al 1988) .
On introduction of normal Rfe into the retinoblastoma line
the growth rate of the cells was significantly decreased
and tumorigenicity in nude mice was suppressed. On
introduction into the osteosarcoma line growth in culture
was more severely inhibited by Rb. Such results underline
ft
the fact that one oncosuppressor gene may have different
effects depending on the background on which it acts.
Presumably, co-operation with different unknown factors





1.16 Qncosuppression bv p53
A second oncosuppressor gene which has been
functionally tested by specific gene introduction into
tumour cell lines is the previously discussed p53 gene
9
(Finlay et al 1989, Baker et al 1990b, Diller et al 1990,
Mercer et al 1990). On the introduction of a wild type
p53 gene into colonic carcinoma cell lines, 5-10 fold
%
less colonies grew than transfectants receiving the
mutant gene which differed in only one nucleotide (Baker
et al 1990b). In all growing colonies the exogenous p53
i
9
sequences were deleted or rearranged. In the same study,
f
a transient transfection showed expression of the wild
9
type protein to dramatically inhibit progression through
the cell cycle as measured by tritiated thymidine
incorporation. A cell line derived from a benign tumour,
also transfected with the same constructs, showed no
measurable growth inhibition (Baker et al 1990b).
Furthermore, in a separate experiment wild type human p53
cDNA introduced into SV40- transformed hamster cells
*
proved to inhibit but not arrest growth. A decreased
number of colonies were observed with lower saturation
densities and increased doubling times (Mercer et al
9
1990) . Presence or absence of effects of exogenous p53 in
ft
different recipient lines may tentatively be explained in
terms of whether the recipient line has already sustained
some event leading to loss of normal p53 control. SV40
transformation is an example of such an event (Lane and
29
Crawford 1979) . The variety of transfectant phenotypes
observed could be related to recipient line species
differences, but the p53 gene is highly conserved between
species such that a more plausible explanation might be
the co-operation of other genetic lesions of the
recipient cell with the exogenous o53. If so, further p53
transfections of human tumour cell lines of known status
at p53 and other colon-associated loci would prove
informative. Such experiments would elucidate whether
«
other genetic lesions, singly or in combinations, may
modulate or substitute for loss of p53 control in the
pathway to the tumour phenotype.
1.17 Oncosuporession bv chromosomes 5 and 18
MCC and APC on 5q, and DCC on 18q have only recently
been cloned. Consequently no functional analyses are
published to date. However, microcell introduction of
chromosomes 5, 18 or 11 into a colonic cancer cell line
have been described. Introduction of each of chromosomes
f
0
5 and 18 were reported to cause morphological changes
with cells becoming more closely packed or flatter
respectively. Transfectants with either chromosome had
also completely lost the abilities to form colonies in
• *
#
soft agar and to produce tumours in nude mice. Chromosome
11 introduction caused no substantial changes (Tanaka et
ft
al 1991). As the first evidence of oncosuppression by
ft
chromosome 5 or 18 sequences, this result represents an
i
important milestone. Within the recipient cell, however,
tumour specific losses of sequences were known to exist
30
around the 18q locus but for 5q were merely assumed. This
is a daring assumption considering the highest reported
incidence of 5q loss stands at less than 50% (Ashton-
9
Rickardt et al 1989). Furthermore, a search of over 200
i
sporadic cases has revealed only one somatic change in
the APC gene and one in MCC (Nishisho et al 1991). The
large quantity of exogenous DNA introduced by microcell
transfer and lack of characterization of colon-associated
lesions in the recipient cells in this experiment
(
preclude clear conclusions on the effects of specific
% f
genes and their co-operation.
The critical importance of the recipient cell in
»
•
these experiments may be demonstrated by a further study
in which sequences on chromosome 5 were introduced by
microcell transfer into v-Ki-ras transformed mouse
*
fibroblasts (Hushino et al 1991) . Despite confirmation of
the introduction of DNA in which both APC and MCC are
known to reside. tumour formation in mice was not
suppressed.
1.18 Ideal transfection experiments
• •
As discussed, the value of experiments to test
oncosuppressor activity is often limited by lack of
specificity of introduced material, undefined genetic
»
background of the recipient cells, or both. In order to
rectify this situation it would be desirable* to use
recipient cell lines which are representative of the
relevant neoplasm, characterized at all the major tumour-
associated loci and known to be defective for the gene
31
under test. For example, the APC gene would ideally be
tested in a colorectal cancer epithelial cell line in
which tumour specific APC gene defects are characterized,
and for which gene status is known for the other colon-
associated loci. j
1.19 Long-established lines are not ideal recipients
s
Long-established colorectal cell-lines are widely
available and commonly employed. These cell lines,
however, do not fulfil the requirements of the
hypothetical ideal test vehicle for a number of reasons.
Firstly, in no case was the tumour from which they
derived adequately defined in genetic terms. Tumour
%
specific genetic changes can therefore be assigned in
very few cases. Secondly, and contributing to the first
problem, is the tendency for chromosomal rearrangement in
I
culture, so that sub-lines with different morphologies
and karyotypes can be established from a single primary
✓
tumour (Brattain et al 1983). Continuous passage in
vitro will preferentially select for any rearrangement
that leads to increased growth capacity. Due to the
artificially contrived environment in culture, these
changes need not be representative of those occurring in
situ. Indeed reports of karyotypes of various colonic
lines are very diverse and the overlap with those
reported for primary tumours is limited. Some examples of
these reports are summarized in table 1. Of particular
prominence is the common gain of an extra chromosome 7 in






implicated in the genesis of colorectal tumours. A
9
plausible explanation for frequent over-representation in
culture may lie in the fact that the gene coding for
ft
epidermal growth factor (EGF) maps to chromosome 7.
EGF significantly stimulates the growth of human colon
carcinoma cells in culture (Murakami and Masui 1980), and
the extra chromosome 7 may therefore confer a selective
advantage to cultured cells. Presumably in vivo growth of
m
colonic epithelial tumour cells is not constrained by
lack of EGF since chromosome 7 gains are not documented
for solid tumours or xenografts. This example illustrates
ft
the fact that long-established tumour cell lines may be
deceptive in demonstrating consistent, apparently
specific genetic defects that do not reflect changes in
vivo or in situ. Such lines are not therefore good test
Table 1 Karyotypes of colorectal cancer cells
Frequent abnormalities Cells
17p loss and 18 loss solid carcinoma Muleris 1990
17p loss and 8 gain solid carcinoma Reichmann 1981
(modifications 1 and 5)
17p.loss and 18 loss carcinoma xenograft Lefrancois 1989
7 gain carcinoma cell line Chen 1982
(modifications 1 and 2)
7 gain carcinoma cell line Brattain 1983
7 gain carcinoma cell line McBain 1984
(modifications 1, 3 and 21)
7p gain and 13 gain carcinoma cell line Namba 1983
(12, 13, 16, 17 gains, 19, 20 loss)
iso5q carcinoma cell line Semple 1978
absent sex chromosome carcinoma cell line Tom 1976
isolq carcinoma cell line Jenkyn 1987
isolq, isol4q, carcinoma cell line Paraskeva 1984
X: 17 translocation
Notes:
1) All numbers represent chromosomes or chromosome arms
2) Only major modifications are listed
3) *= "et al" omitted from all references
33
systems for genetic manipulation experiments.
9
1.20 Ideal recipient cells
For an ideal test system it would be necessary to
establish and characterize a set of novel cell lines.
These should be characterized with respect to the
original genetics of the parent tumour, such
characteristics ideally beingg unaltered in culture.
Xenografting tumours into immunodeficient animals may
help to avoid rearrangements by providing a less
artificial environment than that of cell culture. Short-
•term, secon darily derived cultures from such xenografts
would be uniquely favourable vehicles for functional
analysis of colon-associated genes in various known
genetic backgrounds. Such assays may provide precise
information about the functions of oncosuppressor genes
and the effects of co-operating loci.
1.21 Aims of this thesis
The aim of the work described in this thesis was to
propagate and characterize a number of colorectal
adenocarcinomas as ideal experimental systems. In so
doing it was hoped to generate information on colonic
epithelial cells in xenograft and in culture. Preliminary
investigations into transfection of such cells, and the
effects of oncosuppression in vitro were also planned.
34
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Human colorectal cancer xenografts were estab lished
in immunosuppressed CBA, or SCID (severe combined immuno-
deficient) mice, resulting in take rates of 38% and 92%
respectively. Tumour xenografts were shown, without
exception, to retain phenotypic and genotypic features of
original primary tumours. The stability of 12 xenografts,
maintained iii 5 cases for over one year, was defined in
terms of allelic status at colon-associated
oncosuppressor loci on 5q, 17p and 18q, immuno-
cytochemical detection of p53 mutations, ploidy and
histological features. Xenografts could be stored frozen
in a viable form yet retained the original defined
features after re-implantation. Phenotypic and genotypic
features of propagating xenografts reflected those
observed for unselected carcinomas with 2 possible
exceptions. p53 over-expressing tumours were under-
ft 9
represented and mucinous histology was unexpectedly
common for xenografts in immunosuppressed CBA hosts.
«4
Regardless of selection of primary tumours, the stable
characterized xenografts represent outstanding material
for a variety of experiments. Besides their obvious value
in proposed experiments to test, oncosuppressor gene
ft
activity, they provide a renewable resource of purified
m
human tumour ideal for DNA sequence studies. The variety
of lesions represented by the xenograft set will provide
the opportunity to observe the effects of specific
ft





2.2.1 Xenografts in tumour analyses
Tumour xenografts in immunodeficient animals provide
valuable models of human colorectal cancer. The practice
0
of propagating tumour tissues as xenografts has many
c»
advantages over direct culture of cells. Firstly,
preliminary results from other studies have suggested
that tumours growing as xenografts may conserve some
primary tumour features (Lefrancois et al 1989). Should
0
this represent lack of tumour progression or evolution,
xenografts will be faithful representatives of colorectal
•l
cancers. Such stable systems would be preferable
experimental tumour models to the changing long-
J
established cell lines (discussed in chapter 1 and
described in table 1). A second advantage of xenografts
%
over primary culture is the capacity of immunodeficient
*
host animals to limit some bacterial infections by non-
0
specific defence mechanisms such as macrophages and
complement. In contrast even low levels of infection by
antibiotic-resistant bacteria are generally terminal for
cell cultures. This is of particular significance for
colonic explants which carry contaminating micro-
organisms co-transplanted from the bowel. A third
0
advantage of xenografted tumours is the replacement of
%
their connective tissue stroma by cells from the animal
host (Kopf-Maier and Kestenbach 1990). Whereas primary
cultures imply growth of tumour cells and normal human
stroma cells in competition, the stroma of xenografted
u-
4
human tumours is excusively from another species. This
species difference can be exploited in xenograft tumour
samples for differential recognition of human tumour from
non-tumour cells, allowing specific elimination of the
4
latter in xenograft derived cultures. Furthermore, loss
of human stroma in xenografted tumours will, for many
experiments, make them preferable tumour resources to the
primary tumours. In DNA studies of primary tumour tissue,
such as PCR amplification of sequences or detection of
altered RFLPs by Southern blotting, non-tumour DNA from
admixed stromal cells often confounds the detection of
tumour-specific alterations. Indeed, for allele loss
studies in Southern blots, areas of tumour tissue are
often selected by cryostat sectioning to minimise
contamination of the neoplastic cell population with
stromal non-neoplastic cells (Vogelstein et al 1988). The
absence of non-neoplastic human cells in xenografted
tumours eradicates this problem.
Owing to size, breeding rate and ease of husbandry
the animal of choice for graft propagation has been the
mouse. Host immunodeficiency is essential to prevent
graft rejection and three main kinds of immunodeficient
mice are described.
2.2.1.1 The nude mouse as a xenograft vehicle
In 1962 a spontaneous hairless mouse mutant was
discovered. The trait is recessive, and homozygous
animals were found to lack a thymus gland (Pantelouris
1968). The impaired keratinization that renders these so-
38
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called nude mice hairless may result from the same
ectodermal developmental defect that is responsible for
the absence of thymus. Lack of thymus and consequent
lack of mature T-lymphocytes results in deficient cell
mediated immunity and hence the acceptance of foreign
tissue grafts. Accordingly it has become common practice
to use the nude mouse system for clinical and biological
research on human malignant tissues.
Several factors affect the success of human
heterotransplants in nude mice including health and
receptivity of the animal host, graft preparation,
implantation site and type of graft (Reid et al 1978).
Breast tumours, for example, were found to require 6
months before developing in nude mice whereas colon
tumours showed little to no dormancy before growth. Such
differences may be attributed to differing dependence on
angiogenesis and other factors such as hormones. Over the
last 20 years a number of groups have maintained
%
colorectal cell lines as xenografts in nude mice (Carrel
et al 1976, Morikawa et al 1988) and established that
these xenografted tumours do not metastasise on
subcutaneous implantation (Giavazzi et al 1986).
2.2.1.2 The immunosuppressed mouse as a xenograft vehicle
As an alternative to nude mice as xenograft
recipients, techniques were developed in the .early 1970s
for immunosuppression of immunocompetent CBA mice by
thymectomy and whole-body irradiation. Such animals,






radiation by previous injection of cytosine arabinoside,
were found to be more receptive to human adenocarcinoma
xenografts than were nude mice (Steel et al 1978).
Furthermore, CBA mice, even after immunosuppression, are
thought to.be more robust and less susceptible to minor
infections than nude mice. Indeed the high incidence of
minor infections such as eye abscesses commonly
experienced with nude mice were rarely seen in immuno-
suppressed CBA mice. However, some deg ree of
immunorecovery was noted about 5 weeks after
immunosuppression suggesting these mice to be useful for
$
the propagation of rapidly growing tumours only.
Xenografts propagated in this immunosuppressed host were
V
shown, like those in nude mice, to maintain biological
9
characteristics during serial passage (Houghton and
Taylor 1978) thus comparing favourably with the nude
mouse as a vehicle for propagation of human colorectal
cancers.
2.2.1.3 The SCID mouse as a xenograft vehicle
More recently a third type of host for xenografts
emerged with the discovery of the severe combined
immunodeficiency syndrome (or SCID) mouse. The SCID
<
mutation was found in BalbC derived mice to segregate as
a single autosomal recessive gene not linked to the major
9
histocompatability locus. Phenotypically, mice homozygous
for the mutation are congenitally deficient in both B and
A
T lymphocytes with thymus and lymphoid organs less than
one tenth the normal size (Bosma et al 1983). This lack
40
$
of functional lymphocytes is now thought to be the result
of an inability to correctly rearrange the immunoglobulin
and T-cell receptor genes by site-specific recombination
due to defective V(D)J joining (Schuler and Bosma 1989).
A pleiotropic effect of this mutation is hypersensitivity
9
to ionizing radiation and a deficiency in DNA double-
4
strand break repair (Biedermann et al 1991) . It has been
suggested that the SCID gene product performs a similar
function in both the double-strand break-repair and V(D)J
recombination pathways and may be an ubiquitous protein
(Hendrickson et al 1991). The early arrest of B and T
cell maturation, although proving leaky in 15-25% of
young adults and in all older adults (Bosma and Carroll
1991), qualifies the SCID mouse as a third vehicle to
receive xenogeneic grafts. Indeed, the success of human
tumour grafts into SCID mice has in some cases improved
on and in no case been poorer than their success in nude
mice (Phillips et al 1989).
+
2.2.1.4 Using all three xenograft hosts
Since diverse biological mechanisms underlie the
above three types of human xenograft host, variable
xenograft success may be observed in each. By comparing
growth of groups of tumours in these different vehicles
it may be possible to obtain information . about tumour
properties which may limit xenograft success in any one
host.
2.2.2 Novel xenografts of colorectal cancer




propagation and characterization of xenografted
*
colorectal tumours. Take rates and maintenance rates,
established for xenografts in both CBA (immunosuppressed
by thymectomy and irradiation) and SCID mice, allowed
4
preliminary comparisons between the receptivity of SCID
and CBA hosts. Besides maintenance by continuous passage,
methods were devised for the cold storage of viable
9
xenograft tissue. Of primary importance to this study was
the analysis of characteristics of xenografted tumours to
9
ascertain if they were stably representative of original
primary tumours. Phenotypic characteristics were defined
$
by gross morphology, passage interval, histology and
electron microscopy. Flow cytometry was used to measure
DNA ploidy, while specific colorectal cancer associated
genes were studied by Southern analysis and
immunocytochemistry. RFLPs (restriction fragment length
polymorphisms) in Southern blots were used to detect
f
tumour specific allele loss as an indicator of
oncosuppressor gene loss. Over-expression of p53 was
detected immunocytochemically by the mouse monoclonal
antibody PAbl801 which is specific for human p53 (Banks
0
et al 1986) .
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2.3 Results
2.3.1.1 Improved xenograft take in SCID mice
Two different xenografting experiments were
performed. The first consisted of two runs of the same
design in which colorectal carcinomas from consecutive
*
operations were implanted into immunosuppressed CBA, or
occasionally nude, mice. In the second experiment
individual carcinomas were implanted into bot"h
immunosuppressed and SCID mi ce to allow comparisons of
f
host receptivity to individual tumours.
In two consecutive sets of 28 and 26 primary
colorectal carcinomas implanted into CBA mice, 11 and 10
xenografts respectively grew to passage. These results
give a take rate of 39% in both cases. Of 14 tumours ■
0
xenografted into both immunosuppressed and SCID mice 11
grew to passage in at least one of its 2 host types
9
giving an overall take rate of 78%. For only 12 of these
tumours did the iramunosuppressed CBA host mice survive. 4
of these 12 grew to passage giving a 33% take rate in
Table 2 Xenograft take in CBA and SCID host mice
Experiment Host l°ry Xenograft take % take
Exp.l, run 1 CBA 28 11 39%
Exp.l, run 2 CBA 26 10 39%
Exp. 2 CBA 12 4 33%u /v u « *1
Total CBA 66 25 38%*
Exp. 2 SCID 13 12 92%
Total SCID 13 12 9 92%*
Exp. 2 Both 9 9
9
in SCID 100%
4 in CBA 44%
Notes:
1) l°ry= primary tumours
2) * PC0.001
t
immunosuppressed mice, a figure similar to the 39%
recorded in the first set In contrast, SCID mice
survived for 13 of the tumours xenografted, 12 of which
grew to passage giving a SCID take rate of 92%. Of 9
tumours xenografted into both immunosuppressed and SCID
mice where at least one mouse of both groups survived, 4
grew in both host types and 5 grew only in SCID mice.
Take rates are summarized in table 2.
2.3.1.2 Xenografts passage continuously for over 2 years
9 of the 12 successful implantations survived
at least 5 serial passages in mice, and 5 were observed
over 10 passages or more. One tumour xenograft has now
reached 25 passages (greater than 2 years) in mice. The
passage history of all 12 xenografts is summarized in
table 3 along with the Dukes stage of the corresponding
primary tumours.
Table 3 Passage history of first 12 xenografts














































1) Xen.= xenograft line
2) Duke's stage applies to corresponding primary tumour.
3) Passages refers to continuous passages achieved from
primary implantation.
4) Reason for loss can only be suggested in some cases
5) *=frozen stored tissue available
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Two of the lines surviving only 2 passages were
notable for their long passage intervals averaging 60
days. It is known that immunosuppressed CBA mice recover
some degree of immunity by about 5 weeks post-thymectomy
(Steel et al 1978), and hence such slow growing tumours
may be selected against. Bacterial contamination of the.
xenograft leading to line termination was confirmed
histologically in 2 animals, and there were a number of
* *
host mouse deaths due to severe radiation sickness
amongst both tumour bearing animals and their non-
experimental litter mates. In one case (AGDU) the
original tumour xenografted was of metastatic origin and
doubt exists about the origin of the primary tumour. This
4
could not therefore be included with full certainty as a
colonic adenocarcinoma for subsequent analysis and was no
longer passaged.
The second run of xenografts implanted in imrauno-
suppressed mice was established more recently. So far
only one tumour has grown for more than 5 passages, while
2 others are growing slowly at third passage. All other
tumours were lost after 1 or 2 xenograft passages. The
maintenance rate in this experiment is clearly poorer
than for the previous set and may reflect the receptivity
and health of the host mice: both extensive thymic
regeneration and high mortality were noted. The similar
take rate to that of the first run may be explained by
the fact that 4 hosts rather than 2 (as in the previous
run) were implanted with every primary tumour, and those
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with subsequent host death were removed from the set.
Low passage maintenance data available for tumour
xenografts in SCID hosts was incorporated in a life table
o
s
(figure 8). A Log-rank test (adjusted for tumour p53
status also included in the table) shows the difference
in survival between xenografts in SCID or CBA hosts to be
significant (P<0.001). According to the preliminary
information available, behaviour of xenografts growing in
SCIDs is similar to that observed in immunosuppressed CBA
0
hosts. Passage intervals were occasionally 3 days to 1




2.3.2 Xenografts can be stored frozen in viable form
In order to establish a permanent renewable tumour
4
tissue resource, a means of cold storage was devised. As
described in the materials and methods section, a
procedure was adopted which amalgamates conventional
cultured cell freezing and preparation of tumour tissue
suspensions for injection into animals or for primary
culture. Re-implantation was found to reconstitute tumour
growth for 5 lines (table 3) which have been frozen for a
number of weeks or longer, after 8, 11, 14, 17 and 18
xenograft passages. In no case has any altered growth
characteristic been apparent despite the tissue
*
disruption, freezing and re-injection to which the tumour
was exposed. One line is currently passaging without any
✓
sign of change 6 months after freezing and re-injection.
Histological patterns of re-injected frozen tumours are
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shown alongside those of routine xenografts in figure 5.
2.3.3.1 Xenografts faithfully reproduce tumour histology
All xenografts surviving at least one passage were
confirmed as adenocarcinomas by histology. While local
infiltrative behaviour was evident in most xenografts, no
metastases were observed in mice.
The original histological pattern was conserved from
the primary tumour throughout serial passage in every
case studied (figure ' 5). The case of MUCO is of
particular note since the well differentiated pattern of
the primary tumour is conserved at 25th passage
corresponding to more than 2 years in mice, and after
freezing and re-injection at a number of passages.
Although the other extreme of poor differentiation can
also be seen in this set, the majority of xenografts fell
into the class of adenocarcinomas of average degree of
differentiation, with a possible preponderance of
mucinous tumours (table- 4). Histological examination
including those tumours not yielding xenograft growth
showed the growing subset to otherwise be a fair
representative of the set as a whole.
2.3.3.2 Xenografts display epithelial features
Electron microscopy confirmed the epithelial nature
of tumours harvested' at 5th passage: they comprised
polarised cells arranged around acini or mucin lakes.
Apical microvilli with underlying exocytotic vesicles
were commonly seen. At the basal end of these cells long
v
fibroblastic cells, copiously secreting collagen, were
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Figure 5 Histological comparisons of original colorectal tumours
with the corresponding xenografts (all xlOO). A; A moderately
differentiated primary adenocarcinoma GRBO. B; Corresponding
xenograft at 6th passage. C; A well differentiated
adenocarcinoma RHSP. D; Corresponding xenograft at 17th passage.
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E; A well differentiated primary adenocarcinoma JACA. Pj
Corresponding xenograft at 2nd passage. G; A well differentiated
primary adenocarcinoma CHKE. H; Corresponding xenograft at 9th
passage.
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I; A well differentiated primary adenocarcinoma MUCO. J;
Corresponding xenograft at 23rd passage. K; Corresponding
xenograft after freezing and storage of 9th passage tissue. L;
Corresponding xenograft after freezing and storage of 18th
passage tissue.
50
M; A moderately differentiated primary adenocarcinoma DABU. N;
Corresponding xenograft at 5th passage. 0; A poorly
differentiated primary adenocarcinoma MASM. P; Corresponding
xenograft at 11th passage.
51
Q; A moderately differentiated primary adenocarcinoma JOMcL. R;
Corresponding xenograft at 11th passage. Sj Corresponding
xenograft, after freezing and storage of 4th passage tissue.
52
Tj A poorly differentiated primary adenocarcinoma JOWR. U;
Corresponding xenograft at 2nd passage. V; A moderately
differentiated primary adenocarcinoma ARNE. W; Corresponding
xenograft at 6th passage.
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X.j A poorly differentiated metastatic adenocarcinoma AGDU. Y;
Corresponding xenograft at 9th passage- Zj A moderately
differentiated primary adenocarcinoma CARO. Zaj Corresponding
xenograft at 2nd passage.
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Figure 6 Electron microscopy of 5th passage xenografts showing
conservation of epithelial cell markers. A; Polarised cells with
apical microvilli in DABCJ xenograft (x3800) , B; Apical tight
junctions and desmosomes in RHSP xenograft (xl7000), C; Apical
microvilli, a variety of junctions and a large pocket of mucin
secretion from a goblet cell in CHKE xenograft (xl7000), D;
Desmosomes in DABU xenograft (x24000).
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clearly observed. At apical cell borders tight junctions,
a hallmark of secretory epithelial cells, were observed
and desmosomes were plentiful (figure 6).
2.3.3.3 Xenografts display characteristic behaviour
The tumours which grew successfully as xenografts
tended to show consistent, individually characteristic
patterns (table 4a) and rates (table 4b) of growth.
Variations in extent of mucin production and tumour
morphology were, however, hard to quantify since they
depend upon subj ective evaluations.
Table 4a Bioloaical characteristics of xenocrrafted tumours
Xen Histol Mucin Passacre interval Additional features
GRBO M ++ 25d 7) (2.64)* Highly angiogenic
RHSP H ++ 34d 18) (1.66)
JACA M 0 126 2) (13.43) Grew firm attachments
MUCO H ++ 296 24) (1.28)
CHKE H + 426 11)(2.64)*
DABU M + 286 5) (4.14) Much necrosis
MASM P + 3 Id 12) (2.32) Well attached, angiogenic
JOMCL M + 42d 12)(1.42) Highly angiogenic
JOWR P 0 29d 2) (3.90) Much necrosis
ARNE M + 38d 9) (2.58) Much necrosis
AGDU P 0 32d 9) (2.48)
CARO M + 6 7d 2) (3.20)
Notes:
1) xen= xenograft lines
2) Histol= degree of histological differentiation;
P= poor, M= moderate, H= high
3) Mucins degree of mucin production;
0= negligible, += moderate, ++= high
4) Passage= average passage interval (d= in days)
(n) = number xenograft passages contributing to average
(n) = standard error
5) * P<0.002, Mann-Whitney U test
2.3.4 Tumour DNA ploidv is conserved in xenografts
DNA index (DI) was measured by flow cytometry and
the diploid peak was defined according to an internal
chicken standard as described in chapter 7 (materials and
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j L»-ii in -
Xenograft (p5)
i
Fiqure—2 Flow cytometric comparison of an aneuploid
primary tumour (DNA index 1.7); arrowed, with the
xenograft at passage 5 (DNA index 1.9). Diploid peak
position is marked *.
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methods). The diploid peak was given a value of 1.0 and
DI of any aneuploid peak could be calculated by dividing
its channel number by that of the diploid peak. Half peak
coefficients of variation were typically less than 3.5.
Of the first 11 primary tumours which gave rise to
xenografts, 5 were aneuploid. In all cases studied the DI
of the xenograft was similar to that of the relevant
primary tumour. This DI conservation includes both
diploid and aneuploid examples after more than a year in
mice (12 passages), and in one case retention of the
diploid status over 24 passages (more than 2 years). DI
for tumours and xenografts at various passages are
summarized in table 5.
Table 5 DNA index of primary colorectal cancers and
corresponding tumour xenografts
DNA index
Tumour Primary Xenograft (passage number)
GRBO 1.0 1.0 (5)
RHSP 1.7 1.9(5),(12)
JACA 1.6
MUCO 1.0 1.0 (5) , (12) , (14), (19), (24)
CHKE 1.1 1.2 (5),(9)
DABU 1.0 1.0(3)
MASM 1.0 1.0 (5), (9)
JOMCL 1.0 1.0 (5), (9)
JOWR 1.0
ARNE 1.5 1.6 (5)
AGDU* 1.0 1.0 (5)
CARO 1.4
Notes:
*= Metastatic tumour of unknown primary origin
-= Not done
A diploid peak was noted in every sample whether from
tumour or xenograft and, by flow cytometry on a sample of
mouse liver, the mouse diploid peak position was
confirmed to be indistinguishable from that for human
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diploid. The ubiquitous diploid peak was therefore
assumed to represent the mouse derived stromal component
of the tumour.
For the three aneuploid tumours surviving to fifth
passage the proportion of cells in the diploid peak
remained a constant in two cases, one of which is shown
in figure 7. This peak profile was conserved over 11
passages, signifying conservation of histology since it
reflects the number of stromal cells in a standard size
block of tissue. The alternative interpretation- that
balanced proportions of diploid and aneuploid tumour
passage together- is unlikely for 2 reasons. Little
chance exists; firstly that the correct proportions of
both populations would be selected for passage during 11
serial transplants, and secondly that 2 tumour stemlines
should grow at exactly equal rates over the entire
history of passage, as required to maintain a stable
profile. In the third case (ARNE), the fifth passage
xenograft has a relatively smaller diploid peak than seen
in the tumour yet has conserved histological pattern.
This probably reflects ploidy heterogeneity, commonly
observed in primary tumours (Quirke et al 1985), with
preferential expansion of the aneuploid stemline.
2.3.5 Xenografts maintain genotypes at critical loci
Linked DNA markers were used as probes to detect
allelic loss of oncosuppressor loci at 5q21, 17pl3 and
18q22. Appropriate genomic digests and conditions for
chromosome 5 probes and those on other chromosomes are
59
summarized in chapter 7 in tables 17a) and 17b)
respectively. In these studies, 6 probes spanning the APC
locus over no more than 15 Mb, 2 probes to 17p lying
close to the p53 gene and a single 18q probe situated
within the DCC gene were used. These probes were Pi227,
Cllpll, L5.62, L5.71, EF5.44, YN5.48; YNZ22, pMCT35.1;
and BV15.65 respectively. The patterns detected by some
of the probes and examples of allelic losses and
retentions are shown in figure 30 in chapter 7.
Samples of constitutional and primary tumour DNA
from each patient were analysed together with
corresponding xenograft DNA from various passages.
In all cases, at each locus and at each serial
passage studied, xenografted tumours maintained the
Table 6 Allelic status of colorectal tumour xenografts
at 3 oncosuppressor loci
chromosome 5 chrom 17 chrom. 1
Xen. Pi227 L562 L571 EF544 YN5 4 8 YNZ2 2 MCT3 5 BV1565
GRBO R, 2 NI, 4 R,4 R, 2 NI, 2 R, 4 R, 4 R, 2
RHSP NI, 10 NI, 10 L, 10 NI, 10 NI, 14 NI, 10 L, 10 L, 10
JACA NI, 2 ND ND L, 2 NI, 2 L, 2 ND L, 2
MUCO R, 14 NI, 10 NI, 14 NI, 10 R, 14 R, 14 NI, 10 R, 14
CHKE NI, 2 R,4 NI, 9 NI, 4 R, 4 R,9 R, 4 R,9
DABU R, r7 NI, r5 NI, r NI, r5 R, r7 R, r7 ND NI, 7
MASM NI, 9 NI, 5 R, 9 NI, 5 NI, 9 R,9 NI, 5 R, 9
JOMCL R, 7 NI, 4 R, 7 NI, 4 NI, 7 R, 7 R, 4 NI, 7
JOWR R, 1 R, 1 NI, 1 NI, 1 R, 1 R, 1 ND R, 1
ARNE NI, 8 NI, 4 R, 4 NI, 4 NI, 8 L,8 L, 4 L, 8
AGDU* NI, 4 R, 4 R, 4 NI, 4 R, 4 R, 4 ND R, 4
CARO NI, 1 NI, 1 L, 1 NI, 1 L, 4 L, 1 ND L, 1
Notes:
1) xen.= xenograft lines
2) R= retention of heterozygosity
3) L= loss of heterozygosity
4) NI= non-informative (constitutional homozygosity)
5) ND= not done
6) numbers= highest xenograft passage number analysed
7) r= grown briefly in culture after 4th passage and
re-implanted as a xenograft
8) *= metastatic tumour of unknown primary origin
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allelic status of the parental primary ttumour (table 6).
Allele losses or rearrangements at the critical loci
never appeared during up to 14 passages of tumours that
were initially heterozygous. Neither were homozygous
losses ever observe d during up to 10 passages of tumours
originally showing allele loss.
Loss of heterozygosity was detected for at least one
locus in 4 primary tumours within the xenograft set.
Cases of retention of both alleles at all 3 loci and of
allelic loss at all three loci are represented. In all
cases where loss at one oncosuppressor locus was
detected, coincident loss of at least one other locus was
also always detected.
2.3.6 No p53 mutated tumour grew to 5th xenograft passage
Intra nuclear p53 accumulation was detected immuno-
cytochemically in only 2 of the first 11 colorectal
adenocarcinomas that grew to xenograft passage. Moreover,
neither of these tumours nor any subsequent xenograft
carrying a p53 mutation to date, has reached 5th passage
in CBA immunosuppressed mice. Of the accumulated series
of 66 primary tumours implanted in immunosuppressed mice
regardless of xenograft success, 28 were p53 positive
giving an incidence of p53 mutation in primary tumours of
42%. This is in keeping with the 46% incidence of
mutations observed in a large set of unselected tumours
previously gathered by our group (Purdie et al 1991). The
lack of p53 mutations in 9 xenografts at passage 5 in
immunosuppressed CBA hosts differs significantly from this
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Figure 9 p53 immunocytochemistry with the mouse monoclonal
PAbl801. A; Rare positive nuclei in C280 xenograft (xlOO), B;
Positive adenocarcinoma control (xlOO).
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incidence in the primary tumours used for xenografting
(P< 0.05, Fishers exact test). In order to incorporate
p53 information from the preliminary passage history of
more recently established xenografts (for whom the
outcome is still unknown), standard life-table analysis
was performed. The 4 groups of xenografts (divided
according to p53 status and SCID or CBA hosts) , were
plotted in a single life table (fig ure 8). Log-rank tests
showed no significant effect of p53 status on the
survival of xenografts in either CBA hosts or SCID hosts
alone, but that when numbers (irrespective of host type)
were combined in a stratified test, the effect of p53
status on survival was significant (P<0.05).
Direct comparisons of the relative abilities of SCID
mice and immunosuppressed mice to support primary tumour
growth are available in 9 cases . For these 9 primary
tumours, the distribution of p53 mutations is shown in
table 7. Tumours carrying p53 mutations are distributed
evenly throughout the table. These results, however,
apply only to tumours which take, and the p53 bias
previously noticed was more pronounced at higher passage
numbers (figure 8).
Table 7 p53 expression for primary tumours xenoqrafted
into both SCID and immunosuppressed CBA mice
PAbl801 detection of p53
+ -
Growth in CBA mice only 0 0
Growth in SCID mice only 2 3
Growth in both mice groups 2 2
Growth in neither group 0 0
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For one p53 over-expressing tumour (JACA) which grew
to second xenograft passage in CBAs, sequence information
is available (courtesy of C Purdie). This case was of
extreme interest since codon 180 in exon 5 was found to
carry a mutation leading to an unscheduled stop codon,
causing the resulting truncated protein to conserve the
epitope detected by PAbl801. Stop mutations are not
commonly detected in the p53 gene. Furthermore, 1 of only
3 p53 mutated tumours ever to reach passage 3 is also
unusual in that staining is cytoplasmic rather than
nuclear.
Rare p53 positive nuclei were detected in many later
passage xenografts. The pattern of staining was unusual
and ambiguous in that positive nuclei always stained
faintly and were widely separated amongst a great
majority of negative cells. For comparison,
transplantable tumours derived from a cultured colorectal
cell line, C280 (see chapter 3), were studied. Although
rare positive nuclei were also observed in these tumours
(figure 9), the cells cultured in vitro were uniformly
negative. This occasional non-specific staining in
xenografts was therefore considered artifactual.
Within the xenograft set, 5 tumours showed either
loss of a 17p allele or mutation in the p53 gene but not
both together (table 8), despite their reported tight
linkage in colon cancers (Baker et al 1990a).
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2.4 Discussion
2.4.1 Xenografts provide a valuable experimental resource
The value of the xenografts described in this
chapter resides in their genotypic and phenotypic
stability, homogeneous tumour cell population,
differences from each other and capacity for growth after
storage at low temperature.
Stability in the xenograft of features present in
the primary tumour has been demonstrated at every passage
number and for each phenotypic and genotypic parameter
studied. This stability extends to tumours passaged for
over a year (and in one case for over 2 years), a
substantial proportion of the natural history of such
human tumours. Moreover, stability was unaffected by
storage in frozen form, with subsequent re-implantation
to mice. Since aneuploidy is detected by flow cytometry
in 60% of colorectal tumours and may be associated with a
mixture of specific and random rearrangements, it was
extremely gratifying that xenograft DI was never notably
different from that of its corresponding primary tumour.
In particular, it was demonstrated that xenografts
faithfully maintained primary tumour allelic status at
three relevant oncosuppressor loci.
The homogeneous tumour cell population of xenografts
depends on the entire replacement of the human stromal
component of the tumour with mouse stromal cells (Kopf-
Maier and Kestenbach 1990). Indeed, after passage of
tumour in mice during this study, Southern blots in which
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allele losses were detected showed immediate and complete
elimination of background alleles due to removal of
contaminating normal cells.
The variety of xenografts results from the inclusion
within the defined set of members with and without loss
of heterozygosity at oncosuppressor loci, diploid and
aneuploid members, and members with and without Ki-ras
mutations. The variety of lesions represented in the
xenograft set are summarized in table 8.
locations oof tumours
l°rv location 5a 17p 18a DI P53 Ki-ras
GRBO distal R R R 1.0 - +
RHSP distal L L L 1. 9 - +
JACA distal L L L 1 . 6 +
MUCO proximal R R R 1 . 0 - WT
CHKE distal R R R 1.2 - +
DABU proximal R R NI 1 . 0 - WT
MASM proximal R R R 1.0 - WT
JOMCL proximal R R NI 1 . 0 - WT
JOWR proximal R R R 1 . 0 + +
ARNE distal R L L 1 . 6 - +
AGDU* secondary R R R 1 . 0 + WT
CARO distal L L L 1 . 4 — WT
Total Incidences 27% 36% 44% 45% 18% 50%
Notes:
1) l°ry location= location of primary tumour in bowel
2) 5q/17p/18q= colon-associated oncosuppressor loci
3) DI= DNA index
4) p53 mutations were detected immunocytochemically and,
for GRBO and JACA xenografts, status was confirmed by
sequencing performed by C Purdie of this group
5) Ki-ras analysis was performed on PCR amplified DNA dot
blots with radioactive oligo probes for wild type and
mutated sequence, by S Lang of this group
6) R= retention of heterozygosity, L= allelic loss,
NI= non-informative
7) += mutated, -= no mutation detected,
WT= both alleles wild type
8) *= carcinoma of unknown primary origin
9) Total incidences refer to % loss for oncosuppressor
loci, % aneuploidy for DIs, and % mutated for
p53 and Ki-ras
10) AGDU lesions were not included in calculations of
total incidences (see note 8)
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The ability to preserve xenografted tumours at low
temperature is of particular practical significance. Not
only does this mean that tumours can be preserved without
continuing provision of host animals, but this process
converts each xenograft into a permanent renewable
resource for analysis.
2.4.1.1 Experimental uses for xenografts
The variety of renewable, uncontaminated, stable
tumours represented in this xenograft set makes them
outstanding material for colon tumour analysis.
Firstly, in culture, they will provide uniquely
favourable vehicles for proposed tests of oncosuppress or
gene function discussed earlier and in chapter 5.
Secondly the xenografts provide ideal material for
gene mutation analysis. It is imperative in PCR studies
that tumour specific sequences are not contaminated with
corresponding sequences from non-tumour cells. In
particular, mutations in the recently identified APC gene
may be particularly cumbersome to find owing to the
enormous size of the gene predicted by its 9.5Kb
transcript (Kinzler et al 1991b). The renewable purified
tumour xenografts will facilitate simpler identification
of sequences without the risks of contamination with non-
tumour sequences, or exhaustion of the tumour resource.
Xenografts also permit the analysis of tumours with large
stromal components which are often uninterpretable in
primary tumour studies due to the extent of human stromal
contamination. This contamination is removed in the
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xenograft so that the human tumour genotype can be
ascertained without ambiguity. Moreover, after
characterizing specific mutations in tumour xenografts,
possibly in combination with those at other loci, the
associated tumour biology can be observed in vivo against
the background of a whole organism showing far less
individual variation than human patients. The variety of
genotypes and phenotypes represented in the xenograft set
will allow a number of combinations to be addressed. The
study of DCC mutations in the xenografts described here
is already under way in Dr B Vogelstein's laboratory.
Finally, by virtue of any of the described
properties of the xenograft set, they may become useful
in diverse and unpredictable studies. The replacement of
the stromal component of the tumour with that of the host
may allow analysis into stromal-tumour interaction. New
genetic tumour associations may come to light or local
environmental effects on tumour biology may be
discovered. Regardless, the variety of stable, renewable,
pure tumour cells growing in the xenograft set will be
readily available for analysis.
2.4.2 Xenografts are representative of colorectal tumours
The variety of genetic lesions present within the
xenograft set are broadly representative of those
observed in unselected primary carcinomas. Incidences of
these lesions, derived from large series of primary
tumours studied in Edinburgh or elsewhere, are compared
in table 9 with those in the xenograft set.
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Table 9 Genetic lesions of colorectal cancer
% Incidence from (n) tumours
Lesion xenografts primary Reference(et al)
18q allele loss 44% (9) 73% (56) Vogelstein 1988
17p allele loss 36% (11) 75% (60) Fearon 1987
5q allele loss 27% (11) 42% (194) Ashton-Rickardt 1991
p53 mutation * 18% (11) 46% (86) Purdie 1991
Ki-ras mutation 50% (10) 40% (104) This group unpub.
Notes:
* = detected immunocytochemically
unpub.= unpublished
The combinations of allelic loss detected in the
xenograft set are representative of those combinations
detected in large numbers of unselected carcinomas as
described by Delattre et al 1989. Delattre found tumours
to frequently divide into 2 clear groups: tumours with
severe aneuploidy and coincident LOH at more than one
locus which were significantly associated with a distal
location in the bowel, and a diploid group rarely showing
LOH which were most often found to be proximal tumours.
In agreement with this, 10 of the 11 primary tumours
within the xenograft set were either proximal and diploid
(5) or distal and aneuploid (5). All of the proximal
tumours showed retention of heterozygosity at all 3
studied loci while 4 of the 5 distal tumours showed LOH
at more than 1 site.
While tumours showing co-incident allele loss may
have arisen through accumulation of lesions in the
adenoma-carcinoma sequence (Fearon and Vogelstein 1990),
those without allele loss or aneuploidy must have arisen
by alternative mechanisms. The xenograft set therefore
supports the evidence for a model of colorectal cancer
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which allows for divergent pathways of tumorigenesiss,
such as depicted in figure 1. Ki-ras mutations fall
equally into both groups suggesting this lesion to be
determined by mechanisms independent of those involved in
LOH and aneuploidy.
2.4.3 Selection against xenografts carrying p53 mutations
Selection of primary tumours is to some extent
inevitable in this study since all tumours included were
required to grow as xenografts in immunosuppressed mice.
Faster growing tumours will be favoured in these
circumstaances since, as discussed in the introduction,
some degree of host immunorecovery is observed making
slower growing tumours, therefore, vulnerable to
rejection. An unexpected finding, however, was the fact
that within the xenograft set no continuously passaging
tumour carrying a p53 mutation has grown in
immunosuppressed mice despite their reported growth in
congenitally athymic nudes (Nigro et al 1989).
Furthermore, the survival of tumours carrying p53
mutations is significantly poorer than those without in a
combined group of CBA and SCID mice, despite many with
p53 mutations surviving at the currently available low
passage numbers in SCID hosts.
The take rate discovered in this work for colorectal
adenocarcinomas in SCID mice is greater than twice that
found by ourselves and others in CBA and nude mice
(Houghton and Taylor 1978, Lefrancois et al 1989). Such
increased receptivity may be attributed to the increased
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severity of the immune deficiency in SCID mice (Bosma et
al 1983).
Since p53 mutations appear to disable tumour growth
in all hosts, but apparently moreso in those with less
severe immune defects, it may be suggested that the
ability to sustain p53 over-expressing tumours is related
to the severity of the immune defect. Implicit in this
suggestion is the assumption that such tumours are more
immunogenic than tumours expressing wild-type p53. The
accepted nuclear location of the p53 protein does not
preclude the existence of immunogenic cell surface
epitopes specifically associated with aberrant p53. The
existence of such epitopes would have important
therapeutic implications, particularly when one considers
the wide range of tumours known to sustain p53 defects.
However, a metastatic carcinoma of unknown primary
origin (AGDU) was observed to over-express the p53
protein over 5 xenograft passages. The most likely
primary origin of AGDU is now thought to be breast. It is
possible that the nature and effects of p53 mutations
associated with breast cancer may vary from those in
colon tumours, or that this tumour carried a rare variant
of mutation not leading to immunogenicity. Indeed, the
sequence of one of the few p53 expressing colonic tumours
which grew briefly in xenograft was found to carry an
unusual mutation leading to a truncated protein, where
the majority of mutations lead to full length proteins
with altered conformation. However, the rare growth of
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xenografted p53 expressing tumours may indicate that
selection is occurring, not against mutated p53. but
against associated events in colonic tumours.
Within the passaging set in immunosuppressed CBA
mice there is a preponderance of mucinous carcinomas
(table 4). Mucinous carcinomas are observed to be less
p53 immunoreactive to the antibody used in this study
than other adenocarcinomas (Campo et al 1991). Lack of
p53 mutated xenografts may therefore be a secondary
effect of their lack of association with mucinous tumours
whose prominence in the CBA mice xenograft set, may be
trivially explained in terms of growth rate. The majority
of tumour tissue implanted becomes degenerate on
implantation while host fibroblasts invade the area
(Kopf-Maier and Kestenbach 1990). Only then do tumour
cells close to the stromal cords start to divide and does
the tumour regenerate. Logically, a smaller number of
cell divisions in conjunction with copious mucin
secretion is required to regenerate a tumour of mucinous
histology than the number of divisions required to
regenerate more densely populated tumours. Mucinous
tumour growth can therefore be achieved considerably
faster than that of more poorly differentiated types
which may become growth limited by host immunorecovery.
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Chapter 3: Characterizing established lines
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3.1 Abstract
Establ ished colorectal cell lines were characterized
as immediate experimental resources. While findings
helped to justify our main strategy of deriving new
lines, the established lines nonetheless had interesting
properties.
5 of the lines, deriving from studies on sporadic
colorectal tumours in Nottingham, were shown by genetic
analysis to represent a single fast-growing line. After
confirming its colorectal epithelial nature, the cells
were shown to include a heterozygous Ki-ras mutation,
retain heterozygosity at oncosuppressor loci on 17p and
18q, and probably have lost an allele at 5q21. The line
was clonable and highly malignant in animals, showing
local infiltration and lymph node metastases. This line
is therefore suitable for genetic manipulations involving
functional tests of exogenous oncosuppressor genes.
Genotypic studies were also conducted in a separate
series of human colorectal cell lines from Bristol. These
were originally derived from an adenoma of a FAP patient
and had been exposed in vitro to a variety of agents
resulting in increased tumorigenicity. Coincidental with
appearance of tumorigenicity, there arose unusual allele
losses and imbalances, all remarkably at key loci on 5q,
17p, 18q and Ki-ras. This emphasises the importance of
these sites in colorectal cell growth, even in vitro, and
so highlights the significance of their stability in the
newly derived lines described in chapter 2.
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3.2 Introduction
In the previous chapter the generation of colorectal
adenocarcinoma xenograft lines with defined and stable
genotype relative to the patient of origin are described.
Although successful, the process of line generation is
slow as is growth in vitro of these lines. Growth in
vitro is a pre-requisite for genetic manipulation
exper iraents. In order to start to define the parameters
and methods for gene transfer in colonic epithelial
cells, and to explore existing resources, some existing
human colorectal lines were analysed. For this purpose
cell lines were chosen which had been established within
the past 4 years, and for which there was a possibility
of defining the genotype of the patient of origin. I am
grateful to Dr LG Durrant of Nottingham University and Dr
C Paraskeva of Bristol University for kindly supplying
these lines.
3.2.1 Nottingham lines
The cell lines from Nottingham, C146, C168, C224,
C27.7 and C280 were all established 1-2 years previous to
this study (Durrant et al 1986, Durrant et al 1987). They
were derived from primary colorectal carcinomas by growth
in soft agar in order to isolate stem cells for
experimental immunotherapy, and had been characterized
with a number of antibodies. They had all been shown to
express the tumour associated antigens expressed on
colorectal carcinoma cells which are recognised by the
monoclonal antibodies C14 and 719T/36 (Durrant et al
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1987). CAM5.2, which recognises cytokeratin, was also
used to confirm their epithelial origin. Two of these
lines, C146 and C168 were further defined in terms of DNA
content, proliferative capacity and tumorigenicity
(Durrant et al 1986). Although constitutional DNA of the
patients from whom the original primary tumours came had
not been sampled, some of these patients were known to be
alive, and were thus available for sampling if necessary.
3.2.2 Bristol lines
The cell lines from Bristol were all derived from a
single line (PCAA) established, 4 years prior to this
study, from an adenoma of a familial adenomatous
polyposis patient (Paraskeva et al 1984). Various
selection pressures were placed upon this line to
generate altered sublines with more aggressive growth.
The purpose of deriving these lines was to provide a
model for studying the changes associated with
progression from adenoma to carcinoma. A summary of the
events involved in this progression is illustrated in
figure 10.
In brief, the original PCAA cultures were passaged
in vitro until an immortalized subline emerged (Paraskeva
et al 1988). On further continuous passage sublines
appeared in which the cells became aneuploid and adopted
the morphology of a transformed phenotype. On continuous
passage these cells became tumorigenic in nude mice (C
Paraskeva, personal communication). Meanwhile, a rare
clonogenic variant (AAC1) isolated from the early passage
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Figure 10










































diploid line was also found to be aneuploid and, after
sodium butyrate treatment, gave rise to cells with an
increased colony forming efficiency on plastic. Sodium
butyrate was chosen since butyric acid is a naturally
occurring fatty acid produced by the intestinal flora,
and has been shown to induce differentiation. There may
therefore be a link between the production of this
substance and dietary factors implicated in colorectal
cancer. It is interesting to note that in this experiment
the cells pre-treated with sodium butyrate became
insensitive to growth inhibitory effects on further
treatment with the same concentration and less sensitive
to higher concentrations, and that this phenotypic change
represented a stable event since the resulting increased
colony forming efficiency was maintained throughout the
study. These cells however remained anchorage dependent
as determined by colony forming efficiency in soft agar,
and non-tumorigenic in mice. Subsequent treatment with
the potent carcinogen N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG) did yield an anchorage
independent line which on continuous passage finally
became tumorigenic in mice (Williams et al 1990). MNNG
treated cells which had not been exposed to sodium
butyrate (but otherwise parallel in their passage
history) were not tumorigenic. This observation
reinforces the idea that the sodium butyrate treatment
represents a stable and necessary change in this pathway
of progression.
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The aims in developing these altered sublines in
culture were thus the converse of the aims described in
chapter 2 of this thesis. Rather than demonstrating
stability of phenotype and genotype, the Bristol lines
were treated expressly in order to elicit alterations.
The colonic epithelial origin of these lines had
been confirmed by staining with an antibody to epithelial
keratin filaments, and also by the ultrastructural
presence of desmosomes, microvilli and mucin droplets.
Minisatellite DNA probes were used in Bristol to confirm
derivation of all lines from a single stock. No
karyotypic abnormalities were detected in the original
diploid line cytogenetically although it was known to
carry a Ki-ras mutation (Farr et al 1988) . Because the
patient of origin had familial polyposis at least one
aberrant copy of the APC gene on chromosome 5 must be
present constitutively. Constitutional DNA had also been




3.3.1.1 Nottingham lines are highly suitable for cloning
These cells were small, refractile and pleomorphic
in appearance. They grew under standard conditions in 10%
NCS and were passaged by the one step trypsinisation
method described in chapter 7. They grew rapidly
requiring frequent splitting at high ratios (at least
1:10 once a week). Clonal outgrowth from single cells
after trypsinisation was routine. All lines were alike in
these repects.
3.3.1.2 Nottingham lines are highly tumoricrenic
From each cell line, 107 cells were injected sub-
cutaneously into each of 3 immunosuppressed mice. 20 days
after injection large infiltrative tumours were removed
from every mouse but one. Tumours produced by all 5 lines
were histologically indistinguishable. All were poorly
differentiated and often infiltrated the underlying
muscle and connective tissue. Necrosis was evident as was
a high cell turnover indicated by many mitotic and
apoptotic bodies. In the case of tumours which had
penetrated the full thickness of the peritoneum,
secondary masses and enlarged lymph nodes were seen.
Although secondary tumour masses were confirmed
histologically, examination of heart, lung and liver in
each case showed no distant metastases. The histology of
these tumours is shown in figure 11.
3.3.1.3 Nottingham lines are epithelial and glandular
In view of the extreme similarity between phenotypes
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Figure 11 Poorly differentiated histological pattern of
C280 cells growing as xenograft (xlOO).
Figure 12 Electron microscopy of C280 xenograft showing
conservation of epithelial cell markers. A; A variety of basal
cell junctions including desmosomes (xl7000), B; Luminal
microvilli and a variety of junctions (xl3600).
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of all 5 lines only one, C280, was prepared for electron
microscopy. Although histologically no cell polarization
or gland formation could be seen, organised groups of
polarised microvillous cell surfaces surrounding small
luminal spaces were seen by electron microscopy (figure
12). Exocytosis of microvesicles into the lumen from
these microvillous surfaces was also noted. Belt
junctions and desmosomes were prominent throughout the
specimen, confirming the epithelial origin of this line.
3.3.1.4 Nottingham lines share the same genotype
To ascertain whether these cells had retained
heterozygosity at colon-associated loci, RFLP analysis
was carried out using the probes Pi227, L5.62, L5.71,
EF5.44, YN5.48 for chromosome 5; YNZ22 and MCT35.1 for
chromosome 17 and BV15.65 for chromosome 18. The
conditions for usage of these probes [table 17a) and
17b)] and some of the patterns detected and examples of
allelic losses and retentions [figure 30] are shown in
chapter 7.
Allelic status detected for the DNA of these lines
was identical for every probe tested on each of the
samples. DNA was made and probed for each line on 2
separate occasions, both yielding the same result. These
results are shown in table 10.
Allele frequencies for all the chromosome 5 probes
used excepting L5.71 are available (Dunlop et al 1990),
and L571 allele frequencies were scored from a series of
over 100 patients presenting with colonic or lung
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Table 10 Alleles detected in Nottingham lines
chromosome 5 chrom 17 chrom.
LINE Pi 2 2 7 L571 L562 EF544 YN5 4 8 MCT3 5 YNZ2 2 BV1565
C146 A2 A1 A1 A1 A2 A1 A1A2 A1A3
C16 8 A2 - - A1 A2 - A1A2 A1A3
C224 A2 - - A1 A2 - A1A2 -
C227 A2 A1 A2 - A1A2 -
C280 A2 A1 A2 A1 A1A2 A1 A3
Notes:
1)-= not done.
2) Where the DNA was found to be homozygous with a probe,
only one allele is shown since the case may in reality
be homozygous or hemizygous.
cancers, from whom constitutional DNA was probed by
various members of this department. These allele
frequencies are included in table 17 in chapter 7.
With respect to the probe EF5.44 the single allele
carried by all lines is found in the population at a
frequency of only 0.18. The probability that 5 different
unrelated patients carry this allele is therefore 0.185,
which is less than 2 in 10000. The respective
probabilities of 5 unrelated patients carrying the
alleles shown at Pi227 and YN548, of 3 patients carrying
the alleles shown at BV1565, and of 2 patients carrying
the MCT35 allele shown are; 0.465, 0.555, (2x 0.17x
0.49)3, 0.75*•. The combined probability of observing the
identical genotypes shown in table 10 in 5 unrelated
patients is 5.09x 10-10 , or 5 in ten thousand million. It
can therefore be assumed beyond all reasonable doubt that
all 5 represent a single line. Reassuringly, the
identical bands detected by these 8 probes were of the
expected sizes indicating this cell line to be of human
origin. The line was henceforth designated C280.
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C280 was found by flow cytometry to have a diploid
DNA content.
By immunocytochemistry (using the mouse monoclonal
human specific antibody PAbl801) faint, scattered p53
positive nuclei were detected in xenografts of this line
(figure 9). This pattern was similar to that previously
noticed for some primary tumour xenografts (chapter 2).
However, fixed preparations of C280 cultured cells in
agar were unambiguously negative when stained for p53,
despite the positivity of a control line prepared by the
same method. Faint, scattered positive nuclei detected in
xenografts were accordingly considered to be artifactual.
3.3.2.1 Genetics of Bristol lines: specific 5ct21 change
DNA was studied from cell lines at various stages of
the progression of the adenoma derived PCAA line to the
tumorigenic lines PCAA86 and AAC1SB10. RFLP analysis was
carried out using the probes LI.4, MLZ74, Pi227, L5.62,
L5.71, EF5.44, YN5.48, MC5.61 and lamdaMS8 for
chromosome 5; YNZ22 and MCT35.1 for chromosome 17, YNH24
for chromosome 2, EFD64.2 for chromosome 3 and EFD75 for
chromosome 10. The conditions for usage of these probes
[table 17a) and 17b)] and examples of allelic losses and
retentions detected [figure 30] are shown in chapter 7.
In the results to follow, the DNA samples from
different sublines were numbered 1-10 for simplicity, as
indicated in figure 10. In summary clone 1 represents the
early passage diploid cells, clone 2 the spontaneously
transformed line, clones 3 and 4 are aneuploid clonogenic
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variants, clones 5-8 represent non-tumorigenic cells
after sodium butyrate treatment and 9 and 10 are taken
from cells cultured after growth as tumours in animals.
For each probe, the ratio of intensities of
hybridising bands was confirmed by quantitative scanning
densitometry and these results are shownn in table
11. With some probes, bands were detected which were not
predicted by the known allele size. In all cases these
unexpected bands were shown, by re-probing filters with
labelled pBR322, to be due to contaminating plasmid in
the DNA.
Within the DNA set, 2 kinds of changes in allele
ratio were observed. The first category of changes
involved most probes and constituted transient variations
in allele ratio which were not maintained in samples from
subsequent stages of the progression. Such random
variations were probably due to the arisal of transient
subpopulations within the cultures.
In contrast, the second category of changes was
noted only with certain probes. In these cases, a
consistent bias in allele ratio was seen at later stages
of the progression which was not evident in preceding
samples. With the probes L5.71 and YN5.48 in particular,
clones 5-10 showed increased intensity of allele 2 in
comparison with allele 1, whereas clones 1-4 showed
roughly equivalent ratios of allele intensity (figure
13). Clones 5 and onwards represented cells treated with
sodium butyrate and thereafter throughout the progression
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Table 11 Allele ratios of PCAA DNA (chromosome 5)
PCAA Probe (location on chromosome 5)
DNA LI. 4 MLZ74 Pi227 L5 .62 *—1r-in►-3 EF 5.44 YN5.48 1MS8
5pf 5ac 5q21 5a21 5a21 5a2 1 5a2 1 5qt
1 NI 0.9:1 1:0.8 1.9:1 ND NI ND ND
2 NI 2.5:1 1:0.7 ND ND NI ND 0.9:1
3 NI 1.1:1 1:1.1 2.3:1 1.2:1 NI 1.3:1 1.6:1
4 NI ND 1:1.4 ND 1.0:1 NI 0.5:1 ND
Mean 1.5:1 1:1.0 2.1:1 1.1:1 0.9:1 1.3:1
s. d 0.7 0.3 0.2 0.1 0.4 0.4
5 NI 1.3:1 1:1.0 3.7:1 1.9:1 NI ND 0.4:1
6 NI 0.2:1 1:1.2 2.6:1 1.7:1 NI 2.0:1 1.0:1
7 NI 0.8:1 1:1.4 4.3:1 ND NI 4.9:1 1.2:1
8 NI 0.4:1 1:1.6 ND 1.6:1 NI 2.3:1 0.7:1
9 NI ND ND 3.8:1 2.1:1 NI 3.0:1 ND
10 NI 1.0:1 1:1.1 ND 2.7:1 NI 2.0:1 ND
Mean 0.7:1 1:1.3 3.6:1 2.0:1 to 00 h-* o oo M
s.d 0.4 0.2 0.6 0.4 l. 1 0.3
(continued) Allele ratios of PCAA DNA (other sites^
PCAA Probes (chromosomal location1
DNA YNH2 4 EFD64.2 EFD75 YNZ2 2 MCT35.1
111 111 (10) d7p) (17P)
1 ND NI ND 1:1.0 ND
2 ND NI 2.1:1 ND ND
3 o 00 • NI 0.2:1 1:1.5 0.5:1
4 ND NI ND ND ND
Mean 0.8:1 1.1:1 1:1.2 0.5:1
s.d 0 0.9 0.2 0
5 ND NI 0.8:1 1:5.2 ND
6 0.8:1 NI 0.8:1 ND ND
7 0.5:1 NI 1.5:1 1:3.8 1.6:1
8 0.5:1 NI 1.1:1 ND 2.7:1
9 ND NI ND ND ND
10 ND NI 1.0:1 1:3.3 3.3:1
Mean 0.6:1 1.0:1 1:4.1 2.5:1





4) PCAA DNA 1-10= clones 1-10 in progression (figure 10)
5) NI= non-informative (homozygous)
6) ND= not done
7) MLZ74 constant allele excluded
8) L562 relative intensities for paired smaller alleles
added and used as one allele
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but not the spontaneously transformed example (clone 2).
Although this bias in allele ratio at clone 5 was
consistently seen throughout subsequent samples with
these 2 probes, no corresponding chaange was detected by a
subtelomeric probe on the same chromosome arm (lambda
MS8) or with the probe Pi227 which lies less than 15Mb
centromeric (figure 13) . In view of the surprising nature
of this observation Pi227 results were confirmed by
densitometry on 4 different autorads none of which gave
notably different results from those shown. For DNA from
before the stable phenotypic change associated with
sodium butyrate treatment, mean allele ratios (and
standard deviations) for the 4 ordered probes Pi227,
L571, YN548, lamdaMS8 were; 1: 1.0 (0.3), 1.1 (0.1), 0.9
(0.4), 1.3 (0.4) respectively. For DNA from cells after
this change, mean allele ratios (and standard deviations)
for the same 4 probes were 1: 1.3 (0.2), 2.0 (0.4), 2.8
(1.1), 0.8 (0.3) respectively. The allele imbalance
consistently seen for the 2 middle probes after sodium
butyrate treatment, did not therefore extend to flanking
regions. The consistency and specificity of the
rearrangement imply duplication of a region of 5q21-22
and selective maintenance of this duplication thereafter.
Similarly, chromosome 17p probes detected a 3-5 fold
increase in the presence of one allele after sodium
butyrate treatment (table 11). Probes to other non
tumour-associated loci on chromosomes 2, 10 and 5p did
not show consistent rearrangements (table 11). The
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pattern detected by a chromosome 10 probe is shown in
figure 14.
3.3.2.2 Genotypes show PCAA constitutive DNA to be wrong
In the course of this work DNA was supplied to us
from fibroblasts of the patient from whose polyp PCAA was
derived. On Southern blot analysis it soon became
evident, however, that this DNA could not derive from the
same patient as PCAA, since different alleles
(incompatable with a shared origin) were detected by many
of the probes (particularly VNTR sequences where many
alleles are possible). Further studies with minisatellite
probes in Dr C Paraskeva's laboratory confirmed this
disturbing finding. It would appear that at some point
prior to the material being sent to Edinburgh, the donor
fibroblasts had been lost and replaced accidentally by
cells of another patient.
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3.4 Discussion
3.4.1 Results support the strategy of this thesis
The characterization of established lines described
in this chapter highlights some of the problems
associated with the use of long-established lines as
models of colorectal cancer. It is clear from our work
that the 5 Nottingham lines had all been colonised by a
single cell type. Without this identification the cells
would be considered to be 5 different lines with similar
phenotype, and characteristics peculiar to this line
wwould be erroneously taken to be common characteristics
of colonic cell lines. Unintended cross contamination of
cultures by fast growing cell lines is well known but the
fact that this had happened without being recognised
before the lines came to Edinburgh raises doubts as to
the true identity of these cells. Similarly, the Bristol
lines- although initiated from a known patient- in the
end fell short of expectation in that no constitutional
DNA resource could be provided and the patient (a private
patient from Turkey) was lost to follow-up. Despite these
drawbacks, however, both lines possess useful features,
and some of the missing information can be deduced from
the studies described here.
3.4.2 Further identification of the Nottingham line
DNA finger-printing was considered in order to
establish the true origin of this line. Although
possible, the tracing of patients, blood collection and
analysis involved would have been at some personal
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discomfort and expense to the 5 patients and our
Nottingham colleagues. Moreover the possibility remained
that the dominant line came from yet another source
again, as it had grown out at an unspecified time after
establishment of the cultures, and during a period when
multiple colorectal lines from different patients were
being initiated and grown. The line's colorectal
carcinoma origin was not in doubt since this was the only
tissue type being handled in the Nottingham laboratory.
Furthermore, we confirmed its human origin by detecting
human alleles in RFLP analysis, and its epithelial origin
was confirmed by electron microscopy. Previous
cytochemical evidence had also confirmed a colonic
origin. As an alternative to a possibly fruitless search
for constitutional DNA it was considered worthwhile to
compute the probability of allele status by less direct
means.
The line clearly conserves both alleles in 17p and
18q and is near diploid. In 5q, however, it is notable
that none of the 5 probes detected heterozygosity. There
are 2 possible explanations for this; either the line is
constitutively homozygous at all 5 loci or allele loss
has occurred. As already mentioned, allele frequencies
are known (table 17), and can be used to calculate the
probabilities of genotypes. The probability of being
homozygous for any one allele is the square of its
frequency, which for the 5 loci involved calculate as;
0.21, 0.87, 0.16, 0.03, 0.30. The product of these
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frequencies gives the probability of co-incident
homozygosity at all 5 loci and is 2.63x10-^, or less than
3 in 10,000. Such a low probability for the detected
genotype constitutionally suggests that this cell line
has sustained an allelic loss on 5q. This calculation
assumes the absence of linkage groups such that
homozygosity with any one of these markers does not
increase the likelihood of homozygosity with any other.
Such an assumption seems reasonable from the experience
of our laboratory of over 200 patients studied with
probes in 5q21. While the recent isolation of both the
MCC and APC genes on 5q will in the near future allow
specific definition of any mutations present, the
currently known status of this colorectal epithelial line
is shown in table 12.
Table 12 Genetic lesions of C280
Lesion C280




p53 Not detected by immunocytochemistry
Ki-ras Heterozygous mutation
Notes:
1) 5q,17p and 18q represent oncosuppressor loci
2) DI= DNA index as measured by flow cytometry
3) Ki-ras mutation was detected by PCR DNA amplification
and sequencing by the method of Sanger, carried out
by P Romanowski of this group.
3.4,3 Nottingham line is useful for genetic manipulation
This colonic epithelial line is rapidly growing and
easily clonable and will therefore be useful for gene
transfer studies. Analysis of the effects of introduction
of exogenous oncosuppressor genes will be particularly
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suited to this line owing to its aggressive
turaorigenicity in imraunodeficient mice. The preceding
characterization will make experiments to replace the
proposed lost MCC and APC genes, or to specifically
target and disable the retained p53 and DCC genes,
particularly informative.
3.4.4 Specific changes at critical loci in Bristol lines
Bristol lines which had progressed from benign
colorectal cells to a tumorigenic cell line were selected
in vitro. Multiple genetic changes associated with this
altered phenotype were of 2 types; transient changes
presumably representing subclones with no growth
advantage, and changes that persist in a stable manner.
The striking finding of this investigation is that
these stable changes, selected for in the artificial
environment of in vitro culture, involve the critical
loci affected in human colorectal carcinogenesis; 5q,
17p, 18q and Ki-ras.
Since the adenoma derived cell line PCAA originates
from a patient with Familial Polyposis Coli where one
defective APC gene is assumed to be present by
inheritance, it is interesting to note that progression
to carcinoma appears, in this case, to have involved a
stably maintained acquired allele imbalance in the
immediate vicinity of the APC and MCC loci. Indeed, the
probe L5.71 which detects the rearrangement has recently
been shown to lie within the open reading frame of MCC
(Kinzler et al 1991a), while the APC gene is included in
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the region of DNA between this probe and YN5.48 (Kinzler
et al 1991b) which is also involved in the rearrangement.
During tumorigenesis in situ. oncosuppressor genes such
as APC are thought to undergo somatic loss or
inactivation, and not amplification. Gross changes seem
not to be necessary in vitro since the independent
spontaneous progression to PCAA86 (clone 2) tumorigenic
cells shows no detectable changes in allele copy number
(although small rearrangements and point mutations cannot
be ruled out). However, the selective maintenance of the
5q21 rearrangement in AAC1SB10 cells (clones 7,9 and 10)
does suggest its crucial importance, at least in this
pathway, to the tumorigenic phenotype. The apparent
duplication demonstrated here during progression in vitro
may represent an increase in relative copy number of the
pre-requisite aberrant copy of the APC gene, and thereby
illustrate a gene dosage effect. Perhaps an excess of
mutant protein may act in a dominant-negative fashion
sequestering wild type protein and disrupting normal
function, ultimately permitting tumorigenic behaviour.
Unfortunately, no DNA is available from other family
members, precluding rapid discovery of the phase of the
inherited defect.
It was previously noted that the phenotypic changes
associated with sodium butyrate treatment of this cell
line represented a stable event involving acquired
resistance to growth inhibition after further treatment,
and an increased colony forming efficiency throughout the
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duration of study (Williams et al 1990). It is
interesting to note that diminished response to this
proposed differentiating agent (which is a normal
constituent of bowel lumen contents) should be associated
with altered gene copy number around the APC and the MCC
loci. Xn situ. a single copy of defective APC is
permissive for the generation of large numbers of polyps
while reduction to homozygosity at this locus is
associated with the occurrence of tumours. Furthermore,
MCC is reported to bear similarity to the neural cell
adhesion molecule. Should this gene be involved in cell-
cell contacts as has been suggested, its disruption or
over-expression could easily lead to alterations in cell
differentiation.
An allele imbalance in 17p, probably including the
p53 locus, was also detected after sodium butyrate
treatment (clones 5-10). Although p53 over-expression
(detected by western blots) increased at stages
throughout the progression, no mutation has been found,
to date, in any of the 4 hot-spots (C Paraskeva,
personal communication). While mutation elsewhere in the
gene remains a possibility, the observed 3-5 fold
increase in copy number may alone be responsible for this
phenomenon.
PCAA and AAC1 cells (clones 1,3 and 4) have been
shown karyotypically to have only one chromosome 18,
whereas the highly tumorigenic AAC1SB10 cells (clones 9
and 10) have lost both normal chromosomes. However, a
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translocation has occurred involving chromosomes 1 and 18
and cells, even at later stages, do express some DCC
sequence (C Paraskeva and B Vogelstein, personal
communication). This translocation may also involve a
rearrangement on the short arm of chromosome 1, detected
as a novel sized allele in association with tumour
progression (A Williams,, personal communication).
Although PCAA27, PCAA86 and AAC1 are heterozygous
for a Ki-ras mutation, AAC1SB10 cells are homozygous for
the mutated allele (C Paraskeva and C Marshall, personal
communication). This outgrowth of a population of cells
with allele loss at Ki-ras is unexpected since Ki-ras
mutations are thought to be dominant and effective
despite the presence of the remaining wild type copy. The
observed allele loss gives rise to the unusual suggestion
that a further growth advantage is attained by
elimination of normal Ki-ras function. This idea gains
support from other work. In carcinogen induced mouse skin
tumours, the loss of wild type alleles in tumours
heterozygous for H-ras mutations has been clearly
associated with tumour progression (Bremner and Balmain
1990) .
It is striking that stable rearrangements were not
observed at loci on chromosomes 2> 5p, and 10, chosen for
lack of implication in tumour growth (figure 2). Instead
stable changes appear to specifically involve colon
tumour-associated sites. Epidemiology from such diverse
populations as Japan and the U.S.A. implicates the same
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small group of key genes as central to colorectal cell
growth control. This subset of genes is implicated
despite different dietary and other risk factors, and
large variations in disease incidences and trends be tween
populations. The specific involvement of the same genes
even under the artificial conditions of cell culture is
re markable and points strongly to the critical nature of
these genes in defining colorectal cell behaviour. It is
therefore reassuring and significant to note the
stability of such critical genes demonstrated in long-
passaged tumour xenografts in chapter 2.
3.4.5 Bristol lines demonstrate that 5ct21 is responsive
The duplication and specific maintenance of a 5q21
region, containing the APC and MCC genes, occurred in
association with acquisition of tumorigenicity. This
finding has important implications for the future aim
described in this thesis of in. vitro analysis of
oncosuppressor genes. While evidence exists that t>53
(chapter 1) and DCC (Fearon, unpublished) have effects on
colorectal tumour-derived cells in culture, evidence for
APC function comes only from weak effects on transfection
into mouse fibroblasts (Hushino et al 1991), and its
inferred involvement in polyposis and tumorigenesis. The
specific 5q21 change described in association with
acquired tumorigenicity of colorectal epithelial cells in
culture, although accompanied by changes at other sites,
does provide evidence that functionally important genes
residing at 5q21 have detectable effects in vitro.
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3.4.6 Bristol lines are suitable for replacement of AAPC
Tumorigenic cell lines within this set grow clonally
and will be useful for manipulation and cloning
experiments to test oncosuppressor genes. Since all cell
lines retain heterozygosity at 5q21, they must carry the
inherited defective copy of APC. According to the gene
dosage hypothesis previously mentioned, this defective
copy may be duplicated and the excess aberrant APC
protein product may influence the phenotype. All
mutations reported to date in the APC gene result in
unscheduled stop codons (Groden et al 1991), leading to
truncated and presumably non-functional protein. The
selective increase in mutant gene copy number proposed
for the cell line AAC1 suggests that the mutation carried
in this APC gene results in a functional protein and is
therefore an interesting mutation for study. On the other
hand the inherited APC mutation may abrogate function and
bear no significance to the selective 5q21 duplication
seen, but somatically acquired mutation of the MCC gene
may have a dominant effect leading to selection for the
observed rearrangement. In either case the situation will
be clarified by sequence information and consequent
characterization of mutations at either or both loci.
According to the nature of the specific 5q21
mutations involved in this rearrangement a number of
possibilities exist for informative genetic manipulation
experiments. For example, should the defect reside at the
APC locus alone, specific replacement with the wild type
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gene by gene target replacement vectors should result in
either no change due to replacement of the endogenous
wild type copy, or a return to the unrearranged 5q21
status by replacing one of the defective copies. In the
latter situation phenotypic effects specific to the 5q21
rearrangement would be apparent since none of the co¬
inciding rearrangements would be reverted. Should
mutations be detected in both genes, their functional
significance can be tested by replacement firstly of
either alone and then of both together with wild type
genes. Numerous other permutations of specific
replacement or disablement of colon-associated genes will
also be possible and informative.
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Chapter 4: In vitro biology of primary cell cultures
100
4.1 Abstract
Growth in. vitro was demonstrated for 8 xenografted
tumours. Unlike the original human tumour tissue, such
xenografts are free from microbial contamination, do not
contain human stromal cells and provide a stable
renewable resource for repeated culture attempts. The
cultures established in vitro had an epithelial
morphology with one exception, which proved to be a
transformed fibroblastic line of non-human (presumably
murine) origin. The epithelial cultures displayed
individual morphological characteristics. However, most
grew very slowly, some were non-progressive and none was
cloned. A number of factors were added to or varied in
culture in an attempt to assist growth. Although no vital
missing factor was discovered, stable xenograft resources
will allow an unlimited further search.
2 cultures were expanded sufficiently in vitro to
allow re-implantation into immunodeficient mice,
producing adenocarcinomas with similar histology to the
original primary tumours and xenografts. For 1 of these
cultures genetic analysis showed the reimplanted tumour
to retain its DNA diploid status as well as allelic
status on 5 separate chromosomes including the three
oncosuppressor loci on 5q, 17p and 18q. Such stability
over short periods in culture may be valuable in future
experiments to assay in vitro the effects of replacement
or manipulation of these genes.
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4.2 Introduction
A number of factors require attention during
derivation of colonic cancer epithelial lines. Problems
fall into three broad categories; microbial
contamination, stromal overgrowth, and cell requirements,
both nutritional and environmental.
4.2.1 Microbial contamination
Due to the abundant microbial flora in the bowel
lumen, all tumour tissues taken for culture contain
micro-organisms. In order to prevent their co-culture
with the epithelial cells, it is necessary to pre-
incubate or wash the fresh specimen vigorously in an
antibiotic cocktail and to grow primary cultures in an
antibiotic rich medium. In addition to this, by first
xenografting tumours into immunodeficient animals, low
level contamination may be eradicated by the non-specific
immunity (macrophages, neutrophils and complement) of the
host.
4.2.2 Stromal over-growth
Efforts to retain clumps of dissociated tumour
cells, for initiation of growth, often result in the
retention of small explants containing both tumour and
stromal cell types. The slowly growing epithelial element
often becomes dominated and excluded by faster growing
fibroblasts.
A technique known as spill-out (Leibovitz et al
1976) which involves sequential settling of dissociated
tumour tissue, facilitates the separation of small clumps
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of epithelial cells both from single fibroblast cells and
larger heterogeneous explants. However, collagenase
digestion of the specimen is a popular alternative since
collagenase is said to inhibit fibroblastic growth (Namba
et al 1983, McBain et al 1984). Fibroblast removal with
rubber policemen, subculture using dispase (a neutral
protease) which preferentially detaches sheets of
epithelial cells, and an antibody-ricin cconjugate
(directed to the Thy-1 antigen found on human fibroblasts
but not on colonic epithelium), have also been employed
(Paraskeva et al 1984). The simplest and most common
method of fibroblast elimination however, involves their
differential removal during short, repeated treatments of
the primary culture with trypsin.
During passage of human tumours as xenografts, prior
to culture, the stromal cells of the tumour become
replaced with host mouse stromal cells (Kopf-Maier and
Kestenbach 1990). Although these stromal cells then
feature in cultures established in vitro. the species
difference between them and the human tumour cells can be
exploited. For example, an antiserum raised in rabbit to
mouse melanoma cells has been applied to a human cell
line grown from a xenografted colorectal adenocarcinoma
in order to specifically lyse the mouse fibroblasts
(Murakami and Masui 1980) .
4.2.3.1 Cell nutrition
Fully defined media have been described for
colorectal epithelial cells, incorporating putative
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detoxifiers and growth stimulators (Leibovitz et al 1976)
and various hormonal supplements (Murakami and Masui
1980). However, the undefined nutrition present in serum,
commonly supplemented with hydrocortisone and insulin, is
thought to support the growth of most colorectal cancer
cells. A strong dependancy is noted of normal epithelial
cells on fibroblast conditioned medium (Moyer 1983) which
seems also to benefit the growth of tumour cell lines (C
Paraskeva, personal communication).
4.2.3.2 Cellular environment
In early attempts at tumour culture .in vitro. it was
observed that some tumour cells flourished only after
outgrowth of a fibroblast monolayer (Tompkins et al
1974). Murine fibroblasts with replication incapacitated
("feeders"), were later shown to enhance plating
efficiency by three to five-fold (Brattain et al 1982).
The beneficial properties of feeder cells are thought to
be two fold: the secretion of basement membrane
constituents by the fibroblasts may help the epithelial
cells to develop polar orientations as in tissue; and
feeder cells (which have no growth requirement) produce
growth factors and may bind some of the toxic factors
present in the uncharacterized serum, or produced by the
tumour cells themselves.
Epithelial-mesenchymal interactions have been
studied for colorectal carcinoma cells growing in
monolayer cultures and in collagen matrices (Richman and
Bodmer 1988). The presence of fibroblasts commonly
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induced differentiated structures in the adjacent tumour
epithelium, as detected by morphology and immuno-
cytochemistry with monoclonal antibodies to components of
goblet and columnar cells. The cell lines varied,
however, in their capacity to respond, and it is
therefore to be expected that feeder cells will be
ineffective in supporting cultures of certain
unresponsive tumours.
The basal ends of epithelial cells in situ are in
contact with the basement membrane, where fibroblasts
secrete large amounts of collagen. Collagen coated
surfaces (like feeder cells) are often used in vitro to
mimic this effect. Although collagen is used routinely in
colorectal cultures, it was found to be beneficial in the
primary culture of only 50% of a set of fourteen newly
established lines (Lewko et al 1989). Alternatively,
complex basement membranes are available such as that
extracted from the mouse Engleberth-Holm-Swarm tumour.
This biomatrix (known as matrigel) has been shown to
induce not only differentiation but biochemical function
and morophogenesis of mammary epithelial cells and
hepatocytes (Stoker et al 1990) .
4.2.4 Colonic cultures: common characteristics
Reports of the establishment and characterization of
colonic epithelial cell cultures describe many common
cell properties. Cells are always described as small,
closely packed, polygonal or pleomorphic, with large
nuclei and scanty cytoplasm. Initially, primary cultures
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always grow as islands of epithelial cells showing a
strong preference for high density seeding, and enhanced
growth over a fibroblast layer or collagen surface is
generally described. Ultrastructural presence of
microvilli and secretion of large amounts of
carrinoembryonic antigen (CEA) are also commonly reported.
4.2.5 Colonic cultures: diverse properties
Despite these common features in many colonic
epithelial cells in culture, there is also a wealth of
diversity. Perhaps the most striking is the variability
in growth rate of primary cultures including length of
lag period before growth and subsequent time before first
subculture. Lag periods of between two weeks and six
months are reported (Leibovitz et al 1976), while the
period of growth before first subculture ranges from less
than 4 weeks (MCBain et al 1984) to more than a year
(Leibovitz et al 1976). The afore-mentioned differential
responses to fibroblast feeders, and to a collagen
substrate support this idea of diversity as does the wide
variety of colonic culture karyotypes summarized in table
1, and discussed more fully in chapter 1. Other variable
characteristics reported include lack of substrate
adherence, ability to form tumours in animals (Park et al
1987), and morphological features such as "doming" of
cellular aggregates within epithelial islands (Leibovitz
et al 1976) . This diversity of colonic epithelial cell
cultures is not surprising on consideration of the
heterogeneity of colonic adenocarcinomas, both
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phenotypically and genotypically (Quirke et al 1985,
tables 4 and 8 in this thesis).
4.2.6 Xenograft to primary culture in this study
Growth in. vitro is a pre-requisite for the
introduction of exogenous DNA into cells by transfection.
We therefore wished to initiate such growth from
colorectal tumours. Initial attempts to establish primary
cultures directly from fresh tumour specimens were
largely unsuccessful in this study, and the growth rate
of those which grew was restrictively slow. Accordingly
tumours were first xenografted into immunodeficient mice
in order to reduce contamination problems in culture and
to provide a permanent, well-characterized resource as
described in chapter 2. This chapter describes the growth
of these tumour xenografts after explanting in. vitro and




4.3.1 Primary cultures grew from all tumour xenografts
In a series of attempts to culture colorectal
tumours directly in vitro. without an intermediate
xenograft stage, only 5 of 40 primary tumours (12.5%)
showed any measure of success. All 5 grew continuously
for between 9 and 16 weeks. No culture reached confluence
and all were eventually lost in a single bout of
bacterial infection of unknown origin. 1 culture derived
from an adenoma yet was not notably different in
morphology or growth pattern from the others.
Although unproductive, this period allowed
observation of the effects of varying some of the factors
of the culture process. Variables included percentage
serum in the medium, numbers of feeder cells added,
growth in a humidified C02 equilibrated incubator versus
closed flasks, collagenase digestion versus mechanical
tissue dissociation, seeding of different size fractions
of dissociated tissue, and incomplete removal of spent
medium during feeding. Assessment of benefit in any
particular set of conditions was subjective, but led to
the adoption of a general protocol, slightly modified
from the original method of Paraskeva et al (1984), for
subsequent use (chapter 7).
In contrast to this lack of success with direct
culture of primary tumours, cultures were grown on at
least 2 occasions from each of the 8 continuously
passaging colonic adenocarcinoma xenografts described in
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chapter 2. In general, all 8 primary cultures exhibited
the expected morphology, growing as epithelial islands of
small polygonal cells with large nuclei. However, from
observation over 2 to 9 months after a number of repeated
seedings, it was apparent that each xenograft line
generated cultures with characteristic properties.
4.3.1.1 Characteristics of GRBO in primary culture
GRBO grew well in culture and cells were
particularly refractile (figure 15). On two occasions
immediate outgrowth followed by 2 passages in culture was
achieved over 2 months. Thereafter, however, growth
arrested and no further passage was possible. One
preparation of frozen dissociated xenograft tissue seeded
for culture gave rise to a different pattern. Small
pleomorphic cells grew in clusters but without close cell
contacts as seen in islands. As the clusters grew into
colonies a curious thread-like pattern was evident over
the top of the colony (figure 15), which at high power
was seen to consist of aggregates of these cells. Feeder
cells were required for the maintenance of these
pleomorphic cells which, after a few weeks, stopped
forming these threads and grew as flatter colonies.
4.3.1.2 Characteristics of RHSP in primary culture
Primary cultures of RHSP were seeded on more than 5
occasions and grew well over 3 or 4 passages in culture.
Outgrowth was immediate on seeding but arrested after
about three months. RHSP culture is shown in figure 16.
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4.3.1.3 Characteristics of MUCO in primary culture
Primary cultures of MUCO were seeded on more than 5
occasions and grew very poorly. Despite the obvious
presence of many clusters of epithelial cells in the
preparation seeded for culture, only a few islands were
ever visible a week later. Most of the cell islands soon
become vacuolated and degenerated. Occasional non-
vacuolated islands survived but remained static over a
number of months. During this period, the islands became
surrounded by a cellular debris and fibroblast outgrowth.
Eventually the epithelial cells degenerated, developed
vacuolation or gradually detached from the substratum. An
area of MUCO becoming vacoulated is shown in figure 17.
4.3.1.4 Characteristics of CHKE in primary culture
Primary cultures of CHKE were seeded on 2 occasions.
Both attempts produced immediate but slow growth of
islands very similar in appearance to RHSP shown in
figure 16. Unfortunately both cultures were accidentally
lost as was the xenograft line.
4.3.1.5 Characteristics of ARNE in primary culture
Primary cultures of ARNE were seeded on 2 occasions.
Both attempts produced immediate but slow outgrowth of
islands morphologically similar to RHSP but showing
copious mucin production. In one case, 2 passages were
achieved over about 100 days before the culture was
overcome by yeast infection.
4.3.1.6 Characteristics of DABU in primary culture
Primary cultures of DABU seeded on 2 occasions had a
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distinctive cell morphology. After a few weeks of
dormancy, fast growing islands were observed. These
islands consisted of cells of a more spindly appearance
than those in other primary cultures (figure 18) and
cells in the centre of the islands often piled up to form
rounded domes. DABU cells were sometimes difficult to
distinguish from fibroblasts because of their fusiform
appearance. A mass culture of mixed epithelial and
fibroblastic cells was expanded and is described later in
this chapter.
4.3.1.7 Characteristics of MASM in primary culture
Primary cultures of MASM seeded on 3 occasions had a
slow growth rate. As in the other 8 xenografts, organoids
of epithelial cells were observed during seeding which
generally settled to form the flat islands observed.
However, in the case of MASM, these organoids continued
to grow as three-dimensional clumps from which dense
sheets of cells began to emanate. Once the epithelial
sheet was established, the central clump budded off
leaving an island similar to those observed for other
lines. In the islands of MASM, however, the cells were
more densely packed and often showed signs of polarity in
the form of groups of cells with parallel alignment.
Figure 19 shows several of these features. Growth was so
slow that passage without splitting, merely to decrease
cell density, was only possible after 6 months in one
case. This slow growth made these cultures particularly
vulnerable to infection, to which the only second passage
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representative finally succumbed after 9 months in
culture.
4.3.1.8 Characteristics of JOMCL in primary culture
Primary cultures of JOMCL, on more than 5 occasions,
grew immediately and strongly upon seeding. The cells
within the islands had a variable morphology ranging from
rounded or polygonal to spindly and similar to the cells
observed in DABU cultures. The two extremes were often
present in the same flask and were not related to the
length of time in culture. Polygonal cells from a 4th
passage culture and spindly cells from 1st passage are
shown in figure 20. In the 4th passage culture large
numbers of small pleomorphic cells were noticed, growing
close to but not always in direct contact with
neighbouring cells. These were similar in appearance to
the cells described in GRBO cultures but did not form the
thread-like structures. Their location was always near to
an established epithelial island from which they seemed
to emanate, arising most often in coves around the
coasts of the islands.
JOMcL cells grew well even in short periods of
absence from feeders and collagen. When seeded on culture
dishes without collagen, epithelial islands formed as
usual but with the addition of three-dimensional buds as
described for MASM primary cultures. In JOMCL these buds
appeared to grow, often on stalks, from the centre of the
islands (figure 20). These buds tended to break off and
could be harvested from the medium. Histologically they
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Figure 15 Phase contrast photomicrographs of GRBO cells in
primary culture. A; A flat island (x69>. B; Altered cells
clumping and forming cords (x28). C; Cellular basis of the cord
(x221) .
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Figure 16 Phase contrast photomicrograph of RHSP cells in
primary culture showing flat islands surrounded by feeder cells
(x69).
Figure 17 Phase contrast photomicrograph of MUCO cells in
primary culture showing vacuolation (x69).
Figure 18 Phase contrast photomicrograph of DABU cells in
primary culture showing spindly appearance <x69).
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Figure 19 Phase contrast photomicrographs of MASM cells in
primary culture. A; Primary culture showing density of cells and
presence of 3-dimensional tissue implant (X28). B; Flat islands
with indented organisation within (x69). C; Edge of growing
island showing polarised cells of columnar appearance (x69).
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c
Figure 20 Phase contrast photomicrographs of JOMcL cells in
primary culture. A; Densely packed polygonal cells of 4th
passage culture (x221). B; Spindly cells of 1st passage culture
<x69). C; 3-dimensional buds forming within islands when grown
without a collagen substrate (x28).
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Figure 21 JOMcL organelles produced in primary culture.
A; Histology of organelles showing glandular structure (xlOO),
B; Histology of organelles showing cell polarity <x252).
C & D; Electron microscopy of organelles showing tight junctions,
desmosomes and apical microvilli (xlOOOO ft 25500 respectively).
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proved to be small foci of adenocarcinoma, with well-
formed central lumens surrounded by polarised tumour
cells. In the electron microscope this was confirmed,
apical microvilli and lateral tight junctions and
desmosomes being clearly seen (figure 21).
JOMCL cells have to date grown continuously in
culture over 4 passages with no signs of senescence.
4,3.1.9 Characteristics of AGDU in primary culture
Despite the uncertain origin of the tumour giving
rise to the xenograft AGDU, 2 primary cultures were
attempted. The appearance and behaviour in culture of
this line was distinctly unlike any of the others. Small
cauliflower-like florets of cells formed centres from
which grew long threads of cells. No flat epithelial
islands were seen before cultures were terminated after
10 weeks.
4.3.2 Primary cultures of frozen xenografts
In chapter 2, the growth of xenografts from tissue
which had been stored at -70°C is described. In this
chapter cell culture growth from identical frozen
preparations is described. By the same method as for
seeding fresh preparations of tissue, cultures of JOMCL,
GRBO and RHSP were succesfully seeded from thawed
xenograft specimens. Such dual purpose storage of tissue
precludes the necessity to freeze both tissues and cells
of any one line.
4.3.3 Mouse feeder cells are adequate and necessary
In an attempt to assist or boost growth of primary
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cultures, a number of culture conditions were vvaried.
As it seemed possible that feeder cells might retard
growth i_n vitro by inducing terminal differentiation, all
cultures were grown for some time, and most were seeded
on one occasion, in the absence of feeders. All cultures
excepting JOMCL were severely inhibited by the lack of
feeder cells.
A second possibility was that human colonic
fibroblasts might provide distinctive growth support to
colorectal carcinoma cells. Accordingly, human
fibroblasts which grew out from an early primary culture
established directly from a carcinoma, were treated with
mitomycin C and used as substitute feeder cells for a
short period of time. No changes were seen in either
growth rate or morphology in cultures receiving these
human fibroblast feeders in comparison with murine
fibroblast feeders, and routine use of the latter was
resumed.
4,3.4 Type I collagen is adequate and necessary
Since collagen substratum has been shown to benefit
only 50% of primary colonic epithelial cultures (Lewko et
al 1989), samples of most of the cultures were seeded on
tissue culture plastic alone. Growth in the absence of
collagen was noted only for JOMCL; the resulting budded
growth of adenocarcinoma was described above. Type IV
collagen is secreted in the basement membrane in situ and
is therefore advocated for coating of flasks for culture
purposes. Owing to the expense of this type of collagen,
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the ability of cells to grow on the considerably cheaper
type I collagen was tested and growth was found in no
case to be limited in comparison with growth on type IV.
Accordingly type I collagen was routinely used
thereafter.
4.3.5 A defined medium does not alter JOMCL growth
Because of the report by Murakami and Masui (1980)
that cells grew 3 times faster in a defined hormone
containing medium, its effects on primary culture growth
were tested. The serum-free medium was supplemented with
insulin, glucagon, epidermal growth factor, transferrin,
hydrocortisone, triiodothyronine, selenium, and ascorbic
acid. Parallel cultures of JOMCL were seeded and grown
over 1 passage in either colonic culture medium with 10%
serum as described in chapter 7, or in this defined
medium. No differences in passage interval or growth
pattern were observed between cells in either media.
4.3.6 EGF does not increase success
Epidermal growth factor (EGF) was applied at lOng/ml
to an established growing culture, derived from an
adenoma and described in chapter 3 (PCAA). Parallel
flasks of PCAA with and without EGF were seeded and grown
to passage and for 2 subsequent weeks. Over this time,
constituting about 6 weeks, no differences in morphology
or passage interval were noted between EGF containing or
non-EGF sister cultures.
In the primary culture MUCO no appreciable growth
could be attained and degeneration was observed in most
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or all seeded cells. To test if EGF could alleviate this
situation by providing essential stimulation absent from
serum alone, cells were seeded in medium containing
lOng/ml EGF. Vacuolation and degeneration were, however,
noted as usual and no useful effects of EGF could be
discerned.
4.3.7 MASM. MUCO and JOMCL are not clonogenic
Passage of all cultured cells described in this
chapter was effected by dispase digestion, as described
in chapter 7, which detaches the cells from the
substratum as sheets rather than in single cell
suspensions. To test the clonability of some of the
cultures, MASM, MUCO and JOMCL were treated with trypEDTA
as described in chapter 7. Although single cell
suspensions were obtained none of these three cultures
grew, with or without addition of feeder cells.
4.3.8 Tumoriaenicitv of primary cultures
Growth in vitro may select for properties not
uniformly present in the original xenografted tumours.
Under such circumstances, it would not be possible to use
these cell lines for the ultimate aim involving
comparison of the stable xenografted tumour with derived
cells specifically manipulated in. vitro at oncosuppressor
sites. Accordingly it was important at this stage to
observe the behaviour on re-implantation in. vivo of cells
cultured in vitro. 2 of the primary cultures, JOMCL and
DABU grew at a sufficient rate to allow re-implantation,
both producing adenocarcinomas.
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Figure 22 Histological patterns of A; JOMcL primary tumour, B{
Xenograft produced by re-implantation of JOMcL primary culture
(both xlOO).
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For JOMCL cell re-implantations half the contents of
a 150cma flask of cells were harvested and re-injected
into 2 nude mice. Although cell clumping precluded even
approximate counting of cell number, by comparison of the
cell pellet size with pellets of known cell number this
innoculum was low, due to slow growth and resulting lack
of availability of cells. After 72 days the resulting
tumour was large enough to harvest. Histological
examination of fixed sections of this tumour showed
morphology indistinguishable from that of both the
primary tumour and the passaged xenografts (figure 22).
Sufficient material is not yet available from this re¬
injected tumour to allow genetic analysis.
Within DABU cultures, the fusiform appearance of
epithelial cells made them impossible to distinguish from
neighbouring fibroblasts. This cell mixture grew well
after trypsinisation and was rapidly expanded in culture.
10^ cells were injected subcutaneously into each of 2
immunosuppressed mice. Both mice developed tumours which
were passaged twice without any signs of senescence, but
the 2 sub-lines grew at widely different rates. A large
infiltrative tumour was harvested from the first mouse 32
days after injection, and subsequent passages were
conducted after 23 and then only 13 days. In contrast,
the second mouse grew a moderately sized tumour which was
not large enough to harvest until 54 days after injection
and which subsequently took 44 days to grow to passage.
The summarized history and important features of this
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ESTABLISHMENT OF A CARCINOMA CELL LINE
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Figure 23 Derivation of DABU culture and its
re-implantation.
Notes:
1) DI= DNA index, R= retention of heterozygosity
2) 5q, 6, 17p, 21= chromosomal locations
3) x2 or x4= 2 or 4 xenograft passages respectively
4) feeders= 3T3 feeder cells
5) s/c= subcutaneous
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Figure 24 Electron microscopy of DABU culture re-
implanted as xenograft. A; Slow growing adenocarcinoma
line showing cell polarity, a variety of junctions and
luminal microvilli (x3570), B; Fast growing sarcoma line
showing absence of desmosomes or cell polarity (x6800),
C; Collagen bundle, found abundantly throughout sarcoma
line (X34000).
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chain of events are illustrated in figure 23.
Histologically, the fast growing tumour was a poorly
differentiated spindle cell tumour that appeared to be a
sarcoma. The slow growing tumour was a moderately
differentiated adenocarcinoma with morphology closely
similar to DABU prior to growth in vitro. By electron
microscopy the sarcoma was seen to consist of fibroblasts
secreting collagen, whereas in the adenocarcinoma the
predominant cell type was a polarised columnar cell with
apical microvilli and lateral desmosomes (figure 24).
DNA index (DI) for each line was determined by flow
cytometry. The sarcoma line DI was 1.6, while the DI for
the adenocarcinoma line was 1.0 denoting a diploid tumour
similar to the original DABU primary carcinoma. To
establish the origin of these lines, DNA was extracted
from both the sarcoma and adenocarcinoma and subjected to
RFLP analysis with probes to a number of human sequences:
YN5.48, L5.71 and Pi227 on chromosome 5; YNZ132 on
chromosome 6; YNZ22 on chromosome 17; BV15.65 on
chromosome 18 and MCT15 on chromosome 21. Conditions for
each probe are summarized (tables 17a and 17b), and
examples of patterns detected by some probes are shown
(figure 30) in chapter 7.
In no case did any probe hybridise to specific
restriction fragments in the digested DNA of the sarcoma.
In contrast, under the same conditions all probes
detected alleles in the adenocarcinoma DNA identical to
those in the blood of the original patient and in the
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3) -= no alleles detected
corresponding xenograft (table 13). 3 of these probes are
VNTRs detecting up to 30 different alleles in the
population. This DNA fingerprinting exercise therefore
confirms that the adenocarcinoma was identical in origin
to the original DABU line while the sarcoma was clearly
not of human origin. In view of its fibroblastic
appearance and fast growth the fibrosarcoma was presumed
to originate from transformed mouse fibroblasts. During
the early stages of DABU growth there was an occasion
where feeder cells were used that may not have been
rendered completely incompetent for replication by
mitomycin treatment. The DABU culture may therefore have
become contaminated with immortalized 3T3 fibroblasts,
which would be liable to selection for spontaneous
transformation during long periods of over-crowding in
the primary culture. Alternatively, murine stromal
fibroblasts from the xenograft explant may have undergone
transformation during culture, although the ready
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transformation of this 3T3 line experienced under other
circumstances supports the former explanation.
Despite this fibroblast contamination, the above
results confirm that the slow growing tumour produced by
DABU human adenocarcinoma cells had stably conserved DNA
ploidy and, more specifically, allelic status at loci on 5
different chromosomes. In particular, variants at the key
colon-associated loci on 5q, 17p and 18q had not been
selected for during short-terra culture.
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4.4 Discussion
4.4.1 Valuable, stable xenograft resources
Since tumour characteristics are stably maintained
during propagation in immunodeficient animals (chapter
2), the xenografts described provide stable resources for
repeated culture attempts. Such xenograft derived
cultures avoid previously experienced problems of primary
culture contamination with co-cultured bowel microbes.
Moreover, the replacement of the stromal element of the
tumour with host derived cells prevents culture
contamination with human fibroblasts. The species
difference can be exploited and in this study has allowed
identification of murine fibroblast outgrowth by genetic
means which would not have differentially detected human
fibroblast contamination. Xenografting prior to culture
is therefore a valuable and powerful tool.
4.4.2 Diversity of cultures
Variable phenotypes and growth characteristics were
noted in the 8 primary cultures described despite
identical environmental conditions. Growth in vitro.
although observed in all cases, was generally slow and
for many cultures was non-progressive despite continuous
growth as xenografts. This suggests the general culture
protocol lacks vital factors which are available in vivo.
Human fibroblast feeders, EGF, type IV collagen or a
hormone containing defined medium did not provide the
missing factors to the cultures tested. Because of the
availability of genetically stable tumour xenografts-
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some preserved at low temperature- practically unlimited
numbers of further candidate growth factors can be
screened.
With the high take rate in SCID mice (described in
chapter 2), 92-100% of colonic adenocarcinomas have grown
as xenografts. This provides an opportunity for unlimited
analyses of in vitro requirements for the entirety of
unselected adenocarcinomas. Such analyses could provide
valuable information about all co-operations of colon
tumour cells with other cells, growth factors and various
components of the extracellular matrix.
4,4.3 Is clonabilitv necessary?
Of the 8 primary cultures described, growth was
observed in vitro for only one after trypsinisation to
single cells, with epithelial cultures derived from
xenografts commonly exhibiting non-clonal growth from
clumps of cells. In contrast to this and the slow growth
generally observed in these cultures, long-established
colorectal lines are often reported to grow both rapidly
and clonally. The ultimate aim in attempting culture in
vitro is to provide a suitable host cell in which to test
the function of genes associated with colon cancer.
Clonability is generally a pre-requisite for experiments
involving gene transfer or targetting, since selection of
the small number of successfully manipulated cells is
necessary. Although it may be possible to achieve clonal
growth in vitro for the described cultures by severe
selection, such an act would be in opposition to the
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original aim of stably maintaining tumour cell
properties. It may therefore be more constructive to
search for a highly efficient method of transfection,
such that clumps of transfectant cells may be selected
together, as will be discussed in chapter 5. Genes
introduced in retroviral vectors become widely spread
throughout the infected population of cells and may
therefore be a feasible alternative to transfection.
Indeed, viral vectors earring mvc and sre oncogenes have
been shown to induce dysplasia on introduction directly
into rat colon allografts (D'Emilia et al 1991) .
4.4,4 Stability in vitrp
Stability of xenograft characteristics conserved
from original primary tumours is shown to extend through
short periods in culture for 2 lines. In particular, 1
line retained critical features such as ploidy and
allelic status on many chromosomes including key colon-
associated oncosuppressor loci on 5q, 17p and 18q despite
its rapid growth and clonability in. vitro. Particularly
if transfection of non-clonal cells proves a possibility,
the stable xenograft and short term culture system may be
ideal for gene transfer and functional assays of colon
tumour-associated genes.
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Chapter 5: Oncosuppression by transfection
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5.1 Abstract
Preliminary experiments were conducted to explore
means of transfection and effects of oncosuppressor genes
in colorectal tumour cell lines. Although transfection
efficiencies were poor, there were several arresting
observations.
The Krev gene was found to suppress tumorigenicity,
inhibit growth and induce apoptosis in a transformed
murine cell line. On transfection into a tumorigenic
colonic line the same gene completely arrested growth. No
transfectants could be selected from non-clonable colonic
cultures. These experiments helped to expose and define
problems inherent in selection of cells that might grow
less well than their parental lines. The values and
difficulties of selecting transfectants from non-clonable
cultures were also considered. Methods are discussed
which may overcome these problems in the future.
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5.2 Introduction
The xenografts described in this thesis display a
variety of genetic defects and some have generated in
vitro passaged lines. Moreover, major changes were not
detected in genotype or phenotype on re-implantation in
vivo. The xen ografts therefore appear suitable for assay
of oncosuppressor gene effects against a variety of
backgrounds. The question arises as to how such activity
would manifest itself and how cells expressing it could
be selected.
5.2.1 Effects of oncosuppressor activity
Loss of tumorigenicity is perhaps the most dramatic
and definitive effect that an oncosuppressor gene may
exhibit. Tumorigenicity is, however, a complex function
which may not always be inhibited, despite oncosuppressor
activity, due to the effects of other genes within the
cell. Such genetic interplay may result in gene transfer
of candidate oncosuppressor genes blocking tumorigenicity
in one but not another recipient cell background. The
possibility of such variable effects justifies the
approach described in this thesis of characterizing
multiple lines of different genotypes, to allow
oncosuppressor assay in a variety of known backgrounds.
An oncosuppressor gene assay may, alternatively,
result in growth arrest or retardation in. vitro. Although
a potentially interesting effect, growth inhibition
creates problems for further study. In the case of growth
arrest, selection of transfectants (which relies on
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proliferation) is not possible. In either case, if
transfectants are selected the observable spectrum of
phenotypic effects is automatically narrowed since growth
inhibitory effects are selected against.
Another possible effect of cellular action of an
oncosuppressor gene is increased apoptosis, for which
assays exist. There is a precedent for modulation of
apoptosis by oncosuppressor gene expression in the
recently described effects of wild-type r>53 on myeloid
leukaemic cells (Yonish-Rouach et al 1991) . In accord
with the previous argument, however, the increased
apoptosis would be required to co-exist with continuing
replication to avoid loss of transfectants. Furthermore,
no means currently exist to select for apoptotic
behaviour and with continuing cell culture there is
therefore the risk that it will be eliminated from the
phenotype.
Finally, oncosuppressor assays may cause decreased
cellular response to appropriate growth-supportive
signals, or increased response to corresponding
inhibitory signals. The oncosuppressor DCC gene codes for
a sequence suggesting a cell adhesion molecule (Fearon et
al 1990), and thus may exemplify an oncosuppressor gene
which modulates responses to cell-cell signals. Such
signals may be vital, particularly to cells for which
clonal growth is not a feature. At present there is no
means of assaying these effects.
Published literature does not indicate whether these
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problems will be trivial or extensive. A further long-
appreciated problem is the difficulty of expressing
exogenous genes in human cells compared to rodent cells.
This section of the thesis attempts to make a preliminary
assessment of these issues.
5.2.2 Methods for efficient transfection
Experiments intended to define transfection
parameters for the proposed biological tests of
oncosuppressor function in the new colorectal cell lines
are described. Preliminary experiments were conducted to
investigate means of transfection and expression of
exogenous DNA in these lines.
Transfection methods were chosen which were reported
to be applicable to a broad range of cell types, and to
repeatedly give high efficiencies of stable transfection.
Electroporation was chosen also for its usefulness, due
to its physical rather than chemical means of gene
transfer, for cells which are refractory to other methods
(Potter et al 1984). However, the success of
electroporation is associated for most cell types with
killing 50-75% of cells by the electrical pulse.
Synthetic amphiphiles were chosen for their reported lack
of toxicity and ability to transfect primary neuronal
cells without altering important cellular physiology
(Loeffler et al 1990). The amphiphiles entrap exogenous
DNA on the basis of charge and spontaneously associate
with natural anionic headgroups in cellular membranes,
internalising the DNA by endocytosis (Behr et al 1989,
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Feigner et al 1987). Amphiphile-mediated gene transfer is
reported to be 5 to >100 times more efficient than the
commonly used calcium phosphate method (Feigner et al
1987). Furthermore, this reagent has previously been used
for efficient transfection of human epithelial cells such
as Hela and of the colon cells CXI, and MIP (J Bubb,
personal comunication).
5.2.3 Selectabilitv of a putative oncosupppressor
Experiments were performed in order to compare the
selectability and effects of an exogenous oncosuppressor
in murine fibroblasts with its selectability and effects
in both clonable and non-clonable human epithelial cells.
One long term goal of this work was to study the function
of oncosuppressor genes known to be involved in
colorectal carcinogenesis, in particular the 5q genes
MCC and APC. These genes were not cloned until August
1991 and it is clear, on account of its huge size (9.5 Kb
of cDNA), that special techniques will need to be
employed to transfect APC. Accordingly Krev was chosen
for initial study: it is a relatively small, readily
available putative oncosuppressor gene, with well
described immediate function, but still incompletely
defined cellular activities.
The Krev gene was isolated as a human cDNA that
suppressed tumorigenicity and caused reversion of
phenotype in vitro on transfer into a viral Ki-ras
transformed mouse 3T3 cell line (Kitayama et al 1989,
Noda et al 1989). The gene- independently isolated by low
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stringency hybridization of human DNA with a drosophila
ras-related gene (Pizon et al 1988)- is variously termed
raol and, its protein product, smg p21A (Kawata et al
1988). The 21Kd protein product has 50% amino acid
homology with ras p21, including the C-terminal cysteine
used for membrane anchoring, GTP binding regions and the
putative effector domain. Such homology together with its
apparent ability to inhibit growth led to the proposal of
Krev as a ras antagonist, perhaps by competitive
inhibition of GAP (GTPase activating protein) mediated
activity. Ras p21 GAP was indeed found to bind Krev p21
tightly without increased hydrolysis (Freeh et al 1990),
which would allow Krev expression to modulate ras p21
activity by direct competition. It has been hypothesised
that deregulation of such ras antagonists may be involved
in tumorigenesis and indeed, tumour specific decreases in




5.3.1.1 Optimised electroporation of colonic cells
In order to define the optimal parameters for
electroporation into colonic epithelial cells, the
established line C280 (chapter 3) was electroporated
under a variety of conditions with pSV2neo (the Tn5 aoh
gene driven by the SV40 promoter and enhancer region,
Southern and Berg 1982). Expression of the anh gene
confers neomycin resistance on transfectant
permits their selection with geneticin (G418),
analogue. The results are shown in table 14.
Table 14 C280 electroporation
Number cells treated plasmid (ug) pulse (Kv^ Result
cells and
a neomycin
107 20 0.4 +
107 20 0.8 +
107 20 1.6 ++
5x106 20 0.8 0
5x106 20 1.0 +
5x106 20 1.2 +
5x106 20 1.4 0
5x106 20 1 . 6 0
5x106 20 1. 8 0
106 20 1. 4 ++
5x105 20 1 . 4 +
5x106 2 1.4 +
5x106 5 1. 4 ++
5x106 10 1 . 4 0
5x106 40 1 . 4 ++
Notes:
1) Colonies were not counted but pooled since separate
colonies often arose close together, or cells dispersed
causing an apparent increase in colony number. Success
was based on the speed of pooled colony growth and
therefore indirectly on the number of transfectant cells.
2) 0= No transfectants, += growth, ++= rapid expansion
3) 25uF capacitance used throughout
All rapidly expanding transfections were effected
with pulse voltages of 1.4 or 1.6 Kv and, although not
discriminated in the table, transfection of only 5ug of
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Figure 25




plasraid gave notably the best result.
That the plasmid DNA was successfully introduced
into these cells was confirmed by Southern analysis. DNA
from transfected cells was blotted from a gel with DNA
from non-SV2neo transfectants and control plasmids. The
blot was probed with pSV2neo, linearized with Hindlll and
nP labelled. Hybridising fragments were detected in the
autorad only for G418 resistant cells and control
plasmid.
5.3.1.2 G418 selection
Hygromycin resistance was con sidered as a dominant
selectable marker but, in preliminary tests, the new
cultures were particularly sensitive to low
concentrations (50ug/ml), and the preferred marker was
neomycin resistance. In order to find the appropriate
G418 concentration for selection of a clonable colorectal
cell line, 106 C280 cells were seeded in each of a series
of 32x 50mm diameter Petri dishes, variously treated with
200ug/ml, 500ug/ml, lOOOug/ml G418, or untreated as
control. All were grown in 10% HINCS and kept in a C02
humidified incubator. Dishes were removed at 3 day
intervals over a period of 15 days and cells were
counted, in duplicate, in a glass slide haemocytometer.
For each G418 concentration the number of cells remaining
at day 9 was used to calculate percentage cell death
relative to the untreated control. The resulting dose
response curve is plotted in figure 25. From this curve,
the minimum concentration of G418 to kill all cells (and
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thus the appropriate concentration for selection), is
approximately lmg/ral, active G418 concentration 500ug/ml
according to the batch potency of 500ug/mg (chapter 7).
5.3.2 Transfection efficiencies
A number of test transfections were carried out in
order to compare efficiencies by different methods and of
various recipient cells. Cells were treated by either
electroporation or one of two commercial reagents for
amphiphile-mediated transfection. Results are summarized
in table 15.
Table 15 Transfection efficiencies
cells method vector ef f ic comments
PCAA EP pH05Tl 0 high cell kill, non-sel
PCAA EP pKrev-1 0 high cell kill, non-sel
PCAA TRANSF pHMR 0 non-sel
PCAA LIPOF pKrev-1 0 non-sel
PCAA LIPOF pSV2neo 0 non-sel
JOMCL LIPOF pKrev-1 0 non-sel
JOMCL LIPOF pSV2neo 0 non-sel
C280 EP pSV2neo + confirmed (see text)
C280 TRANSF pKrev-1 10-& growth arrested (text)
C280 TRANSF pH05Tl 10-5 (see text)
C280 TRANSF pSV2neo 6x10-_6
3T3 TRANSF pSV2neo 1.5x10-6
Notes:
1) EP= electroporation
2) TRANSF= amphiphile mediated transfection using
TRANSFECTAM reagent (IBF, Columbia, USA)
3) LIPOF= lipofection using LIPOFECTIN amphiphile reagent
(GIBCO BRL, Paisley, Scotland)
4) non-sel= non-selectable
8) effic.= transfection efficiency. Number of transfectant
colonies divided by number of cells originally
transfected
9) += transfectant colonies not counted but pooled
10) pH05Tl; expressing activated H-ras (Spandidos and
Wilkie 1984), pKrev-1; (Kitayama et al 1989), pHMR;
resistance gene to hygromycin B, (Bernard et al 1985).
11) Negative controls lacking construct were also
transfected in every case
Transfection efficiencies for C280 cells were lower
than expected comparing poorly with classical methods
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such as calcium phosphate procedures where efficiencies
of 10-4- are reported (Southern and Berg 1982) .
Efficiencies of 10-3 are commonly reported for amphiphile
reagents. Efficiencies of C280 transfection compared
favourably, however, with control murine 3T3
transfections for which high efficiency transfection is
commonly reported. Low efficiencies in our experiment are
not therefore due to colonic lines being refractory to
transfection but indicate the need for finer tuning of
parameters in transfection experiments.
No transfectants were selected in the non-clonable
colonic lines PCAA (chapter 3) and JOMCL (chapter 4).
Inability to grow from single cells would prevent
selection of isolated transfectants and necessitate high
efficiencies of transfection such that neighbouring cells
may be transfected and selected together. In an attempt
to meet this requirement, pHMR transfected PCAA cells
were allowed to grow to passage twice over a period of 6
weeks before selection, in the hope that selectable
clones of transfectants may grow. Despite a subsequent 3
month period of alternating selection and recovery with
fresh feeder cell addition, a final 2 week selection
period eliminated all growing colonies.
Despite low transfection efficiencies throughout
this work there were a number of striking results of
oncosuppressor gene transfer.
5.3.3.1 Krev in murine cells: increased aooptosis
5ug of pKrev-1 (Kitayama et al 1989) were
143
Figure 26 Morphology of early Krev transfectants,
A; Early Krev transfectants forming clumps of cells (xl08),
B; Non-transfectants at a similar density showing no clump
formation (x69).
Figure 27 Contact inhibition of Krev transfectants (both x69),
A; Krev transfectant monolayers showing contact inhibition,





Cell no. (x million)
Time (days)
' Series 1 + Series 2
DABU Krev DABU
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transfected by electroporation into 8x10s DABU
transformed murine fibroblasts (chapter 4). An aoh gene
also expressed from pKrev-1 allowed G418 selection of
Krev transfectants. Early transfectants adopted a
clustering behaviour with cells growing in clumps, while
the parental line at a similar density did not (figure
26). Due to slow growth, transfectant clones were pooled
and grown up as a mass culture which required 2 months to
grow to passage in contrast with the parental line which
was generally passaged twice a week. Monolayer contact-
inhibition observed for the transfectant line contrasted
sharply with the behaviour of parental cells at
confluence, which grew over each other forming large
transformed foci (figure 27). Numerous highly refractile
rounded cells budding off into the medium were also noted
in confluent transfectant cultures, yet were not evident
in the parental line. Cells collected from the
supernatant of the transfectant line were shown to be
apoptotic: of 100 cells counted in wet preparations
stained with lOug/ml acridine orange and viewed in
ultraviolet light, 86% demonstrated the characteristic
homogeneous nuclear staining and fragmentation.
5.3.3.2 Krev: growth inhibition
The growth rates of the parental and transfectant
lines were compared. 50mm Petri dishes were each seeded
with 10s cells from either line, were fed 10% HINCS at 3
day intervals and grown in a C02 humidified incubator.
Cells were harvested and counted in quadruplicate at
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either 2 or 3 day intervals over 15 days. Cell numbers
were plotted against time to give comparable growth
curves (figure 28).
A 2-fold increase in doubling time, and a 2-fold
decrease in the plateau phase monolayer density was noted
for the Krev transfectants. During growth in log phase
(at day 6) the numbers of Krev transfectants were
significantly less than those of parentals (P=0.028,
Mann-Whitney U test). Similarly, the plateau phase
concentration (days 10-16) was significantly lower in
Krev transfectants (P=0.005, U test).
5.3.3.3 Krev: abolished tumorioenicitv
In order to test tumorigenicity, 2xl06 Krev
transfectants were injected either subcutaneously or
intra-peritoneally into each of 21 immunosuppressed mice.
A further 19 immunosuppressed mice each received 2x10*
parental cells. Mice were killed at 21-25 days after
injection and all animals were dissected and examined for
abnormalities in the peritoneal cavity, heart, liver and
lungs. At postmortem, competence of thymectomy was
confirmed in each mouse.
The parental cell line consistently induced
aggressively growing fibrosarcomas with infiltration at
tumour margins and multiple retroperitoneal secondary
tumour masses after intraperitoneal injections. Tumours
were never detected after injection with transfectant
cells and only fat necrosis was found at the site of
injection. As a stringent test of differential
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1= 3T3 mouse fibroblast cell line DNA
2 = Spontaneously transformed 3T3 parental cell line
3= 3T3 SV2neo transfectants
4= Transformed line Krev transfectants
5= Transformed line Krev transfectants
6= Human placental DNA
7= Human placental DNA + Krev plasmid equivalent to
1/3 copy/ cell
8= Human placental DNA + Krev plasmid, 1 copy/ cell
9= Human placental DNA + Krev plasmid, 3 copies/cell
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tumorigenicity of these 2 lines, subcutaneous injections
of both lines were given to opposing flanks of the same
mouse in 3 cases. In all 3, tumours were found only in
the flank injected with parental cells. Results are
summarized in table 16.
Table 16 Tumorigenicitv of parental
vs. Krev transfectant cells
LLO. SlISL
Parental 9/9 10/10




3) numbers= animals with tumours/ animals injected
5.3.3.4 Krev: instability
Transfectant cells recovered poorly from liquid
nitrogen storage and required expansion in the absence of
selection, whereupon cell morphology was neither flat nor
transformed, and apoptotic bodies were not apparent. In
order to ensure presence of only transfectant cells,
selection could have been re-applied at this point.
However, without further selection DNA was prepared from
these cells for Southern analysis. 20ug of DNA from 3T3
cells, the transformed parental line, 3T3 SV2neo
transfectants and transformed cell Krev transfectants
were digested with each of BamHl or EcoRl. Mixtures of
pKrev-1 and digested human placenta DNA equivalent to 0,
1/3, 1 and 3 copies of Krev /cell were also included in
the blot which was probed with the 2Kb BamHl fragment of
pKrev-1, random prime labelled with radioactive
phosphorus.
149
The pattern of hybridisation with the Krev cDNA
probe for both mouse and human derived cells shows the
expected small number of endogenous Krev alleles (figure
29) suggesting low gene copy number and strong
conservation (Kitayama et al 1989). However, for neither
of the transfected DNAs was the pattern different from
non-Krev transfected controls. Although this demonstrates
that exogenous Krev was not present in these cells
recovered from deep frozen storage, it is likely that the
Krev DNA was present in the original transfectants, as
they grew selectively in G418 and demonstrated a clear
phenotype. It appears probable that Krev has been lost
due to the non-maintenance of selection. This
interpretation suggests instability of exogenous Krev
which may be expected since the Krev DNA is associated
with an obvious growth disadvantage. Such instability
might indicate the need for sustaining selection in
oncosuppressor transfections.
5.3.4 Krev in human cells: growth arrest
5ug of either pKrev-1 or the activated H-ras
containing pH05Tl (Spandidos and Wilkie 1984) were
transfected into 10 C280 cells by amphiphile-mediated
transfection. 10 pH05Tl transfectant colonies were
counted after 6 weeks of selection, giving a transfection
efficiency of 10-5. At that time, only one living Krev
transfectant colony was visible. This single colony was,
however, surrounded by many skeleton colonies consisting
only of dead cell remains organised in a colonial
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fashion. The single Krev transfectant colony survived
selection over one further month yet remained static. No
further growth was noted before the colony eventually
detached from the substratum, and was thereafter
resistant to repetitive attempts at reseeding.
5ug of pKrev-1 or pSV2neo were introduced into non-
clonal human colonic epithelial lines PCAA and JOMCL by
amphiphile-mediated transfection. Since, the former line
carries a Ki-ras mutation yet is non-tumorigenic, while
the latter carries only wild-type Ki-ras and produces
tumours, effects of Krev may have been highly
informative. However successful control transfectants
were not selected as already discussed (5.3.2), and the




Efficiencies of amphiphile-mediated transfection
measured in this study were in all cases 100-1000 times
less than expected. Conditions were not optimised prior
to these experiments and by tuning parameters such as
ratio of DNA: reagent and time in contact with the cells,
great improvements may be achievable. Such improvements
may lead to transfection of nei ghbouring cells allowing
selection of small co-transfected colonies in cell lines
which do not grow from single cells.
Despite low transfection efficiencies a number of
interesting effects were observed and new questions
raised by these experiments.
5.4.2 Krev is an oncosuppressor gene
Krev was isolated from a human cDNA library on the
basis of its ability to induce morphological reversion of
a transformed murine cell line. Loss of tumorigenicity,
observed in original revertants, was not absolute on
secondary transfection with the recovered Krev cDNA
alone and the extent of its suppressive effects were
unclear (Kitayama et al 1989). In this chapter, complete
loss of tumorigenicity together with many other predicted
oncosuppressor gene effects are demonstrated specifically
by Krev DNA.
A tumour-specific decrease in K-rev expression has
been detected in 2 tumour types where K-ras mutations
are not detected (Culine et al 1989). According to the
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oncosuppressive capacity of K-rev and its proposed
antagonism to Ki-ras. it is possible that the effects of
ras activation in human tumours may alternatively be
exacted by Krev inactivation. This may explain the fact
that Ki-ras activating mutations are detected in only 37%
of colorectal tumours (Bos et al 1987). Perhaps defects
in the Krev gene are involved in some of the remaining
63%.
5.4.3 K-rev oncosuppressor effects
Many of the possible oncosuppressor effects
discussed in the introduction to this chapter were
evident following transfection of the Krev gene. Loss of
tumorigenicity, decreased growth rate, growth arrest and
induction of apoptosis were all observed. Different
effects were observed for expression in a human colonic
epithelial line than in a transformed murine line. No
phenotypic effects were recorded in an earlier study in
which Krev was transfected into non-transformed murine
cells (Kitayama et al 1989). Such variable effects
emphasise the necessity for multiple characterized lines
providing a variety of backgrounds in which to assay
oncosuppressors.
The balance between cell division and cell death by
apoptosis determines whether tumour growth, stasis or
regression occurs (Arends and Wyllie 1991). By measuring
apoptosis and mitosis in tumours produced by ras and myc
transfectant rodent fibroblasts, it has been suggested
that ras may inhibit cell death by apoptosis as well as
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inducing proliferation (Wyllie et al 1987). In view of
the hypothesised antagonism of Krev to ras. it is
therefore interesting to note induction of apoptosis by
Krev in this study. Induced apoptosis may diminish the
ability of Krev transfectants to produce tumours, or lead
to the loss of viability observed in C280 Krev
transfectants.
Fin ally, no insight into oncosuppressor modulation
of responses to cell-cell growth control signals could be
obtained owing to the inability to select transfectants
from non-clonable cells. Such cells maintaining cell
contacts may, in more efficient transfections, prove
instrumental in the analysis of oncosuppressor effects on
cell signalling.
5.4.4 Prospective oncosuppressor assays
The methods used to observe the effects of oncogenes
in vitro are clearly insufficient for thorough analysis
of the effects of oncosuppressor genes. The main problem
in designing experiments that involve transfer of
oncosuppressor genes is the need to overcome growth
inhibition (in order to expand the transfectants) without
selecting against the transferred gene (Sager 1986).
One possible solution may be the alternation of
periods of selection for cotransfected selectable markers
with periods of negative selection with 5-
bromodeoxyuridine and UV to kill growing cells. Negative
selection, however, requires oncosuppressor bearing
transfectants to grow less well in vitro than parental
154
cells, which is not necessarily the case.
Oncosuppressor inducibility would prove a valuable
asset allowing expansion of oncosuppressor bearing
transfectants without constitutive inhibitory effects.
Such inducibility would be absolutely necessary to allow
study of genes whose expression results in complete
growth arrest. The fortuitous existence of a temperature
sensitive p53 mutation permits tight control of mutant
expression (Michalovitz et al 1990), and this gene is
therefore particularly suited to regulable gene assays.
Although conditional mutations may be discovered for
other oncosuppressors, in the meantime, their controlled
expression from an inducible promoter may prove valuable.
Inducible elements permitting tight regulation of
expression in vitro include heat-shock promoters and the
MMTV LTR (mouse mammary tumour virus long terminal
repeat) 5' control region (Lee et al 1981).
Finally, use of antisense RNA or other specific
antagonist could be used to prevent constitutive
expression effects of an oncosuppressor. Useful
antagonists would include conditional mutant (and
therefore regulable) oncogenes acting downstream of the
oncosuppressor. On removal or silencing of antagonist,
after selection and expansion of oncosuppressor bearing
transfectants, the oncosuppressor gene expression would
resume and its effects could be observed.
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Chapter 6: Concluding discussion
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Xenograft resources described in preceding chapters
represent a valuable system amenable to widespread
exploitation.
6.1 Tumour classification
By virtue of the fact that renewable stable
xenograft resources allow unlimited genotypic and
phenotypic characterization of individual tumours,
di fferent types of tumours can be identified. A diploid
DNA status has previously been correlated with a low
incidence of p53 mutations (Remvikos et al 1990), which
in turn correlates with a right-sided location and
mucinous histology (Campos et al 1991); while
statistically significant associations are reported of
allelic losses with a left-sided location and the absence
of extracellular tumour mucin (Kern et al 1989). Tumours
within the xenograft set support all these correlations
suggesting the existence of 2 genetically distinct
classes of tumours.
The classification of many tumour xenografts into a
group rarely exhibiting colon-associated genetic changes
demonstrates the incomplete nature of the linear genetic
model for tumour progression (figure 4), implying the
existence of divergent pathways.
6.2 Suggested roles for genes
Under-representation of o53 mutated tumours in CBA
mice, and to a lesser extent in SCID mice may reflect
immune rejection. The therapeutic implications of
immunogenicity specifically associated with the mutated
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form of p53 would be immense both for preventative and
corrective cancer treatment.
The lack of linkage between 17p allele loss and p53
mutations in tumour xenografts may result from selection
pressures within this set but nonetheless, implies
independent effects of these 2 events. Furthermore,
despite the reported tight linkage in colon cancers
(Baker et al 1990a), lack of linkage has been observed in
large numbers of unselected breast tumours (Coles et al
1990), and a similar observation has been made in the
primary colorectal tumours gathered by our group (C
Purdie, unpublished results). It is plausible that the
high frequency of 17p allele losses in unselected tumours
make their detection common in association with o53
mutations, but that linkage is not necessary.
The class of tumours sustaining colon-associated
genetic lesions may be selected against in CBA hosts due
to immunogenicity of p53 or slow growth. The more severe
immune deficiency of SCID hosts seems, however, to allow
indiscriminate xenograft growth. More lesions at key loci
may therefore be detected in sets of xenografts in SCID
mice. The prominent nature of co-operative defects at
these loci in widespread situations was emphasised by
their specific involvement in colorectal progression in
vitro.
The demonstration, also in vitro. of a specific APC
and MCC allele imbalance during colorectal tumour cell
progression implies a dominant negative effect for one or
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both of these genes. Since functions are known for
neither of these genes but the majority of mutations
detected to date are expected to annul protein function,
this putative functional mutation may provide vital leads
to future analysis.
6.3 Sequence analysis
By providing stable renewable resources of tumour
without human stroma, the xenografts will be vital for
sequence analysis. Together with the available paired
normal DNAs, xenografts will facilitate PCR
identification of tumour specific sequence differences,
in particular of DCC. MCC. and APC genes. Furthermore,
the same virtues certify xenograft s as valuable resources
(in conjunction with constitutional DNA resources) for
unlimited search in candidate tumours, for the genetic
defect or defects and further somatic changes responsible
for hereditary non-polyposis cancers.
6.4 Oncosuppressor assays
Oncosuppressor gene assays on the variety of known
genetic backgrounds provided by xenografts will supply
vital information on the effects of co-operating loci.
As well as proposed introduction of wild-type
oncosuppressor genes,, assays of other tumour-associated
genes and their combinations will be informative.
Expression of an exogenous mutated copy of a gene known
to be unrearranged in the recipient cell would allow
investigation of dominance and simulation of in. situ
events in tumorigenesis. Large numbers of possible
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transfection experiments exist according to the variety
of backgrounds available, assays of wild-type or mutant
genes and double transfections with pairwise combinations
of exogenous genes. Besides generating valuable
information on gene co-operation, knowledge would be
gained of both intra- and inter-gene dominance.
More specific transfections in which selected wild-
type oncosuppressor genes are disabled by gene targetting
will also be possible. By disabling firstly one allele
and observing the phenotype and then inactivating the
second allele (Riele et al 1990) precise information on
dominance and gene effects would be obtained. Specific
correction of defects may also be possible by similar
methodology but using replacement vectors.
Less technically demanding experiments which may
also generate very useful data would be the construction
of somatic cell hybrids. The fusion of cells from the
variety of lines available may indicate the existence of
complementable defects not easily otherwise predicted.
Cell fusions from lines carrying known differences at
tumour-associated loci would supply information about
both dominance and the effects of various combinations of
lesions.
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Chapter 7: Materials and methods
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7.1 Routine tissue culture
The conditions described below were applied to the
routine culture of all established lines other than the
adenoma derived colorectal line PCAA. This and primary
colorectal cultures required different conditions,
described in 7.2.
7.1.1 Medium
340ml Deionised distilled water




0.8ml Penicillin/Streptomycin (60,000 Units/mml,
60,000 ug/ml)
pH to 7.2 with 5M NaOH.
Water was pre-sterilized by autoclaving, medium
concentrate was bought sterile and other components were
sterilized by 0.2um filtration. A sample of prepared
medium without antibiotics was always tested for
sterility before use.
7.1.2 Serum
All serum (Gibco or Northumbria biologicals Limited)
was batch tested for the ability to sustain growth of
routinely grown cell lines, and was heat inactivated and
tested for sterility before use. Heat inactivated newborn
calf serum (HINCS) or foetal bovine serum (FBS) was added
to culture medium to give a final concentration of 10%
unless otherwise stated.
7.1.3 Trypsin and EDTA
0.02% EDTA
355ml autoclaved deionised distilled water
40ml xlO PBS (Northumbria Biologicals Ltd.)
4ml 2% EDTA (autoclaved)
Sterility was tested by incubation of a few drops in
medium without antibiotics.
0.1% Trypsin
Powdered trypsin (DIFCO) was prepared as a 0.1%




20ml of 2.5% trypsin in PBS
10ml of 2.0% EDTA in PBS
270ml PBS
Filtered into 20ml aliquots and stored frozen.
7.1.4 Feeding and passaging
Cells were all fed twice weekly by replacement of
used medium with the same volume of fresh medium, unless
passage was required due to confluence. 25cm^- flasks
were always fed with 4 ml of medium, 75craa with
approximately 25ml, and 150cmz with approximately 40ml.
All plastic-ware was bought sterile from Costar. Cells
were routinely passaged by discarding medium and passing
an equal volume of 0.02% EDTA over the monolayer. As
EDTA chelation of Ca2+ and Mg2+ caused cells to round up,
the EDTA was discarded and 4ml of 0.01% trypsin added.
Alternatively, some cells were harvested in one step
by addition of 4ml TrypEDTA and incubation at room
temperature for 2-5 minutes. With gentle agitation the
cells were washed from the surface of the flask and could
be pelleted or divided as required. The desired
proportion of cells were reseeded and when placed in a
new flask, cells were gassed in 5% C02 in air via a
pasteur pipette.
7.1.5 Freezing
Monolayers were routinely harvested and trypsin was
inactivated by adding medium containing serum. Cells were
counted, using a glass slide haemocytometer, pelleted by
centrifugation at lOOOrpm for 5 minutes, and resuspended
in a 1:1 mixture of 20% DMSO (dimethyl sulfoxide) and
HINCS or FBS, at a cell concentration of 5xl0fe-10 /ml.
lml aliquots were placed in polypropylene Bio-freeze
vials (Costar) at -70° in a plastic rack overnight, after
which vials were transferred to liquid nitrogen. To thaw,
vials were removed from liquid nitrogen and thawed
rapidly at 37°C. DMSO was washed from the cell
suspension by spinning at 1000 rpm for 5 minutes in
medium containing 10% serum, and cells were seeded into
25cm2 flasks in 4ml of fresh medium.
7.1.6 Mycoplasma tests
Cells were routinely tested for the presence of
mycoplasma by incubation of 0.1xl0w cells in 4ml medium
with serum at 37°C in a 50mm petri dish in a C02
incubator for 4 days. Medium was then discarded and cells
fixed twice in 3 parts methanol: 1 part acetic acid for 5
minutes each time. The dish was inverted and allowed to
dry and cells were then stained with 4ml of lOug/ml
Hoechet 33258 dye in PBS for 10 minutes. After washing
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the dye off with PBS, a coverslip was placed over cells
for viewing under an UV microscope.
7.2. Culture of colonic epithelial cells
The following special methods were applied to primary
colorectal tumour cultures and the colorectal line PCAA
(Paraskeva et al 1984).
7.2.1 Colonic culture medium
Conditioned medium was obtain ed by feeding confluent
Swiss 3T3 feeder cells 24 hours before pass, and
retaining this conditioned medium at pass.
200ml conditioned medium (sterilized by 0. 2um
filtration)
250ml Glasgow medium, prepared (section 7.1.1)
0.5ml Hydrocortisone stock solution lmg/ml
0.5ml Insulin stock solution 200 Units/ml
50ml HIFBS
A sample of all media was sterility tested by
incubation for a few days in a 37°C incubator prior to
use.
7.2.2 Collagen coated flasks
Calf thymus collagen type I (Boehringer) was
dissolved in 1:1000 acetic acid: water to give a final
concentration of 0.8mg/ml, and was stored at 4°C.
Collagen type IV (Sigma) was dissolved in 1:400 acetic
acid: water to a final concentration of 0.5mg/ml. Up to 5
hours were often required at 4*C or on ice to allow the
collagen to dissolve completely. To coat flasks, 2-4ml of
cold collagen was drawn from the solution through a
sterile 16 gauge syringe needle and displaced onto the
flask surface under sterile conditions. The solution was
spread over the entire flask surface by gentle agitation
and all excess liquid was drawn off for re-use, via the
syringe and needle. Flasks were left in a 37°C room with
loosened lids overnight or until dry, sterilized
overnight under UV, and stored at 4cC until use. After
warming to room temperature, flasks were rinsed in wash
solution (section 7.3) to remove all traces of acetic
acid before seeding cells.
7.2.3 Feeder cells
Early passage 3T3 cells were split once a week and
an extra 75cm* flask was set up for mitomycin C mediated
mitotic arrest. 24 hours after reaching confluence,
medium was replaced with 25ml of fresh medium containing
lOug/ml mitomycin C (stored at lOOx concentration in
250ul aliquots in PBS at -70°C) . The flask was gently
rotated to ensure complete coverage with the poison, and
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incubated at 37cC for 2-3 hours. This medium was
discarded into a chlorine solution as was all Mitomycin C
apparatus, to soak overnight before discarding or
washing. The treated monolayer was then washed 3 times in
PBS before harvesting in the normal way and resuspending
in medium with 10% serum at a concentration of
10*cells/ml. These cells were stored in a plastic
universal at 4°C for up to 7 days, and added dropwise to
cultures as required.
7.2.4 Feeding and passaging
Colonic epithelial cells were fed according to
routine methods other than over the first 10 days after
seeding or passaging. During this period, it was often
necessary to spin used medium for 5 minutes at lOOOrpm to
retain viable cell aggregates which had not yet become
attached. Once pelleted, these aggregates were
resuspended in 4ml of fresh medium and were transferred
back into the flask. At each feed flasks were checked for
an adequate feeder cell content and feeders were added
where necessary. Cells were harvested for passage by
incubation at 37°C for 20-40 minutes in dispase (sterile
grade 1, Boehringer), a neutral protease from Bacillus
polymixa. 5rag vials were dissolved in 15ml of colonic
culture medium with serum, and 2.5ml of this final
solution at 2 Units/ml were used for each passage. Cells
became detached as sheets leaving fibroblasts still
attached, and could be resuspended into small clumps of
cells by gentle repeated flushing over the flask surface
with a sterile fine bore tip on a 5ml Finnpipette. The
dispase was washed out by centrifugation in medium with
serum (lOOOrpm, 5 minutes), and cells were resuspended
and seeded at the required split ratio.
7.2.5 Freezing
Epithelial cells were harvested as for passage
(above) except that the cell pellet was resuspended in
DMSO: serum (1:1) and frozen as described in section
7.1.5. Since cell number in the harvested cell clumps was
not easily counted, the adopted convention was to freeze
the cells of lx 25cm1- flask in each 1ml of freezing
medium.
7.2.6 Mycoplasma tests
For slow growing primary cultures it was not always
possible to harvest cells for the described method of
test (section 7.1.6). Accordingly medium from these
cultures was poured onto preparations of other cells
known to be mycoplasma free, and the test could be
carried out as described.
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7.3 Seeding primary cultures
Maximum amounts of tissue in sterile PBS on ice
were taken to a class II safety cabinet. The PBS was
poured off into a waste flask and the tissue mass was
washed twice in wash solution and deposited in a sterile
plastic petri di sh in a small pool of fresh wash
solution. The tissue was then broken down as much as
possible by repeated slicing with 2 sterile scalpels.
This suspension was transferred to a plastic 20ml
universal and spun for 5 minutes at lOOOrpm in wash
solution. The supernatant was discarded and the pellet
resuspended in 4ml of primary culture medium and seeded
in 25cm1 collagen coated flasks with 8 drops of feeder
cells from a sterile pasteur pipette. Cells were gassed
with 5% C02 in air supplied from the gas cannister via a
fine rubber hose with a pasteur pipette attached, and
flasks were kept in a 37°C room.
Wash solution
400ral Glasgow medium, prepared (section 7.1.1)
lml Stock penicillin /streptomycin
(60,000 U/ml, 60,000 ug/ml)
10% FBS (section 7.1.2)
5ml 2M Hepes (Sigma)
7.4 Fibroblast elimination
7.4.1 Differential settling
Some contaminating indigenous fibroblasts were
discarded at initial feeds during the first 10 days of
primary culture. Before floating cell aggregates were
centrifuged to prevent loss during feeding (section
7.2.4) differential settling of the spent medium was
allowed in order to retain heavier particles (cell
aggregates) only. Discarded medium was placed in a 20ml
plastic universal which was topped up with wash solution
(7.7.1). The mixture was shaken and allowed to settle for
10 minutes before using a fine bore tip on a 5 ml
Finnpipette to draw off the maximum amount of medium
without disturbing the settled pellet. The pellet was
then resuspended in wash solution and spun for 5 minutes
at 1000 rpm to allow re-seeding.
7.4.2 Differential trvpsinisation
Short, repeated treatments with a trypsin solution
were used to remove fibroblasts which outgrew from small
blocks of tissue after epithelial cell attachment to the
substratum. Medium was discarded and replaced with 2.5ml
of TrypEDTA solution and flasks were incubated at 37°C
for 2-3 minutes. TrypEDTA solution was then discarded and
replaced with fresh medium as in feeding.
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TrvpEDTA
20ml of 2.5% trypsin in PBS
10ml of 2.0% EDTA in PBS
270ml PBS
Filtered into 20ml aliquots and stored frozen.
1 week was allowed for recovery from trypsinisation
before repeating the treatment if necessary.
7.5 Carciinoma specimens
Surgical colorectal re section specimens bearing
carcinomas were received directly from the operating
theatre. These were transported on ice to the trimming
room where they were rinsed with cold phosphate-buffered
saline or PBS (Northumbria biologicals Ltd.) A section of
tissue selected on the basis of viable appearance was
removed to wash solution in a 20ml plastic universal.
7.6 Animals
CBA mice were immunosuppressed by thymectomy
followed by cytosine arabinoside injection and whole body
irradiation (Steel et al 1978) . Both immunosuppressed CBA
and congenitally immunodeficient nudes (nunu. OLAC or
B&K, London) were housed within a laminar flow unit which
supplied a constant stream of filtered air. All cages
were autoclaved before use and drinking water contained
3ml of 0.01M HCL /50ml bottle. SCID mice were housed
within an isolation unit where disinfection barrier




400ml Glasgow medium, prepared (section 7.1.1)
lml Stock penicillin /streptomycin
(60,000 U/ml, 60,000 ug/ml)
10% FBS (section 7.1.2)
5ml 2M Hepes (Sigma)
7.7.2 Dorsal xenograft
Portions of carcinoma in wash solution were
transported on ice to a class II safety cabinet and
washed twice in fresh wash solution before slicing with
sterile scalpels into portions no greater than 0.5cm
cubed. These portions were kept in ice-cold wash solution
until xenografted.
Pairs of CBA or nude recipient mice were
anaesthetised with diethyl ether for each xenograft
implantation, and the operation was carried out on an
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alcohol sterilized area of bench. SCID mice were
anaesthetised with a 1:1 mixture of Hypnorm (Janssen) and
Hypnovel (Roche) anaesthetics, diluted to a third of the
total concentration in deionised distilled water. 0.1ml
of anaesthetic/lOg mouse was administered
intraperitoneally and after 10 minutes the anaesthetic
effect was tested by response to tail-pinching. All SCID
operations were carried out in the sterile environments
either of the isolator or of a laminar flow cabinet.
Cages of animals were transferred between the two in
autoclave bags containing sterile air and disinfection
barrier regulations were observed.
All anaesthetized mice were prepared for operation
by alcohol cleansing of the fur. Using sterile scissors
and forceps, a small dorsal incision parallel to the
backbone was made through the skin of each animal. One
tumour portion was implanted into the subcutaneous space
on each side of the incision and wounds were closed with
sterile 12mm skin clips (Avlox), or sewn in 2 stitches
using a sterile silk suture with needle attached
(Ethicon). All xenografts were implanted within 60
minutes of original colorectal resection.
7.7.3 Tissue injections
Portions of carcinoma were collected and washed as
for xenografted tissues, but slicing with scalpels was
continued until a particulate solution was produced which
could be drawn into a 16 gauge syringe needle. This was
pelleted by centrifugation at lOOOrpm in a bench
centrifuge for 5 minutes before resuspension in 0.1ml-
0.3ml of wash solution for each injection. Injections
were given without anaesthetic. Subcutaneous injections
were administered to the inner left flank unless
otherwise stated and intraperitoneal injections were
directed just right of the centre of the abdomen.
7.7.4 Cell injections
Cells were routinely harvested, washed twice in PBS,
and counted using a glass slide haemocytometer. Cells
were resuspended in cold PBS on ice at a known
concentration allowing 106-107 cells in 0.1-0.3ml volume
for each injection. Cultured cell suspensions were
injected via a 25 gauge microlance needle.
7.7.5 Serial xenourafting
As tumours reached an externally visible diameter of
approximately 1cm, or if poor health was observed,
animals were killed by cervical dislocation. At
dissection tumour masses were freed and removed from
surrounding tissues to PBS where approximate sizes were
recorded. After trimming away necrotic tissues with a
sterile scalpel, remaining tumour was divided for
transplantation and analysis. New recipients were
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implanted following the method for initial implantation,
within 10 minutes of tumour removal.
7.8 Tissue freezing
Maximum amounts of excess viable tissue from
xenograft passage were taken in sterile PBS on ice to a
class II safety cabinet. The PBS was poured off into a
waste flask and the tissue mass was washed twice in wash
solution and deposited in a sterile plastic petri dish in
a small pool of fresh wash solution. The tissue was then
broken down as much as possible by repeated slicings with
2 sterile scalpels. This suspension was transferred to a
plastic 20ml universal and spun for 5 minutes at lOOOrpm
in wash solution. The supernatant was discarded and the
pellet resuspended in 10% DMSO: FBS (1:1). Cell
concentration was unknown but excess tissues from an
average sized tumour xenograft were generally frozen in a
volume of 2 ml. 1ml aliquots were placed in polypropylene
Bio-freeze vials (Costar) at -70® in a plastic rack
overnight or for up to 3 days. At this time vials were
transferred to liquid nitrogen for storage. To thaw,
vials were removed from liquid nitrogen and thawed
rapidly at 37°C. DMSO was washed from the cell
suspension by spinning at 1000 rpra for 5 minutes in wash
medium, and cells were either seeded as primary cultures
(section 7.3), or injected into animals (section 7.7.3).
7.9 Histology and immunocvtochemistrv
Representative samples of primary tumours and serial
tumour xenografts were fixed in 10% buffered formalin for
histology. Fixed tissues were processed in paraffin and
sections were cut, stained with haematoxylin and eosin
and mounted on glass slides.
Representative samples of primary tumours and serial
tumour xenografts were fixed at 4°C overnight in
periodate lysine paraformaldehyde dichromate (PLPD) for
histology and immunocytochemistry.
For immunocytochemistry paraffin processed sections
were blocked with normal rabbit serum diluted 1:5 in Tris
buffered saline (NRS-TBS) and primary antibody was
applied in 1:100 and 1:400 dilutions in NRS-TBS for 30
minutes. After rinsing and reblocking with NRS-TBS,
biotinylated secondary antibody was applied in 1:400
dilution in NRS-TBS also for 30 minutes. Antibodies were
detected by an avidin-biotinylated horseradish-peroxidase
complex (ABComplex/HRP kit, DAKOPATTS). A preparation of
the SV80 cell-line, known to over-express p53 protein
(Harlow et al 1985), was also fixed in PLPD and included
in each run as a positive control. To carry out p53
immunocytochemistry on cultured cells, 10^ cells were
routinely harvested and suspended in 1ml of 1% agar.
After chilling at 4°C for 16 hours, the block was removed
to PLPD and treated as above.
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Made up to 50ml in Sorensens phosphate buffer
(0.05M, pH 7.4)
Combine with 5% potassium dichromate in 50ml distilled
water immediately before use.
7.10 Electron microscopy
For electron microscopy, small sections of
xenografted tumour freshly excised from the animal were
sliced separately with a fresh scalpel to lmra cubes in
gluteraldehyde fixative.
Gluteraldehvde fixative
3% gluteraldehyde in 0.1M Cacodylate buffer
Post-fixed in 1% osmium tetroxide in 0.1M Cacodylate
buffer and embedded in araldite.
Representative areas of tumour were selected from lu
semi-thin araldite sections. Ultra-thin sections of
chosen areas were secured on 0.35mm copper grids (old
400s, Athene) and viewed on a Joel 100S transmission
electron microscope.
7.11 Flow cytometric analysis
7.11.1 Cell dispersal and staining (Vindelov et al 1983)
Portions of tissue of diameter less than 0.25cm were
suspended in 200ul of citrate buffer and cut into small
pieces using a sterile scalpel. 450ul of trypsin solution
and 15ul of chicken red blood cells at 106/ml were added
in an eppendorf tube and incubated for 10 minutes at room
temperature mixing vigorously after 5 and 10 minutes. The
same incubation process was carried out after the
addition of 325ul of trypsin inhibitor/RNAase solution,
and for a third 10 minute period on ice after addition of
250ul dye solution. The final mixture was filtered




Dissolve in 800ml distilled water
Add 50ml dimethyl sulfoxide
Make up to 1000ml with distilled water.
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Stock solution pH7.6




Make up to 2000ml with distilled water.
Trypsin solution










Final nuclear suspensions were analysed on a Coulter
epics CS flow cytometer at an excitation wavelength
of 488nm. The chicken red blood cells served as an
internal standard allowing the identification of the
normal human diploid G0/G1 peak, since the DNA content
of that of the chicken is about 35% of the human peak.
7.12 Genomic DNA extraction
At both original resection and most xenograft
passages, portions of tumour approximately 0.25cm
diameter were placed in sarstedt freezing vials and
immersed in liquid nitrogen before subsequent storage at
-70°C. Portions of normal colorectal mucosa from the
tumour bearing patient were snap frozen in the same way,
and peripheral blood was also taken from each patient as
a second source of somatic DNA.
7.12.1 DNA from frozen tissue
Pieces of tissue approximately 0.25cm diameter were
each sliced in 500ul TE-9, within a class 2 safety
cabinet using sterile scalpels. This fine mince was
transferred to an eppendorf tube and incubated at 48°C
overnight in the presence of 1% sodium dodecyl sulfate
(SDS) and 500ug/ml proteinase K (Boehringer) to allow
cell lysis and protein digestion.
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TE-9
500mM Tris pH 7.6
20mM EDTA
The resulting extract was mixed with an equal volume
of TE saturated phenol, spun in a microfuge for 5 minutes
and the top phase was removed to a clean eppendorf. This
step was repeated twice, firstly with an equal volume of
PC-9, and for the resulting top phase with chloroform:
iso-amyl alcohol (24:1). DNA was precipitated in 2
volumes of absolute ethanol and 0.25 volumes of 7.5M
ammonium acetate at -70°C overnight, and was collected by
centrifugation for 15 minutes at 4°C in a
microcentrifuge. Pellets were then routinely resuspended
in 200ul of TE on ice. Optical density readings at 260nm






Equal volumes of phenol and TE were mixed, allowed





Mixed repeatedly allowed to settle and top phase
discarded.
7.12.2 DNA from blood
Blood samples were collected into 0.2% EDTA to
prevent coagulation. Whole blood was lysed in an equal
volume of lysis buffer for 30 minutes at room
temperature. This was mixed with an equal volume of TE
saturated phenol and spun at 3000rpm for 20 minutes and
the top phase was precipitated at -20°C overnight in 0.25
volumes of 7.5M ammonium chloride and 2 volumes of
isopropanol. The pellet was air dried and subsequently








7.12.3 DNA from cultured cells
1 or 2 x ISOcra'2" flasks of cells were routinely-
harvested (sections 7.1 and 7.2) and pelleted. 500ul of
TE-9 with proteinase K and SDS were added to the cell
pellet following the method for tissues, and subsequent
procedures for digestion and cleaning were as before.
7.13 Southern analysis (Sambrook et al 1989)
7.13.1 Genomic digests
lOug of each DNA sample were digested overnight
under standard conditions, but in a minimum 2-fold excess
of restriction enzyme and a total volume of 30ul. The
following morning a further lul of enzyme was added to
each digest and allowed a further 5-9 hours of
incubation. Each digest together with 2 ul of loading
buffer was then loaded into one well of an 0.8% agarose
(electrophoretic grade, Bethesda research laboratory)
500ml slab gel made up in Tris borate EDTA solution (TBE)
and immersed in 2.5 volumes of TBE. Large gels were run









After running, genomic gels were stained with ethidium
bromide at 0.5ug/ml in TBE for 15 minutes, destained
briefly in distilled water and visualized on an UV
transilluminator where the image was recorded by a camera
linked to a Mitsubishi video copy processor.
7.13.2 Transfer
Gels were trimmed to 20cmx20cm, denatured for 30
minutes in 0.5M NaOH 1.5M Tris on an orbital shaker and
transferred onto the blotting apparatus. Whatman 3mm
paper was pre-soaked in 0.5M NaOH 1.5M Tris and placed on
a plate suspended over a glass dish containing the same
alkaline solution, with the ends of the paper serving as
a wick to draw up this solution. A 20cmx20cm charged
nylon membrane (Hybond N, Amersham) was also pre-soaked
and placed gently on top of the gel which was then
covered with 4 layers of pre-soaked 3mra paper cut to the
size of the gel. Any bubbles between gel and membrane
were rolled out using a large glass pipette. Exposed
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edges of the gel were sealed with cling film to prevent
buffer by-passing the filter, and a 3 inch stack of
absorbant paper towels topped with a weight was placed on
top to aid capillary movement of the buffer. The
apparatus was left for 12-16 hours to allow transfer of
the DNA onto the membrane after which the membrane was
neutralised in 3M NaCl 0.5M Tris pH 7.4 for about 1 hour
and allowed to dry face up on filter paper at room
temperature.
7.13.3 Prehvbridization
Filters were placed between net meshes in sealed
plastic hybridization bags (Hybaid) and prehybridisation
solution was added to one port with a plastic syringe
ensuring that all air bubbles were withdrawn.
Prehybridisation was carried out for 6 hours in a 65aC
water bath with 50ml of prehybridization solution per




15mM Tri sodium citrate
Made up in distilled water as a 20x concentrated solution





lOOug/ml denatured and snap-cooled salmon sperm DNA
7.13.4 Probe preparation
Probe inserts were digested from plasmids with the
appropriate restriction enzymes. In most cases known
amounts of digests were run out on 1% low melting point
agarose gels containing 0.5ug/ml ethidium bromide. Insert
bands were identified under UV light and sliced from the
gel in the minimum possible volume of agarose using a
scalpel. 3ml of distilled water were added for every O.lg
of agarose and each sample was boiled for 7 minutes in an
eppendorf tube and aliquoted into samples containing 25ng
of insert in a volume no greater than 25ul. For some
probes this insert isolation procedure was not necessary
and digests could be diluted directly and aliquoted. In
either case, 25ng aliquots were boiled further for 1
minute and transferred immediately to a 37°C water bath
for 10-60 minutes prior to labelling. Probes in agarose
were always labelled for 12-16 hours at room temperature
in a lead casket, while unpurified probes were often






5ul alpha- 31T[dCTP] (50uci)
2ul Klenow fragment
The buffers and reagents were supplied in kit form
(Amersham).
Labelled DNA was separated from unincorporated
radioactivity by passing the sample through a nick-column
(Pharmacia) and collecting the DNA containing fraction.
This was spun for 2 minutes in a microfuge with an equal
volume of phenol, and the top layer was removed and
precipitated in 2 volumes of absolute ethanol and 1/10
volume 3M Na acetate at -20°C for no less than 10
minutes. The precipitate was pelleted by spinning in a
microfuge for 15 minutes and inverting the tube on a
paper towel to dry.
7.13.5 Hybridization
1) Basic method- Probes were denatured in TE containing
lOOug/ml salmon sperm DNA at 92-100®C for 10 minutes and
added directly to the filter. About 20ml of the
prehybridization solution was drawn from the bag via one
of the ports using a large plastic syringe and denatured
probe was added and mixed well before expelling the
liquid back into the bag.
2) VNTR and other probes with high non-specific binding-
In these cases it was necessary to pre-incubate the
denatured probe in a solution containing denatured human
DNA. This was done by denaturing lOOug/ml placenta DNA as
above and adding this to 50ml of fresh prehybridization
solution at 65 C. Probe pellets were denatured in 1ml of
this solution, as above, and added to the human DNA
solution and incubated at 65°C for 1 hour. At this point
pre-hybridization solution was discarded from the bag and
replaced with the pre-incubated probe solution.
In both cases hybridization was carried out for 12-16
hours in a 65°C water bath.
7.13.6 Washing and detection
Hybridization solution containing probe was
discarded down a radioactive designated sink and unbound
radioactivity was washed off by firstly running 500ml of
2xSSC over the filter using the hybaid vacuum pump
system. 250ml of 0.5xSSC, 1%SDS was then added to the
bag which was incubated at 65°C for 2x10 minute periods
or until no radioactivity above background was detected























































































































































































































































3) x(number)= xenograft passage number
4) A= allele
5) C= constant allele
6) Allelic losses are shown with probes YNZ22, L5. 71 &
BV15.65
7) Allelic retentions are shown with probes YNZ22, L5.71,
Pi22.7, L5.62 4 MLZ74
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minutes gentle agitation in 0.2xSSC at room temperature.
Membranes were drained briefly on filter paper and
wrapped in cling film to prevent drying. Probe was
detected by x-ray film (Fuji) between intensifying
screens at -70°C for 1-10 days, and the autoradiograph
was developed using standard photographic solutions.
7.13.7 Re-probing
Since some probes detect polymorphisms with the same
enzymes as others, many filters could be stripped of
probe and re-used. This was achieved by boiling filters
for 20 minutes in approximately 150ml/filter of 1%SDS,
O.lxSSC. Filters were allowed to dry face up on filter
paper and could then be used again from the
prehybridization step onwards.
7.13.8 Probe information and patterns
Details of the probes used and thei r conditions of
usage are tabulated for chromosome 5 probes and for other
probes in tables 17a) and 17b) respectively.
Notes for table 17:
a) Probe inserts purified from agarose before labelling.
b) Competition with human DNA required during
hybridization
c) Purified probe purchased from Cellmark diagnostics,
ICI.
Some of the patterns detected by probes together
with some examples of allelic losses and retentions are
shown in figure 30.
7.14 Densitometry
Intensity of bands was measured on a LKB Ultroscan
XL Laser densitometer. For each sample, the relative
intensities of bands were presented as a curve, peaks of
this curve corresponding to the bands were defined and
the relative area under the curve for each peak was
calculated. These relative areas were direct measurements
of the ratios of intensities of bands.
7.15 Plasmid DNA (Sambrook et al 1989)
Transformation of competent bacteria,
minipreparation and large scale isolation of plasmid DNA
were all carried out in adherence with the methods
described.
Unless otherwise stated digests of lug DNA were
routinely cut with lul of enzyme in a total volume of
lOul for 1 hour, and run with lul of loading buffer in
50ml or 100ml 0.8% agarose gels containing 0.5ug/ml
ethidium bromide, for a few hours at room temperature.
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7.16 Transfection of cultured cells
7.16.1 Electroporation
Desired capacitance and voltage were set on the
pulse controller unit of a gene pulser apparatus (Bio-
rad). These were selected such that the peak field
strength in volts/cm would fall in the range of 375-625
for human cells, and 625-700 for mouse fibroblasts as
recommended by Bio-rad, and the pulse time would
approximate 7 milliseconds. Cells were routinely
harvested at 80% confluence, washed twice in cold PBS and
resuspended in PBS at 106/ml. Sterile gene pulsar
cuvettes with built in 0.4cm electrodes (Bio-rad) were
pre-chilled on ice. 0.8ml of cells were placed in each
cuvette and 2-20ug DNA was added. Cells and DNA were held
on ice for 10 minutes prior to electroporation.
Individual cuvettes containing cells and plasraid were
placed in the gene pulsar chamber, pulsed once and
returned to ice for an additional 10 minute incubation
before plating. Cells were washed out with warmed medium
and seeded into either 25cm-2- flasks which were gassed and
placed in a 37°C room, or 100mm petri dishes which were
placed in a 37°C C02 incubator.
7.16.2 Using TRANSFECTAM
Cells at 50-80% confluence were transfected in
either 25cmx flasks or in 60mm petri dishes. TRANSFECTAM
powder (IBF, Northumbria Biologicals Ltd.) was
solubilised in ethanol according to the manufacturers
specifications. 2-5ug of plasmid DNA for each
transfection were added to 250ul 0.3M NaCl (filter-
sterilised) . 3ul of the TRANSFECTAM stock per ug DNA were
diluted to 250ul and plasmid and TRANSFECTAM solutions
were combined. Cells were prepared for transfection by
washing the monolayer twice with cold PBS, and the
combined solutions were added in 1ml prewarmed culture
media without serum. Flasks were placed in a 37°C C02
incubator for 6 hours at which point a further 3ml of the
appropriate growth medium with serum were added. After 48
hours DNA and TRANSFECTAM containing medium was replaced
with 4ml of the appropriate growth medium.
7.16.3 Lioofection
Cells at 50-80% confluence were transfected in
either 25cma flasks or in 60mm petri dishes. 2-5ug
plasmid DNA and 40ug of Lipofectin reagent (GIBCO BRL)
were diluted separately to 50ul in sterile distilled
water for each transfection. The 2 solutions were slowly
combined in polystyrene tubes ensuring that no
precipitation occurred. The combined solutions were left
to stand for 15 minutes to allow formation of lipid-DNA
complexes. Meanwhile the cell monolayers were washed
twice with serum free medium, 3ml of which were added to
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each flask of cells. The lOOul of reagent- DNA complex
was added dropwise but uniformly, while the flask was
gently swirled. Cells were incubated for 24 hours in a
37°C C02 incubator. At this point 3ml of medium
cobntaining 20% FBS were added for a further 48 hours.
Medium containing reagent was then replaced with the
appropriate growth medium.
7.17 Selection of stable transfectants
Selection for transfectants was initiated 48 hours
after transfection. At this time, and twice weekly
thereafter, cells were fed with the appropriate growth
medium containing a known concentration of either
Geneticin G-418 sulphate (Gibco, batch microbiological
potency of 500 ug/mg), or hygromycin-B (SIGMA). If cells
reached confluence before selection had taken full
effect, they were passaged into 2 or 3 flasks all of
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ability of critical genetic lesions in human colorectal carcinoma
Allografts
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Figure 1 Histological comparisons of original colorectal tumours with the corresponding xenografts, a, A poorly differentiated
adenocarcinoma AGDU. b, Corresponding xenograft at 5th passage XAGDU4. c, A well differentiated adenocarcinoma MUCO.
d, Corresponding xenograft at 11th passage XMUCOIO. e, A moderately differentiated adenocarcinoma CHKE. f. Corresponding
xenograft at 6th passage XCHK.E5.
eral genetic lesions are associated with the genesis of
nan colorectal carcinomas including mutational activation
Ki-rzw and p53, and loss of heterozygosity involving
sumptive oncosuppressor loci on 5q21, 17p 13, and 18q22
aron & Vogelstein, 1990). Abnormalities at the 17p 13
us are recorded in many types of tumours (Nigro et al.,
19) but there is no evidence at present that the 5q and 18q
i are involved in sporadic neoplasia other than that of
arectal mucosa. Although the 17p 13 locus is probably
igenic with p53, and the product of the 18q22 gene
tears to be a cell adhesion molecule, the function for all of
se genes in oncosuppression is poorly understood. The
il vehicle for assay and analysis of these unknown gene
ctions would be a colorectal cancer cell line in which the
tosuppressor genes were known to be aberrant or inactive,
theory, replacement of even one copy of the appropriate
ict oncosuppressor gene might then restore phenotype to
mality. Recent studies have demonstrated oncosuppres-
l of this type on introduction of normal DNA from the
noblastoma and Wilms' susceptibility loci, into tumour
lines (Huang et al., 1988; Weissman et al., 1987). How-
r, for none of the long-established colorectal cancer lines
dily available is status at critical oncosuppressor loci
>wn. Moreover long-established lines commonly acquire
litional genetic rearrangements during culture (Brattain et
1983; Park et al., 1987), which may not be reversible by
rection of the original oncosuppressor defect alone. We
refore set out to develop a series of lines from primary
jrectal tumours, defined both in terms of status at onco-
pressor loci on chromosomes 5, 17 and 18, and the
oility of each locus on serial passage.
a c
Portions of carcinoma obtained from surgical resection
specimens were xenografted as described by Lewko et al.
(1989), into pairs of immunosuppressed (thymectomised, ir¬
radiated and arabinoside-C treated) CBA mice (Steel et al.,
1978), with the modification that portions no greater than
5 mm3 were implanted dorsally at initial xenograft and at
subsequent transplantations.
From a consecutive series of 28 cancers implanted, 11 grew
to passage and eight were xenografted for more than five
passages, one of which has now reached passage 16. At each
serial passage excess tumour tissue was divided for analysis
allowing the characterisation of xenografted tumours at var¬
ious passage intervals, and the comparison of these with the
primary tumour (portions of which were always stored both
frozen and fixed at original resection). Haematoxylin and
eosin stained paraffin sections of both primary tumour and
xenografts fixed in 10% buffered formalin at all passages,
showed that the original histological pattern for each primary
tumour was conserved throughout serial passage. Although
most of the lines fell into the class of adenocarcinomas of
average degree of differentiation, extremes of both good and
very poor differentiation were represented (Figure 1). No
metastases were observed in mice.
To study the status of alleles closely linked to each of three
putative colon-associated oncosuppressor loci, genomic DNA
was prepared from frozen xenografted tumours at various
passages, and compared with DNA from primary tumour
tissue and normal colorectal mucosa or peripheral blood
leukocytes from the donor patient. Methods for DNA pre¬
paration, Southern blotting and probes and conditions for
hybridisation have been previously published (Ashton-
e
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Rickardt et al., 1989). Probes used were: for chromosome 5q:
pYN5.48 (Nakamura et al., 1988a), pEF5.44 (Dunlop et al.,
1990) rc227 (Meera Khan et al., 1988; Dunlop et al., 1989),
and two new probes pL5.62 and pL5.713 which map between
Jt227 and YN5.48 (Y. Nakamura, personal communication);
for 17p: pYNZ22 (Nakamura et al., 1988ft), pMCT35.1
(Carlson et al., 1988); and for 18q: pBV15.65 (Vogelstein et
al., 1988). Almost all of these probes detect highly polymor¬
phic sequences. pBV15.65 is situated within the 18q oncosup¬
pressor gene, pMCT35.1 lies close to the p53 gene and the 5q
probes are distributed through the APC locus over no more
than 15mb.
Table I summarises allelic losses or retentions found for
the parental normal and tumour DNA pairs at each locus. In
all cases studied, the allelic status of xenograft DNA was
unchanged from that of its primary tumour. For eight
tumours this genetic stability was demonstrated over at least
four xenograft passages (approximately 4 months) and in two
(one of which showed allelic retention at 5q and 17p) over 11
passages (approximately 11 months). A variety of combina¬
tions of allelic losses and retentions are represented, broadly
similar to those observed by ourselves and others in large
unselected series of primary tumours (Ashton-Rickardt et al.,
1989; Vogelstein et al., 1988). It appears from these observa¬
tions that the selection pressures which encourage growth of
human colorectal cancer xenografts in immunosuppressed
animals do not include allelic losses around the oncosuppres¬
sor loci commonly affected in human carcinogenesis in situ.
Although our primary aim was to establish the stability of
the lines at critical oncosuppressor loci, DNA ploidy was
measured by flow cytometry as a global, if crude, index of
total nuclear DNA content. Frozen tissues from both passage
5 xenografts and primary tumour were dissociated and stained
with 0.62 M propidium iodide as described by Vindelov (1983),
and analysed at an excitation wavelength of 488 nm in a
Coulter Epics CS flow cytometer. On the basis of an internal
chicken red blood cell standard, the presence of a human
diploid peak could be confirmed in every case. This was given
a ploidy value of 1, and any additional peaks were then
assumed to be aneuploid, and their DNA index (DI) derived
from their position relative to the diploid peak. In all cases,
xenograft DI was similar to that of the relevant primary
tumour (example shown in Figure 2), including four tumours
remaining diploid after five or nine serial passages in mice, and
one after 14 passages (15 months). A similarly high degree of
conservation of genetic stability throughout xenograft passage
in immunodeficient mice has been confirmed both karyotyp-
ically and at the genetic level by Lefrancois et al. (1989).
The demonstrated lack of genetic change for defined onco¬
suppressor loci qualifies these xenografts as favourable tu¬
mour models for analysis of oncosuppressor function, by
re-introduction of the normal genes. Since growth in vitro is a
prerequisite for genetic manipulation, tumour tissues re¬
moved immediately on to ice from animals at or following
Table I Allelic status at three oncosuppressor loci, and DNA index for
a set of 11 xenografts
Primary tumour
Line 17p 18q DNA Index
GRBO" R (5) R (4) R (2) 1.0 (5)
MUCO' R (10) R (10) - 1.0 (14)
RHSP' L (10) L (10) - 1.7-1.9 (12)
CHKE' R (4) R (4) R(3) 1.1-1.2 (9)
DABU" R (5) R (5) NI 1.0 (5)
ARNE' R (4) L (5) L(5) 1.5-1.6 (5)
MASM" R (5) R (5) R (2) 1.0 (9)
JOMcL* R (4) R (4) NI 1.0 (5)
JACA L (2) L (2) L(2) 1.6
CARO L (1) L (1) L (1) 1.4
JOWR R (1) R (1) R (1) 1.0
() = highest xenograft passage no. analysed; - = not done;
NI = non-informative (patient homozygous for alleles studied);
R = allele retained; L = allele lost; * = line xenografted over more than
five passages. In all cases the allelic status of the xenografts throughout
passage was identical with that of the primary tumour.
Figure 2 Flow cytometric comparison of an aneuploid primary
tumour (DNA index 1.7); arrowed, with the xenograft at passage
5 (DNA index 1.9). Diploid peak position is marked *.
naa
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Figure 3 Phase contrast microscopy of XRHSP xenograft tu¬
mour epithelial cells growing in culture as islands (I) surrounded
by feeder cells.
passage 5 were processed and seeded as primary cultures on
collagen coated flasks with mouse feeder cells, as described
by Paraskeva (1984). Epithelial cells from every xenograft
line grew in vitro as flat islands of cells spreading radially
across the collagen surface towards neighbouring islands
(Figure 3). Two slightly faster growing lines were observed
over three passages in vitro, and a third has now grown
rapidly over 100 days, requiring a weekly split ratio of up to
1:20. On subcutaneous re-injection into immunosuppressed
mice, these cells continued to show the same allelic status and
morphology as the primary tumour.
In conclusion, the xenograft lines described above repre¬
sent a variety of defined and stable combinations of oncosup¬
pressor gene status and will therefore provide a useful re¬
source for the study of the functions of the genes involved in
human colorectal cancer, and their interactions with each
other.
We thank Dr Y. Nakamura and Dr B. Vogelstein for their gifts of
probes used in this study. This work was funded by grants from the
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dation), and the Cancer Research Campaign.
96 H.A. MCQUEEN et al.
References
ASHTON-RICKARDT, P.G., DUNLOP, M.G., NAKAMURA, Y. & 6
others (1989). High frequency of ape loss in sporadic colorectal
carcinoma due to breaks clustered in 5q21-22. Oncogene, 4,
1169.
BRATTAIN, M.G., MARKS. M.E., McCOMBS, J., FINELY, W. & BRAT-
TAIN, D.E. (1983). Characterization of human colon carcinoma
cell lines isolated from a single primary tumour. Br. J. Cancer,
47, 373.
CARLSON, M„ NAKAMURA, Y„ PAYSON, R. & 4 others (1988).
Isolation and mapping of a polymorphic DNA sequence
pMCT35.1 on chromosome 17p (D17S31). Nucleic Acids Res., 16,
783.
DUNLOP, M.G., STEEL, C.M., WYLLIE, A.H., BIRD, C.C. & EVANS,
H.J. (1989). Linkage analysis in familial adenomatous polyposis:
order of C11P11 (D5S71) and n227 (D5S37) loci at the ape gene.
Genomics, 5, 350.
DUNLOP, M.G., WYLLIE, A.H., NAKAMURA, Y„ STEEL, C.M.,
EVANS, H.J. & BIRD, C.C. Genetic linkage map of 6 polymorphic
DNA markers around the gene for familial adenomatous poly¬
posis on chromosome 5. Am. J. Human Genet., (in the press).
FEARON, E.R. & VOGELSTEIN, B. (1990). A genetic model for col¬
orectal tumorigenesis. Cell, 61, 759.
HUANG, H.S., YEE, J.Y., SHEW, J. & 5 others (1988). Suppression of
the neoplastic phenotype by replacement of the RB gene in
human cancer cells. Science, 242, 1563.
LEFRANCOIS, D„ OLSCHWANG, S„ DELATTRE, O. & 4 others
(1989). Preservation of chromosome and DNA characteristics of
human colorectal adenocarcinomas after passage in nude mice.
Int. J. Cancer, 44, 871.
LEWKO, W.M., LADD, P., HUBBARD, D. & 7 others (1989). Tumour
acquisition, propagation and preservation. The culture of human
colorectal cancer. Cancer, 64, 1600.
MEERA KHAN, P., TOPS, C.M.J., BROCK, M.V.D. & 10 others (1988).
Close linkage of a highly polymorphic marker (D5S37) to familial
adenomatous polyposis (FAP) and confirmation of FAP localiza¬
tion on chromosome 5q21-q22. Hum. Genet., 79, 183.
NAKAMURA, Y„ LATHROP, M„ LEPPERT, M. & 12 others (1988a).
Localization of the genetic defect in familial adenomatous poly¬
posis within a small region of chromosome 5. Am. J. Human
Genet., 43, 638.
NAKAMURA, Y„ BALLARD. L„ LEPPERT, M. & 4 others (19886).
Isolation and mapping of a polymorphic DNA sequence
(pYNZ22) on chromosome 17p (D17S30). Nucleic Acids Res., 16,
5707.
NIGRO, J.M., BAKER, S.J., PREISINGER, A C. & 13 Others (1989).
Mutations in the p53 gene occur in diverse human tumour types.
Nature, 342, 705.
PARASKEVA, C„ BUCKLE, B.G., SHEER, D. & WIGLEY, C. (1984).
The isolation and characterization of colorectal epithelial cell
lines at different stages in malignant transformation from familial
polyposis coli patients. Int. J. Cancer, 34, 49.
PARK, J., OIE, H.K., SUGARBAKER. P H. & 4 others (1987). Charac¬
teristics of cell lines established from human colorectal car¬
cinoma. Cancer Res., 47, 6710.
STEEL, G.G., COURTENAY, V.D. & ROSTOM, A Y. (1978). Improved
immune-suppression techniques for the xenografting of human
tumours. Br. J. Cancer, 37, 224.
VINDELOV, L.L., CHRISTENSEN, I.J & NISSEN, N.I. (1983). A deter¬
gent trypsin method for the preparation of nuclei for flow
cytometric DNA analysis. Cytometry, 3, 323.
VOGELSTEIN, B„ FEARON, E.R., STANLEY, B.A. & 8 others (1988).
Genetic alterations during colorectal tumour development. New
Engl. J. Med., 319, 525.
WEISSMAN, B.E., SAXON, P.J., PASQUALE, S.R.. JONES, G.R., GEI-
SER, A.G. & STANBRIDGE, E.J. (1987). Introduction of a normal
human chromosome 11 into a Wilms' tumour cell line controls its
tumorigenic expression. Science, 236, 175.
